|
Paciente B-PRESENT_ILLNESS |
|
de I-PRESENT_ILLNESS |
|
sexo I-PRESENT_ILLNESS |
|
femenino I-PRESENT_ILLNESS |
|
de I-PRESENT_ILLNESS |
|
10 I-PRESENT_ILLNESS |
|
años I-PRESENT_ILLNESS |
|
edad, I-PRESENT_ILLNESS |
|
oriunda B-PAST_MEDICAL_HISTORY |
|
de I-PAST_MEDICAL_HISTORY |
|
la I-PAST_MEDICAL_HISTORY |
|
provincia I-PAST_MEDICAL_HISTORY |
|
de I-PAST_MEDICAL_HISTORY |
|
Misiones, I-PAST_MEDICAL_HISTORY |
|
que B-PRESENT_ILLNESS |
|
consultó I-PRESENT_ILLNESS |
|
al I-PRESENT_ILLNESS |
|
servicio I-PRESENT_ILLNESS |
|
de I-PRESENT_ILLNESS |
|
Dermatología I-PRESENT_ILLNESS |
|
por I-PRESENT_ILLNESS |
|
presentar I-PRESENT_ILLNESS |
|
múltiples I-PRESENT_ILLNESS |
|
placas I-PRESENT_ILLNESS |
|
de I-PRESENT_ILLNESS |
|
aspecto I-PRESENT_ILLNESS |
|
verrugoso I-PRESENT_ILLNESS |
|
con I-PRESENT_ILLNESS |
|
numerosas I-PRESENT_ILLNESS |
|
pápulas I-PRESENT_ILLNESS |
|
negruzcas I-PRESENT_ILLNESS |
|
sobre I-PRESENT_ILLNESS |
|
su I-PRESENT_ILLNESS |
|
superficie, I-PRESENT_ILLNESS |
|
localizadas I-PRESENT_ILLNESS |
|
en I-PRESENT_ILLNESS |
|
los I-PRESENT_ILLNESS |
|
sitios I-PRESENT_ILLNESS |
|
de I-PRESENT_ILLNESS |
|
apoyo I-PRESENT_ILLNESS |
|
de I-PRESENT_ILLNESS |
|
ambos I-PRESENT_ILLNESS |
|
pies I-PRESENT_ILLNESS |
|
(punta I-PRESENT_ILLNESS |
|
de I-PRESENT_ILLNESS |
|
dedos, I-PRESENT_ILLNESS |
|
metatarso I-PRESENT_ILLNESS |
|
y I-PRESENT_ILLNESS |
|
talones), I-PRESENT_ILLNESS |
|
de I-PRESENT_ILLNESS |
|
reciente I-PRESENT_ILLNESS |
|
aparición. I-PRESENT_ILLNESS |
|
<EOS> I-PRESENT_ILLNESS |
|
Las I-PRESENT_ILLNESS |
|
lesiones I-PRESENT_ILLNESS |
|
le I-PRESENT_ILLNESS |
|
ocasionaban I-PRESENT_ILLNESS |
|
dolor I-PRESENT_ILLNESS |
|
y I-PRESENT_ILLNESS |
|
dificultaban I-PRESENT_ILLNESS |
|
su I-PRESENT_ILLNESS |
|
deambulación. I-PRESENT_ILLNESS |
|
Realizada B-TREATMENT |
|
la I-TREATMENT |
|
extracción I-TREATMENT |
|
quirúrgica, I-TREATMENT |
|
se B-EXPLORATION |
|
obtuvieron I-EXPLORATION |
|
alrededor I-EXPLORATION |
|
de I-EXPLORATION |
|
20 I-EXPLORATION |
|
tungas I-EXPLORATION |
|
y I-EXPLORATION |
|
las I-EXPLORATION |
|
muestras I-EXPLORATION |
|
extraídas I-EXPLORATION |
|
se I-EXPLORATION |
|
enviaron I-EXPLORATION |
|
al I-EXPLORATION |
|
servicio I-EXPLORATION |
|
de I-EXPLORATION |
|
anatomopatología, I-EXPLORATION |
|
que I-EXPLORATION |
|
confirmó I-EXPLORATION |
|
el I-EXPLORATION |
|
diagnóstico I-EXPLORATION |
|
de I-EXPLORATION |
|
tungiasis. I-EXPLORATION |
|
La B-TREATMENT |
|
paciente I-TREATMENT |
|
fue I-TREATMENT |
|
tratada I-TREATMENT |
|
con I-TREATMENT |
|
ivermecti-na I-TREATMENT |
|
vía I-TREATMENT |
|
oral I-TREATMENT |
|
200 I-TREATMENT |
|
µg/kg I-TREATMENT |
|
como I-TREATMENT |
|
terapia I-TREATMENT |
|
coadyuvante, I-TREATMENT |
|
debido I-TREATMENT |
|
al I-TREATMENT |
|
gran I-TREATMENT |
|
compromiso I-TREATMENT |
|
cutáneo I-TREATMENT |
|
y I-TREATMENT |
|
la I-TREATMENT |
|
multiplicidad I-TREATMENT |
|
de I-TREATMENT |
|
lesiones. I-TREATMENT |
|
Las B-EVOLUTION |
|
lesiones I-EVOLUTION |
|
evolucionaron I-EVOLUTION |
|
favorablemente I-EVOLUTION |
|
con I-EVOLUTION |
|
resolución I-EVOLUTION |
|
completa. I-EVOLUTION |
|
<EOS> I-EVOLUTION |
|
|
|
Paciente B-PRESENT_ILLNESS |
|
de I-PRESENT_ILLNESS |
|
sexo I-PRESENT_ILLNESS |
|
femenino I-PRESENT_ILLNESS |
|
internada I-PRESENT_ILLNESS |
|
a I-PRESENT_ILLNESS |
|
los I-PRESENT_ILLNESS |
|
cuatro I-PRESENT_ILLNESS |
|
meses I-PRESENT_ILLNESS |
|
de I-PRESENT_ILLNESS |
|
vida I-PRESENT_ILLNESS |
|
por I-PRESENT_ILLNESS |
|
fiebre I-PRESENT_ILLNESS |
|
y I-PRESENT_ILLNESS |
|
depresión I-PRESENT_ILLNESS |
|
de I-PRESENT_ILLNESS |
|
sensorio. I-PRESENT_ILLNESS |
|
Antecedentes: B-PAST_MEDICAL_HISTORY |
|
recién I-PAST_MEDICAL_HISTORY |
|
nacida I-PAST_MEDICAL_HISTORY |
|
de I-PAST_MEDICAL_HISTORY |
|
término, I-PAST_MEDICAL_HISTORY |
|
de I-PAST_MEDICAL_HISTORY |
|
peso I-PAST_MEDICAL_HISTORY |
|
adecuado I-PAST_MEDICAL_HISTORY |
|
para I-PAST_MEDICAL_HISTORY |
|
su I-PAST_MEDICAL_HISTORY |
|
edad I-PAST_MEDICAL_HISTORY |
|
gestacional, I-PAST_MEDICAL_HISTORY |
|
con I-PAST_MEDICAL_HISTORY |
|
diagnóstico I-PAST_MEDICAL_HISTORY |
|
de I-PAST_MEDICAL_HISTORY |
|
ictericia I-PAST_MEDICAL_HISTORY |
|
por I-PAST_MEDICAL_HISTORY |
|
incompatibilidad I-PAST_MEDICAL_HISTORY |
|
ABO, I-PAST_MEDICAL_HISTORY |
|
tratada I-PAST_MEDICAL_HISTORY |
|
con I-PAST_MEDICAL_HISTORY |
|
luminoterapia I-PAST_MEDICAL_HISTORY |
|
dentro I-PAST_MEDICAL_HISTORY |
|
de I-PAST_MEDICAL_HISTORY |
|
las I-PAST_MEDICAL_HISTORY |
|
primeras I-PAST_MEDICAL_HISTORY |
|
24 I-PAST_MEDICAL_HISTORY |
|
h I-PAST_MEDICAL_HISTORY |
|
de I-PAST_MEDICAL_HISTORY |
|
vida. I-PAST_MEDICAL_HISTORY |
|
Al I-PAST_MEDICAL_HISTORY |
|
momento I-PAST_MEDICAL_HISTORY |
|
del I-PAST_MEDICAL_HISTORY |
|
egreso I-PAST_MEDICAL_HISTORY |
|
los I-PAST_MEDICAL_HISTORY |
|
valores I-PAST_MEDICAL_HISTORY |
|
de I-PAST_MEDICAL_HISTORY |
|
bilirrubina I-PAST_MEDICAL_HISTORY |
|
total I-PAST_MEDICAL_HISTORY |
|
eran I-PAST_MEDICAL_HISTORY |
|
9, I-PAST_MEDICAL_HISTORY |
|
9 I-PAST_MEDICAL_HISTORY |
|
mg/dl I-PAST_MEDICAL_HISTORY |
|
y I-PAST_MEDICAL_HISTORY |
|
directa I-PAST_MEDICAL_HISTORY |
|
0, I-PAST_MEDICAL_HISTORY |
|
5 I-PAST_MEDICAL_HISTORY |
|
mg/dl. I-PAST_MEDICAL_HISTORY |
|
Reingresó I-PAST_MEDICAL_HISTORY |
|
en I-PAST_MEDICAL_HISTORY |
|
Neonatología I-PAST_MEDICAL_HISTORY |
|
al I-PAST_MEDICAL_HISTORY |
|
mes I-PAST_MEDICAL_HISTORY |
|
de I-PAST_MEDICAL_HISTORY |
|
vida I-PAST_MEDICAL_HISTORY |
|
por I-PAST_MEDICAL_HISTORY |
|
ictericia I-PAST_MEDICAL_HISTORY |
|
prolongada. I-PAST_MEDICAL_HISTORY |
|
Durante I-PAST_MEDICAL_HISTORY |
|
la I-PAST_MEDICAL_HISTORY |
|
internación I-PAST_MEDICAL_HISTORY |
|
se I-PAST_MEDICAL_HISTORY |
|
realizó I-PAST_MEDICAL_HISTORY |
|
ecografía I-PAST_MEDICAL_HISTORY |
|
abdominal I-PAST_MEDICAL_HISTORY |
|
cuyo I-PAST_MEDICAL_HISTORY |
|
informe I-PAST_MEDICAL_HISTORY |
|
mencionaba I-PAST_MEDICAL_HISTORY |
|
presencia I-PAST_MEDICAL_HISTORY |
|
de I-PAST_MEDICAL_HISTORY |
|
vías I-PAST_MEDICAL_HISTORY |
|
biliares I-PAST_MEDICAL_HISTORY |
|
intrahepática I-PAST_MEDICAL_HISTORY |
|
y I-PAST_MEDICAL_HISTORY |
|
extrahepáticas, I-PAST_MEDICAL_HISTORY |
|
sin I-PAST_MEDICAL_HISTORY |
|
dilatación. I-PAST_MEDICAL_HISTORY |
|
Laboratorio: I-PAST_MEDICAL_HISTORY |
|
bilirrubinemia I-PAST_MEDICAL_HISTORY |
|
total I-PAST_MEDICAL_HISTORY |
|
11, I-PAST_MEDICAL_HISTORY |
|
3 I-PAST_MEDICAL_HISTORY |
|
mg/dl I-PAST_MEDICAL_HISTORY |
|
y I-PAST_MEDICAL_HISTORY |
|
directa I-PAST_MEDICAL_HISTORY |
|
1, I-PAST_MEDICAL_HISTORY |
|
7 I-PAST_MEDICAL_HISTORY |
|
mg/dl, I-PAST_MEDICAL_HISTORY |
|
FAL I-PAST_MEDICAL_HISTORY |
|
257 I-PAST_MEDICAL_HISTORY |
|
UI/L, I-PAST_MEDICAL_HISTORY |
|
TGP I-PAST_MEDICAL_HISTORY |
|
55 I-PAST_MEDICAL_HISTORY |
|
UI/L, I-PAST_MEDICAL_HISTORY |
|
TGO I-PAST_MEDICAL_HISTORY |
|
69 I-PAST_MEDICAL_HISTORY |
|
UI/L. I-PAST_MEDICAL_HISTORY |
|
Fue I-PAST_MEDICAL_HISTORY |
|
dada I-PAST_MEDICAL_HISTORY |
|
de I-PAST_MEDICAL_HISTORY |
|
alta I-PAST_MEDICAL_HISTORY |
|
y I-PAST_MEDICAL_HISTORY |
|
continuó I-PAST_MEDICAL_HISTORY |
|
en I-PAST_MEDICAL_HISTORY |
|
seguimiento I-PAST_MEDICAL_HISTORY |
|
ambulatorio I-PAST_MEDICAL_HISTORY |
|
por I-PAST_MEDICAL_HISTORY |
|
gastroenterólogo I-PAST_MEDICAL_HISTORY |
|
pediatra, I-PAST_MEDICAL_HISTORY |
|
hasta I-PAST_MEDICAL_HISTORY |
|
la I-PAST_MEDICAL_HISTORY |
|
internación I-PAST_MEDICAL_HISTORY |
|
por I-PAST_MEDICAL_HISTORY |
|
la I-PAST_MEDICAL_HISTORY |
|
hemorragia I-PAST_MEDICAL_HISTORY |
|
intracraneal. I-PAST_MEDICAL_HISTORY |
|
Evolución: B-EXPLORATION |
|
al I-EXPLORATION |
|
ingreso I-EXPLORATION |
|
se I-EXPLORATION |
|
encontró I-EXPLORATION |
|
ictericia I-EXPLORATION |
|
generalizada, I-EXPLORATION |
|
hepatomegalia I-EXPLORATION |
|
y I-EXPLORATION |
|
sopor. I-EXPLORATION |
|
Dentro B-EVOLUTION |
|
de I-EVOLUTION |
|
las I-EVOLUTION |
|
primeras I-EVOLUTION |
|
24 I-EVOLUTION |
|
h I-EVOLUTION |
|
de I-EVOLUTION |
|
internación I-EVOLUTION |
|
presentó I-EVOLUTION |
|
episodio I-EVOLUTION |
|
convulsivo I-EVOLUTION |
|
focal I-EVOLUTION |
|
en I-EVOLUTION |
|
hemicuerpo I-EVOLUTION |
|
derecho; I-EVOLUTION |
|
en B-TREATMENT |
|
la I-TREATMENT |
|
tomografía I-TREATMENT |
|
computada I-TREATMENT |
|
cerebral I-TREATMENT |
|
(TC) I-TREATMENT |
|
se I-TREATMENT |
|
constató I-TREATMENT |
|
hematoma I-TREATMENT |
|
subdural I-TREATMENT |
|
que I-TREATMENT |
|
requirió I-TREATMENT |
|
drenaje I-TREATMENT |
|
quirúrgico I-TREATMENT |
|
y I-TREATMENT |
|
asistencia I-TREATMENT |
|
respiratoria I-TREATMENT |
|
mecánica I-TREATMENT |
|
hasta I-TREATMENT |
|
48 I-TREATMENT |
|
h I-TREATMENT |
|
del I-TREATMENT |
|
postoperatorio. I-TREATMENT |
|
Laboratorio B-EXPLORATION |
|
de I-EXPLORATION |
|
ingreso: I-EXPLORATION |
|
GOT I-EXPLORATION |
|
120 I-EXPLORATION |
|
UI/L, I-EXPLORATION |
|
GPT I-EXPLORATION |
|
180 I-EXPLORATION |
|
UI/L, I-EXPLORATION |
|
FAL I-EXPLORATION |
|
1053 I-EXPLORATION |
|
UI/L, I-EXPLORATION |
|
gammaglutamiltranspeptidasa I-EXPLORATION |
|
1119 I-EXPLORATION |
|
UI/L, I-EXPLORATION |
|
LDH I-EXPLORATION |
|
1262 I-EXPLORATION |
|
UI/L, I-EXPLORATION |
|
bilirrubinemia I-EXPLORATION |
|
total I-EXPLORATION |
|
6 I-EXPLORATION |
|
mg/dl I-EXPLORATION |
|
y I-EXPLORATION |
|
directa I-EXPLORATION |
|
3, I-EXPLORATION |
|
9 I-EXPLORATION |
|
mg/ I-EXPLORATION |
|
dl, I-EXPLORATION |
|
amonio I-EXPLORATION |
|
51, I-EXPLORATION |
|
8 I-EXPLORATION |
|
mcg/dl, I-EXPLORATION |
|
lactacidemia I-EXPLORATION |
|
7 I-EXPLORATION |
|
mmol/L, I-EXPLORATION |
|
tiempo I-EXPLORATION |
|
de I-EXPLORATION |
|
protrombina I-EXPLORATION |
|
59%, I-EXPLORATION |
|
KPTT I-EXPLORATION |
|
100 I-EXPLORATION |
|
segundos I-EXPLORATION |
|
(no I-EXPLORATION |
|
se I-EXPLORATION |
|
le I-EXPLORATION |
|
administró I-EXPLORATION |
|
vitamina I-EXPLORATION |
|
K I-EXPLORATION |
|
ni I-EXPLORATION |
|
plasma I-EXPLORATION |
|
frasco I-EXPLORATION |
|
congelado I-EXPLORATION |
|
previo I-EXPLORATION |
|
a I-EXPLORATION |
|
la I-EXPLORATION |
|
toma I-EXPLORATION |
|
de I-EXPLORATION |
|
muestra). I-EXPLORATION |
|
Serologías I-EXPLORATION |
|
para I-EXPLORATION |
|
VIH, I-EXPLORATION |
|
sífilis, I-EXPLORATION |
|
toxoplasmosis, I-EXPLORATION |
|
hepatitis I-EXPLORATION |
|
B, I-EXPLORATION |
|
hepatitis I-EXPLORATION |
|
A I-EXPLORATION |
|
y I-EXPLORATION |
|
citomegalovirus I-EXPLORATION |
|
negativas. I-EXPLORATION |
|
Se I-EXPLORATION |
|
realizó I-EXPLORATION |
|
centellograma I-EXPLORATION |
|
con I-EXPLORATION |
|
HIDA I-EXPLORATION |
|
que I-EXPLORATION |
|
mostró I-EXPLORATION |
|
falta I-EXPLORATION |
|
de I-EXPLORATION |
|
captación I-EXPLORATION |
|
de I-EXPLORATION |
|
contraste I-EXPLORATION |
|
intrahepático I-EXPLORATION |
|
y I-EXPLORATION |
|
extrahepático, I-EXPLORATION |
|
sin I-EXPLORATION |
|
pasaje I-EXPLORATION |
|
de I-EXPLORATION |
|
contraste I-EXPLORATION |
|
al I-EXPLORATION |
|
intestino. I-EXPLORATION |
|
Se B-TREATMENT |
|
decidió I-TREATMENT |
|
realizar I-TREATMENT |
|
portoenteroanastomosis I-TREATMENT |
|
por I-TREATMENT |
|
laparoscopia, I-TREATMENT |
|
después I-TREATMENT |
|
de I-TREATMENT |
|
confirmar I-TREATMENT |
|
el I-TREATMENT |
|
diagnóstico I-TREATMENT |
|
de I-TREATMENT |
|
atresia I-TREATMENT |
|
de I-TREATMENT |
|
vías I-TREATMENT |
|
biliares I-TREATMENT |
|
durante I-TREATMENT |
|
la I-TREATMENT |
|
cirugía. I-TREATMENT |
|
A B-EVOLUTION |
|
los I-EVOLUTION |
|
6 I-EVOLUTION |
|
meses I-EVOLUTION |
|
de I-EVOLUTION |
|
vida I-EVOLUTION |
|
presentaba I-EVOLUTION |
|
maduración I-EVOLUTION |
|
neurológica I-EVOLUTION |
|
adecuada I-EVOLUTION |
|
a I-EVOLUTION |
|
la I-EVOLUTION |
|
edad. I-EVOLUTION |
|
Requirió B-TREATMENT |
|
trasplante I-TREATMENT |
|
hepático I-TREATMENT |
|
cerca I-TREATMENT |
|
del I-TREATMENT |
|
año I-TREATMENT |
|
de I-TREATMENT |
|
edad. I-TREATMENT |
|
<EOS> I-TREATMENT |
|
|
|
Niño B-PRESENT_ILLNESS |
|
de I-PRESENT_ILLNESS |
|
30 I-PRESENT_ILLNESS |
|
meses, I-PRESENT_ILLNESS |
|
nacido B-PAST_MEDICAL_HISTORY |
|
a I-PAST_MEDICAL_HISTORY |
|
término, I-PAST_MEDICAL_HISTORY |
|
cesárea I-PAST_MEDICAL_HISTORY |
|
programada, I-PAST_MEDICAL_HISTORY |
|
embarazo I-PAST_MEDICAL_HISTORY |
|
controlado, I-PAST_MEDICAL_HISTORY |
|
peso I-PAST_MEDICAL_HISTORY |
|
y I-PAST_MEDICAL_HISTORY |
|
talla I-PAST_MEDICAL_HISTORY |
|
acordes I-PAST_MEDICAL_HISTORY |
|
con I-PAST_MEDICAL_HISTORY |
|
la I-PAST_MEDICAL_HISTORY |
|
edad I-PAST_MEDICAL_HISTORY |
|
gestacional. I-PAST_MEDICAL_HISTORY |
|
Antecedentes I-PAST_MEDICAL_HISTORY |
|
de I-PAST_MEDICAL_HISTORY |
|
dos I-PAST_MEDICAL_HISTORY |
|
episodios I-PAST_MEDICAL_HISTORY |
|
de I-PAST_MEDICAL_HISTORY |
|
otitis I-PAST_MEDICAL_HISTORY |
|
media, I-PAST_MEDICAL_HISTORY |
|
sin I-PAST_MEDICAL_HISTORY |
|
cirugías, I-PAST_MEDICAL_HISTORY |
|
internaciones I-PAST_MEDICAL_HISTORY |
|
previas I-PAST_MEDICAL_HISTORY |
|
ni I-PAST_MEDICAL_HISTORY |
|
alergias. I-PAST_MEDICAL_HISTORY |
|
Inmunizaciones I-PAST_MEDICAL_HISTORY |
|
completas I-PAST_MEDICAL_HISTORY |
|
según I-PAST_MEDICAL_HISTORY |
|
el I-PAST_MEDICAL_HISTORY |
|
calendario I-PAST_MEDICAL_HISTORY |
|
oficial. I-PAST_MEDICAL_HISTORY |
|
Crecimiento I-PAST_MEDICAL_HISTORY |
|
y I-PAST_MEDICAL_HISTORY |
|
desarrollo I-PAST_MEDICAL_HISTORY |
|
normales. I-PAST_MEDICAL_HISTORY |
|
Historia B-FAMILY_HISTORY |
|
familiar I-FAMILY_HISTORY |
|
con I-FAMILY_HISTORY |
|
ambos I-FAMILY_HISTORY |
|
padres I-FAMILY_HISTORY |
|
obesos I-FAMILY_HISTORY |
|
con I-FAMILY_HISTORY |
|
cirugía I-FAMILY_HISTORY |
|
bariátrica I-FAMILY_HISTORY |
|
realizada, I-FAMILY_HISTORY |
|
y I-FAMILY_HISTORY |
|
dos I-FAMILY_HISTORY |
|
hermanas I-FAMILY_HISTORY |
|
mayores I-FAMILY_HISTORY |
|
con I-FAMILY_HISTORY |
|
antecedentes I-FAMILY_HISTORY |
|
de I-FAMILY_HISTORY |
|
asma I-FAMILY_HISTORY |
|
e I-FAMILY_HISTORY |
|
hipotiroidismo, I-FAMILY_HISTORY |
|
respectivamente. I-FAMILY_HISTORY |
|
<EOS> I-FAMILY_HISTORY |
|
Es B-DERIVED_FROM/TO |
|
derivado I-DERIVED_FROM/TO |
|
a I-DERIVED_FROM/TO |
|
nuestro I-DERIVED_FROM/TO |
|
hospital I-DERIVED_FROM/TO |
|
con I-DERIVED_FROM/TO |
|
diagnóstico I-DERIVED_FROM/TO |
|
de I-DERIVED_FROM/TO |
|
síndrome I-DERIVED_FROM/TO |
|
ascítico I-DERIVED_FROM/TO |
|
edematoso. I-DERIVED_FROM/TO |
|
Comenzó B-PRESENT_ILLNESS |
|
una I-PRESENT_ILLNESS |
|
semana I-PRESENT_ILLNESS |
|
antes I-PRESENT_ILLNESS |
|
con I-PRESENT_ILLNESS |
|
un I-PRESENT_ILLNESS |
|
edema I-PRESENT_ILLNESS |
|
palpebral I-PRESENT_ILLNESS |
|
bilateral I-PRESENT_ILLNESS |
|
leve. I-PRESENT_ILLNESS |
|
Dos I-PRESENT_ILLNESS |
|
días I-PRESENT_ILLNESS |
|
después, I-PRESENT_ILLNESS |
|
presentó I-PRESENT_ILLNESS |
|
un I-PRESENT_ILLNESS |
|
exantema I-PRESENT_ILLNESS |
|
urticariante I-PRESENT_ILLNESS |
|
generalizado I-PRESENT_ILLNESS |
|
en I-PRESENT_ILLNESS |
|
todo I-PRESENT_ILLNESS |
|
el I-PRESENT_ILLNESS |
|
cuerpo, I-PRESENT_ILLNESS |
|
no I-PRESENT_ILLNESS |
|
pruriginoso, I-PRESENT_ILLNESS |
|
que I-PRESENT_ILLNESS |
|
revirtió I-PRESENT_ILLNESS |
|
espontáneamente I-PRESENT_ILLNESS |
|
en I-PRESENT_ILLNESS |
|
menos I-PRESENT_ILLNESS |
|
de I-PRESENT_ILLNESS |
|
24 I-PRESENT_ILLNESS |
|
horas. I-PRESENT_ILLNESS |
|
A I-PRESENT_ILLNESS |
|
las I-PRESENT_ILLNESS |
|
48 I-PRESENT_ILLNESS |
|
horas, I-PRESENT_ILLNESS |
|
apareció I-PRESENT_ILLNESS |
|
un I-PRESENT_ILLNESS |
|
edema I-PRESENT_ILLNESS |
|
bipalpebral I-PRESENT_ILLNESS |
|
más I-PRESENT_ILLNESS |
|
pronunciado, I-PRESENT_ILLNESS |
|
distensión I-PRESENT_ILLNESS |
|
abdominal I-PRESENT_ILLNESS |
|
e I-PRESENT_ILLNESS |
|
irritabilidad. I-PRESENT_ILLNESS |
|
Se I-PRESENT_ILLNESS |
|
consultó I-PRESENT_ILLNESS |
|
al I-PRESENT_ILLNESS |
|
pediatra, I-PRESENT_ILLNESS |
|
que I-PRESENT_ILLNESS |
|
constató I-PRESENT_ILLNESS |
|
un I-PRESENT_ILLNESS |
|
aumento I-PRESENT_ILLNESS |
|
de I-PRESENT_ILLNESS |
|
2 I-PRESENT_ILLNESS |
|
kg I-PRESENT_ILLNESS |
|
con I-PRESENT_ILLNESS |
|
respecto I-PRESENT_ILLNESS |
|
a I-PRESENT_ILLNESS |
|
peso I-PRESENT_ILLNESS |
|
previo I-PRESENT_ILLNESS |
|
(2 I-PRESENT_ILLNESS |
|
meses I-PRESENT_ILLNESS |
|
antes). I-PRESENT_ILLNESS |
|
No B-PAST_MEDICAL_HISTORY |
|
tenía I-PAST_MEDICAL_HISTORY |
|
antecedentes I-PAST_MEDICAL_HISTORY |
|
de I-PAST_MEDICAL_HISTORY |
|
infecciones. I-PAST_MEDICAL_HISTORY |
|
Fue B-DERIVED_FROM/TO |
|
derivado I-DERIVED_FROM/TO |
|
a I-DERIVED_FROM/TO |
|
un I-DERIVED_FROM/TO |
|
médico I-DERIVED_FROM/TO |
|
nefrólogo, I-DERIVED_FROM/TO |
|
quien I-DERIVED_FROM/TO |
|
solicitó I-DERIVED_FROM/TO |
|
estudios I-DERIVED_FROM/TO |
|
de I-DERIVED_FROM/TO |
|
laboratorio I-DERIVED_FROM/TO |
|
cuyos I-DERIVED_FROM/TO |
|
resultados I-DERIVED_FROM/TO |
|
mostraron I-DERIVED_FROM/TO |
|
marcada I-DERIVED_FROM/TO |
|
hipoproteinemia I-DERIVED_FROM/TO |
|
e I-DERIVED_FROM/TO |
|
hipoalbuminemia, I-DERIVED_FROM/TO |
|
hipertrigliceridemia, I-DERIVED_FROM/TO |
|
hipocalcemia I-DERIVED_FROM/TO |
|
leve I-DERIVED_FROM/TO |
|
y I-DERIVED_FROM/TO |
|
orina I-DERIVED_FROM/TO |
|
normal. I-DERIVED_FROM/TO |
|
Se I-DERIVED_FROM/TO |
|
trasladó I-DERIVED_FROM/TO |
|
al I-DERIVED_FROM/TO |
|
niño I-DERIVED_FROM/TO |
|
a I-DERIVED_FROM/TO |
|
nuestro I-DERIVED_FROM/TO |
|
hospital I-DERIVED_FROM/TO |
|
para I-DERIVED_FROM/TO |
|
su I-DERIVED_FROM/TO |
|
diagnóstico I-DERIVED_FROM/TO |
|
y I-DERIVED_FROM/TO |
|
tratamiento. I-DERIVED_FROM/TO |
|
<EOS> I-DERIVED_FROM/TO |
|
Examen B-EXPLORATION |
|
físico: I-EXPLORATION |
|
niño I-EXPLORATION |
|
lúcido, I-EXPLORATION |
|
vigil, I-EXPLORATION |
|
orientado, I-EXPLORATION |
|
irritable. I-EXPLORATION |
|
TA I-EXPLORATION |
|
109/78 I-EXPLORATION |
|
mm I-EXPLORATION |
|
Hg, I-EXPLORATION |
|
TAM I-EXPLORATION |
|
92 I-EXPLORATION |
|
mm I-EXPLORATION |
|
Hg, I-EXPLORATION |
|
FC I-EXPLORATION |
|
130 I-EXPLORATION |
|
lpm, I-EXPLORATION |
|
FR I-EXPLORATION |
|
32 I-EXPLORATION |
|
rpm, I-EXPLORATION |
|
temperatura I-EXPLORATION |
|
36, I-EXPLORATION |
|
7°C, I-EXPLORATION |
|
saturación I-EXPLORATION |
|
de I-EXPLORATION |
|
O2 I-EXPLORATION |
|
96% I-EXPLORATION |
|
respirando I-EXPLORATION |
|
aire I-EXPLORATION |
|
ambiente. I-EXPLORATION |
|
Peso I-EXPLORATION |
|
14, I-EXPLORATION |
|
600 I-EXPLORATION |
|
kg, I-EXPLORATION |
|
palidez I-EXPLORATION |
|
generalizada, I-EXPLORATION |
|
facies I-EXPLORATION |
|
abotagada. I-EXPLORATION |
|
Edema I-EXPLORATION |
|
palpebral I-EXPLORATION |
|
bilateral. I-EXPLORATION |
|
Algunos I-EXPLORATION |
|
crepitantes I-EXPLORATION |
|
basales I-EXPLORATION |
|
en I-EXPLORATION |
|
ambos I-EXPLORATION |
|
campos I-EXPLORATION |
|
pulmonares. I-EXPLORATION |
|
Edema I-EXPLORATION |
|
pretibial I-EXPLORATION |
|
bilateral. I-EXPLORATION |
|
Abdomen I-EXPLORATION |
|
globuloso, I-EXPLORATION |
|
distendido, I-EXPLORATION |
|
onda I-EXPLORATION |
|
ascítica I-EXPLORATION |
|
positiva, I-EXPLORATION |
|
sin I-EXPLORATION |
|
hepatoesplenomegalia. I-EXPLORATION |
|
Edema I-EXPLORATION |
|
escrotal I-EXPLORATION |
|
y I-EXPLORATION |
|
suprapúbico. I-EXPLORATION |
|
El I-EXPLORATION |
|
resto I-EXPLORATION |
|
del I-EXPLORATION |
|
examen I-EXPLORATION |
|
no I-EXPLORATION |
|
presentó I-EXPLORATION |
|
particularidades. I-EXPLORATION |
|
<EOS> I-EXPLORATION |
|
Laboratorio I-EXPLORATION |
|
inicial: I-EXPLORATION |
|
leucocitos: I-EXPLORATION |
|
17 I-EXPLORATION |
|
700/mm3, I-EXPLORATION |
|
fórmula: I-EXPLORATION |
|
27% I-EXPLORATION |
|
neutrófilos, I-EXPLORATION |
|
14% I-EXPLORATION |
|
eosinófilos, I-EXPLORATION |
|
49% I-EXPLORATION |
|
linfocitos, I-EXPLORATION |
|
6% I-EXPLORATION |
|
monocitos I-EXPLORATION |
|
y I-EXPLORATION |
|
4% I-EXPLORATION |
|
linfocitos I-EXPLORATION |
|
atípicos. I-EXPLORATION |
|
Calcio I-EXPLORATION |
|
total I-EXPLORATION |
|
7, I-EXPLORATION |
|
4 I-EXPLORATION |
|
mmol/L I-EXPLORATION |
|
(VN I-EXPLORATION |
|
8, I-EXPLORATION |
|
5-10), I-EXPLORATION |
|
proteínas I-EXPLORATION |
|
totales I-EXPLORATION |
|
3 I-EXPLORATION |
|
g/dl I-EXPLORATION |
|
(VN I-EXPLORATION |
|
6, I-EXPLORATION |
|
6-8, I-EXPLORATION |
|
7), I-EXPLORATION |
|
albúmina I-EXPLORATION |
|
1, I-EXPLORATION |
|
6 I-EXPLORATION |
|
g/dl I-EXPLORATION |
|
(VN I-EXPLORATION |
|
3, I-EXPLORATION |
|
5-3), I-EXPLORATION |
|
IgG I-EXPLORATION |
|
136 I-EXPLORATION |
|
mg/dl I-EXPLORATION |
|
(VN I-EXPLORATION |
|
490-1450), I-EXPLORATION |
|
IgE I-EXPLORATION |
|
140 I-EXPLORATION |
|
UI/ I-EXPLORATION |
|
ml I-EXPLORATION |
|
(VN I-EXPLORATION |
|
hasta I-EXPLORATION |
|
75), I-EXPLORATION |
|
triglicéridos I-EXPLORATION |
|
196 I-EXPLORATION |
|
mg/dl I-EXPLORATION |
|
(N I-EXPLORATION |
|
< I-EXPLORATION |
|
150), I-EXPLORATION |
|
TGO I-EXPLORATION |
|
62 I-EXPLORATION |
|
U/L I-EXPLORATION |
|
(VN I-EXPLORATION |
|
< I-EXPLORATION |
|
37), I-EXPLORATION |
|
TGP I-EXPLORATION |
|
43 I-EXPLORATION |
|
U/L I-EXPLORATION |
|
(VN I-EXPLORATION |
|
< I-EXPLORATION |
|
41), I-EXPLORATION |
|
<EOS> I-EXPLORATION |
|
colesterol I-EXPLORATION |
|
total I-EXPLORATION |
|
129 I-EXPLORATION |
|
mg/dl I-EXPLORATION |
|
(VN I-EXPLORATION |
|
< I-EXPLORATION |
|
200), I-EXPLORATION |
|
HDL I-EXPLORATION |
|
25 I-EXPLORATION |
|
mg/ I-EXPLORATION |
|
dl I-EXPLORATION |
|
(VN I-EXPLORATION |
|
> I-EXPLORATION |
|
35). I-EXPLORATION |
|
PCR I-EXPLORATION |
|
1, I-EXPLORATION |
|
3mg/dl I-EXPLORATION |
|
(VN I-EXPLORATION |
|
< I-EXPLORATION |
|
0, I-EXPLORATION |
|
06). I-EXPLORATION |
|
Orina I-EXPLORATION |
|
normal I-EXPLORATION |
|
sin I-EXPLORATION |
|
proteinuria. I-EXPLORATION |
|
Relación I-EXPLORATION |
|
Prot/Cr I-EXPLORATION |
|
0, I-EXPLORATION |
|
26. I-EXPLORATION |
|
Hormonas I-EXPLORATION |
|
tiroideas I-EXPLORATION |
|
normales I-EXPLORATION |
|
y I-EXPLORATION |
|
anticuerpos I-EXPLORATION |
|
para I-EXPLORATION |
|
enfermedad I-EXPLORATION |
|
celíaca I-EXPLORATION |
|
negativos. I-EXPLORATION |
|
Prueba I-EXPLORATION |
|
de I-EXPLORATION |
|
la I-EXPLORATION |
|
tuberculina I-EXPLORATION |
|
negativa. I-EXPLORATION |
|
<EOS> I-EXPLORATION |
|
Al B-EVOLUTION |
|
segundo I-EVOLUTION |
|
día I-EVOLUTION |
|
de I-EVOLUTION |
|
internación, I-EVOLUTION |
|
el I-EVOLUTION |
|
niño I-EVOLUTION |
|
presentó I-EVOLUTION |
|
dos I-EVOLUTION |
|
picos I-EVOLUTION |
|
febriles, I-EVOLUTION |
|
fauces I-EVOLUTION |
|
congestivas, I-EVOLUTION |
|
subcrepitantes I-EVOLUTION |
|
pulmonares I-EVOLUTION |
|
bibasales I-EVOLUTION |
|
leves. I-EVOLUTION |
|
Radiografía B-EXPLORATION |
|
de I-EXPLORATION |
|
tórax I-EXPLORATION |
|
y I-EXPLORATION |
|
ecografía I-EXPLORATION |
|
renal I-EXPLORATION |
|
sin I-EXPLORATION |
|
particularidades. I-EXPLORATION |
|
Ecografía I-EXPLORATION |
|
abdominal I-EXPLORATION |
|
sin I-EXPLORATION |
|
visceromegalia, I-EXPLORATION |
|
con I-EXPLORATION |
|
líquido I-EXPLORATION |
|
ascítico I-EXPLORATION |
|
moderado, I-EXPLORATION |
|
mucosa I-EXPLORATION |
|
gástrica I-EXPLORATION |
|
sin I-EXPLORATION |
|
agrandamiento I-EXPLORATION |
|
ni I-EXPLORATION |
|
hipertrofia I-EXPLORATION |
|
de I-EXPLORATION |
|
pliegues. I-EXPLORATION |
|
<EOS> I-EXPLORATION |
|
Se I-EXPLORATION |
|
descartó I-EXPLORATION |
|
la I-EXPLORATION |
|
etiología I-EXPLORATION |
|
cardiovascular, I-EXPLORATION |
|
renal I-EXPLORATION |
|
o I-EXPLORATION |
|
hepática I-EXPLORATION |
|
por I-EXPLORATION |
|
la I-EXPLORATION |
|
clínica I-EXPLORATION |
|
y I-EXPLORATION |
|
los I-EXPLORATION |
|
estudios I-EXPLORATION |
|
realizados. I-EXPLORATION |
|
<EOS> I-EXPLORATION |
|
Ante I-EXPLORATION |
|
la I-EXPLORATION |
|
sospecha I-EXPLORATION |
|
de I-EXPLORATION |
|
gastroenteropatía I-EXPLORATION |
|
perdedora I-EXPLORATION |
|
de I-EXPLORATION |
|
proteínas, I-EXPLORATION |
|
se I-EXPLORATION |
|
realizó I-EXPLORATION |
|
una I-EXPLORATION |
|
endoscopia I-EXPLORATION |
|
esofagogastroduodenal I-EXPLORATION |
|
con I-EXPLORATION |
|
biopsia, I-EXPLORATION |
|
cuyo I-EXPLORATION |
|
informe I-EXPLORATION |
|
reveló: I-EXPLORATION |
|
esófago I-EXPLORATION |
|
con I-EXPLORATION |
|
cambio I-EXPLORATION |
|
mucoso I-EXPLORATION |
|
a I-EXPLORATION |
|
23 I-EXPLORATION |
|
cm, I-EXPLORATION |
|
mucosa I-EXPLORATION |
|
pálida I-EXPLORATION |
|
y I-EXPLORATION |
|
muy I-EXPLORATION |
|
edematosa; I-EXPLORATION |
|
estómago I-EXPLORATION |
|
con I-EXPLORATION |
|
presencia I-EXPLORATION |
|
de I-EXPLORATION |
|
pliegues I-EXPLORATION |
|
engrosados, I-EXPLORATION |
|
seudopólipos I-EXPLORATION |
|
y I-EXPLORATION |
|
erosiones I-EXPLORATION |
|
de I-EXPLORATION |
|
la I-EXPLORATION |
|
mucosa. I-EXPLORATION |
|
Duodeno I-EXPLORATION |
|
con I-EXPLORATION |
|
pliegues I-EXPLORATION |
|
engrosados I-EXPLORATION |
|
y I-EXPLORATION |
|
mucosa I-EXPLORATION |
|
edematosa. I-EXPLORATION |
|
El I-EXPLORATION |
|
informe I-EXPLORATION |
|
de I-EXPLORATION |
|
la I-EXPLORATION |
|
biopsia I-EXPLORATION |
|
correspondió I-EXPLORATION |
|
a I-EXPLORATION |
|
esofagitis, I-EXPLORATION |
|
gastritis I-EXPLORATION |
|
y I-EXPLORATION |
|
duodenitis I-EXPLORATION |
|
crónica I-EXPLORATION |
|
leve I-EXPLORATION |
|
a I-EXPLORATION |
|
moderada I-EXPLORATION |
|
con I-EXPLORATION |
|
frecuentes I-EXPLORATION |
|
eosinófilos. I-EXPLORATION |
|
No I-EXPLORATION |
|
se I-EXPLORATION |
|
realizó I-EXPLORATION |
|
depuración I-EXPLORATION |
|
de I-EXPLORATION |
|
α1-antitripsina I-EXPLORATION |
|
por I-EXPLORATION |
|
la I-EXPLORATION |
|
falta I-EXPLORATION |
|
de I-EXPLORATION |
|
accesibilidad I-EXPLORATION |
|
al I-EXPLORATION |
|
método. I-EXPLORATION |
|
<EOS> I-EXPLORATION |
|
Se I-EXPLORATION |
|
solicitó I-EXPLORATION |
|
en I-EXPLORATION |
|
sangre, I-EXPLORATION |
|
IgM-IgG I-EXPLORATION |
|
para I-EXPLORATION |
|
CMV: I-EXPLORATION |
|
positivo; I-EXPLORATION |
|
antígeno I-EXPLORATION |
|
temprano: I-EXPLORATION |
|
reactivo; I-EXPLORATION |
|
PCR: I-EXPLORATION |
|
2075 I-EXPLORATION |
|
copias I-EXPLORATION |
|
(no I-EXPLORATION |
|
reactivo I-EXPLORATION |
|
< I-EXPLORATION |
|
750 I-EXPLORATION |
|
copias). I-EXPLORATION |
|
No I-EXPLORATION |
|
se I-EXPLORATION |
|
analizó I-EXPLORATION |
|
material I-EXPLORATION |
|
de I-EXPLORATION |
|
biopsia I-EXPLORATION |
|
para I-EXPLORATION |
|
la I-EXPLORATION |
|
detección I-EXPLORATION |
|
del I-EXPLORATION |
|
virus. I-EXPLORATION |
|
<EOS> I-EXPLORATION |
|
El B-TREATMENT |
|
paciente I-TREATMENT |
|
fue I-TREATMENT |
|
sometido I-TREATMENT |
|
a I-TREATMENT |
|
una I-TREATMENT |
|
dieta I-TREATMENT |
|
hiperproteica I-TREATMENT |
|
y I-TREATMENT |
|
gastroprotectora. I-TREATMENT |
|
Recibió I-TREATMENT |
|
una I-TREATMENT |
|
infusión I-TREATMENT |
|
intravenosa I-TREATMENT |
|
de I-TREATMENT |
|
albúmina I-TREATMENT |
|
(25% I-TREATMENT |
|
1 I-TREATMENT |
|
g/ I-TREATMENT |
|
kg, I-TREATMENT |
|
una I-TREATMENT |
|
dosis), I-TREATMENT |
|
omeprazol I-TREATMENT |
|
20 I-TREATMENT |
|
mg/día I-TREATMENT |
|
por I-TREATMENT |
|
vía I-TREATMENT |
|
intravenosa I-TREATMENT |
|
y I-TREATMENT |
|
espironolactona I-TREATMENT |
|
3 I-TREATMENT |
|
mg/kg/día I-TREATMENT |
|
por I-TREATMENT |
|
vía I-TREATMENT |
|
oral. I-TREATMENT |
|
Al I-TREATMENT |
|
no I-TREATMENT |
|
mejorar I-TREATMENT |
|
clínicamente, I-TREATMENT |
|
a I-TREATMENT |
|
los I-TREATMENT |
|
6 I-TREATMENT |
|
días I-TREATMENT |
|
se I-TREATMENT |
|
comenzó I-TREATMENT |
|
la I-TREATMENT |
|
administración I-TREATMENT |
|
de I-TREATMENT |
|
ganciclovir I-TREATMENT |
|
por I-TREATMENT |
|
vía I-TREATMENT |
|
intravenosa I-TREATMENT |
|
(5 I-TREATMENT |
|
mg/kg I-TREATMENT |
|
cada I-TREATMENT |
|
12 I-TREATMENT |
|
horas). I-TREATMENT |
|
A I-TREATMENT |
|
las I-TREATMENT |
|
48 I-TREATMENT |
|
horas I-TREATMENT |
|
se I-TREATMENT |
|
rotó I-TREATMENT |
|
a I-TREATMENT |
|
valganciclovir I-TREATMENT |
|
oral I-TREATMENT |
|
(400 I-TREATMENT |
|
mg/día) I-TREATMENT |
|
por I-TREATMENT |
|
la I-TREATMENT |
|
imposibilidad I-TREATMENT |
|
de I-TREATMENT |
|
mantener I-TREATMENT |
|
la I-TREATMENT |
|
venoclisis. I-TREATMENT |
|
<EOS> I-TREATMENT |
|
A B-EVOLUTION |
|
los I-EVOLUTION |
|
10 I-EVOLUTION |
|
días I-EVOLUTION |
|
de I-EVOLUTION |
|
internación, I-EVOLUTION |
|
dada I-EVOLUTION |
|
la I-EVOLUTION |
|
buena I-EVOLUTION |
|
evolución, I-EVOLUTION |
|
se I-EVOLUTION |
|
le I-EVOLUTION |
|
otorgó I-EVOLUTION |
|
el I-EVOLUTION |
|
alta I-EVOLUTION |
|
hospitalaria. I-EVOLUTION |
|
Laboratorio B-EXPLORATION |
|
al I-EXPLORATION |
|
alta: I-EXPLORATION |
|
proteínas I-EXPLORATION |
|
totales I-EXPLORATION |
|
4, I-EXPLORATION |
|
6 I-EXPLORATION |
|
g/ I-EXPLORATION |
|
dl I-EXPLORATION |
|
(VN I-EXPLORATION |
|
6, I-EXPLORATION |
|
6-8, I-EXPLORATION |
|
7), I-EXPLORATION |
|
albúmina I-EXPLORATION |
|
2, I-EXPLORATION |
|
6 I-EXPLORATION |
|
g/dl I-EXPLORATION |
|
(VN I-EXPLORATION |
|
3, I-EXPLORATION |
|
5-5), I-EXPLORATION |
|
triglicéridos I-EXPLORATION |
|
254 I-EXPLORATION |
|
mg/dl I-EXPLORATION |
|
(VN I-EXPLORATION |
|
< I-EXPLORATION |
|
150). I-EXPLORATION |
|
Carga I-EXPLORATION |
|
viral I-EXPLORATION |
|
para I-EXPLORATION |
|
CMV I-EXPLORATION |
|
< I-EXPLORATION |
|
750 I-EXPLORATION |
|
copias. I-EXPLORATION |
|
Se B-TREATMENT |
|
indicó I-TREATMENT |
|
continuar I-TREATMENT |
|
con I-TREATMENT |
|
dieta I-TREATMENT |
|
hiperproteica, I-TREATMENT |
|
protectores I-TREATMENT |
|
gástricos I-TREATMENT |
|
y I-TREATMENT |
|
valganciclovir I-TREATMENT |
|
por I-TREATMENT |
|
vía I-TREATMENT |
|
oral I-TREATMENT |
|
hasta I-TREATMENT |
|
completar I-TREATMENT |
|
6 I-TREATMENT |
|
semanas I-TREATMENT |
|
de I-TREATMENT |
|
tratamiento. I-TREATMENT |
|
Cuatro B-EXPLORATION |
|
meses I-EXPLORATION |
|
después, I-EXPLORATION |
|
se I-EXPLORATION |
|
repitió I-EXPLORATION |
|
la I-EXPLORATION |
|
endoscopia I-EXPLORATION |
|
esofagogastroduodenal, I-EXPLORATION |
|
cuyo I-EXPLORATION |
|
resultado I-EXPLORATION |
|
fue I-EXPLORATION |
|
normal. I-EXPLORATION |
|
<EOS> I-EXPLORATION |
|
|
|
Niña B-PRESENT_ILLNESS |
|
de I-PRESENT_ILLNESS |
|
3 I-PRESENT_ILLNESS |
|
meses I-PRESENT_ILLNESS |
|
con I-PRESENT_ILLNESS |
|
lesión I-PRESENT_ILLNESS |
|
eritematosa I-PRESENT_ILLNESS |
|
en I-PRESENT_ILLNESS |
|
antifaz, I-PRESENT_ILLNESS |
|
pequeñas I-PRESENT_ILLNESS |
|
placas I-PRESENT_ILLNESS |
|
redondeadas, I-PRESENT_ILLNESS |
|
ligeramente I-PRESENT_ILLNESS |
|
atróficas I-PRESENT_ILLNESS |
|
en I-PRESENT_ILLNESS |
|
región I-PRESENT_ILLNESS |
|
temporooccipital I-PRESENT_ILLNESS |
|
bilateral I-PRESENT_ILLNESS |
|
y I-PRESENT_ILLNESS |
|
cuello I-PRESENT_ILLNESS |
|
y I-PRESENT_ILLNESS |
|
finas I-PRESENT_ILLNESS |
|
telangiectasias I-PRESENT_ILLNESS |
|
en I-PRESENT_ILLNESS |
|
su I-PRESENT_ILLNESS |
|
superficie. I-PRESENT_ILLNESS |
|
En I-PRESENT_ILLNESS |
|
región I-PRESENT_ILLNESS |
|
genital, I-PRESENT_ILLNESS |
|
lesión I-PRESENT_ILLNESS |
|
eritematosa, I-PRESENT_ILLNESS |
|
atrófica, I-PRESENT_ILLNESS |
|
de I-PRESENT_ILLNESS |
|
bordes I-PRESENT_ILLNESS |
|
definidos I-PRESENT_ILLNESS |
|
de I-PRESENT_ILLNESS |
|
2 I-PRESENT_ILLNESS |
|
meses I-PRESENT_ILLNESS |
|
de I-PRESENT_ILLNESS |
|
evolución. I-PRESENT_ILLNESS |
|
<EOS> I-PRESENT_ILLNESS |
|
Madre B-FAMILY_HISTORY |
|
con I-FAMILY_HISTORY |
|
alopecia I-FAMILY_HISTORY |
|
cicatrizal, I-FAMILY_HISTORY |
|
ojo I-FAMILY_HISTORY |
|
seco, I-FAMILY_HISTORY |
|
boca I-FAMILY_HISTORY |
|
seca I-FAMILY_HISTORY |
|
y I-FAMILY_HISTORY |
|
anemia, I-FAMILY_HISTORY |
|
sin I-FAMILY_HISTORY |
|
diagnóstico I-FAMILY_HISTORY |
|
de I-FAMILY_HISTORY |
|
su I-FAMILY_HISTORY |
|
enfermedad I-FAMILY_HISTORY |
|
al I-FAMILY_HISTORY |
|
momento I-FAMILY_HISTORY |
|
de I-FAMILY_HISTORY |
|
la I-FAMILY_HISTORY |
|
consulta. I-FAMILY_HISTORY |
|
<EOS> I-FAMILY_HISTORY |
|
Exámenes B-EXPLORATION |
|
complementarios: I-EXPLORATION |
|
Hb I-EXPLORATION |
|
11, I-EXPLORATION |
|
2g/dl, I-EXPLORATION |
|
Hto I-EXPLORATION |
|
33%, I-EXPLORATION |
|
TGO I-EXPLORATION |
|
265 I-EXPLORATION |
|
UI/L, I-EXPLORATION |
|
TGP I-EXPLORATION |
|
212 I-EXPLORATION |
|
UI/L, I-EXPLORATION |
|
FAL I-EXPLORATION |
|
927 I-EXPLORATION |
|
UI/L, I-EXPLORATION |
|
C3 I-EXPLORATION |
|
54 I-EXPLORATION |
|
mg/dl, I-EXPLORATION |
|
C4 I-EXPLORATION |
|
2 I-EXPLORATION |
|
mg/dl, I-EXPLORATION |
|
FAN I-EXPLORATION |
|
+ I-EXPLORATION |
|
1/1000 I-EXPLORATION |
|
patrón I-EXPLORATION |
|
moteado I-EXPLORATION |
|
grueso I-EXPLORATION |
|
y I-EXPLORATION |
|
anti I-EXPLORATION |
|
La I-EXPLORATION |
|
positivo I-EXPLORATION |
|
(paciente), I-EXPLORATION |
|
FAN I-EXPLORATION |
|
+ I-EXPLORATION |
|
1/2000 I-EXPLORATION |
|
patrón I-EXPLORATION |
|
homogéneo I-EXPLORATION |
|
y I-EXPLORATION |
|
anti I-EXPLORATION |
|
La I-EXPLORATION |
|
y I-EXPLORATION |
|
anti I-EXPLORATION |
|
Ro I-EXPLORATION |
|
positivos I-EXPLORATION |
|
(madre) I-EXPLORATION |
|
<EOS> I-EXPLORATION |
|
Estudio I-EXPLORATION |
|
histopatológico: I-EXPLORATION |
|
capa I-EXPLORATION |
|
córnea I-EXPLORATION |
|
engrosada, I-EXPLORATION |
|
epidermis I-EXPLORATION |
|
adelgazada, I-EXPLORATION |
|
intensa I-EXPLORATION |
|
vacuolización I-EXPLORATION |
|
de I-EXPLORATION |
|
queratinocitos I-EXPLORATION |
|
basales, I-EXPLORATION |
|
en I-EXPLORATION |
|
dermis I-EXPLORATION |
|
infiltrado I-EXPLORATION |
|
mononuclear I-EXPLORATION |
|
difuso. I-EXPLORATION |
|
Membrana I-EXPLORATION |
|
basal I-EXPLORATION |
|
engrosada. I-EXPLORATION |
|
IFD I-EXPLORATION |
|
negativa. I-EXPLORATION |
|
<EOS> I-EXPLORATION |
|
Valoración I-EXPLORATION |
|
cardiológica I-EXPLORATION |
|
normal. I-EXPLORATION |
|
<EOS> I-EXPLORATION |
|
Tratamiento: B-TREATMENT |
|
Hidrocortisona I-TREATMENT |
|
1% I-TREATMENT |
|
tópico, I-TREATMENT |
|
Pimecrolimus I-TREATMENT |
|
1%. I-TREATMENT |
|
Desaparición B-EVOLUTION |
|
de I-EVOLUTION |
|
las I-EVOLUTION |
|
lesiones I-EVOLUTION |
|
eritematosas I-EVOLUTION |
|
a I-EVOLUTION |
|
los I-EVOLUTION |
|
15 I-EVOLUTION |
|
días I-EVOLUTION |
|
y I-EVOLUTION |
|
persistencia I-EVOLUTION |
|
de I-EVOLUTION |
|
lesiones I-EVOLUTION |
|
atróficas I-EVOLUTION |
|
con I-EVOLUTION |
|
puntillado I-EVOLUTION |
|
petequial I-EVOLUTION |
|
en I-EVOLUTION |
|
cuero I-EVOLUTION |
|
cabelludo, I-EVOLUTION |
|
normalizando I-EVOLUTION |
|
las I-EVOLUTION |
|
enzimas I-EVOLUTION |
|
hepáticas I-EVOLUTION |
|
a I-EVOLUTION |
|
los I-EVOLUTION |
|
10 I-EVOLUTION |
|
meses I-EVOLUTION |
|
de I-EVOLUTION |
|
vida. I-EVOLUTION |
|
<EOS> I-EVOLUTION |
|
Luego, I-EVOLUTION |
|
a I-EVOLUTION |
|
la I-EVOLUTION |
|
madre I-EVOLUTION |
|
de I-EVOLUTION |
|
la I-EVOLUTION |
|
paciente I-EVOLUTION |
|
se I-EVOLUTION |
|
le I-EVOLUTION |
|
realizó I-EVOLUTION |
|
diagnóstico I-EVOLUTION |
|
de I-EVOLUTION |
|
Síndrome I-EVOLUTION |
|
(Sme.) I-EVOLUTION |
|
de I-EVOLUTION |
|
Sjögren. I-EVOLUTION |
|
<EOS> I-EVOLUTION |
|
|
|
Paciente B-PRESENT_ILLNESS |
|
de I-PRESENT_ILLNESS |
|
77 I-PRESENT_ILLNESS |
|
años I-PRESENT_ILLNESS |
|
que I-PRESENT_ILLNESS |
|
acude I-PRESENT_ILLNESS |
|
al I-PRESENT_ILLNESS |
|
servicio I-PRESENT_ILLNESS |
|
de I-PRESENT_ILLNESS |
|
urgencias I-PRESENT_ILLNESS |
|
por I-PRESENT_ILLNESS |
|
dolor I-PRESENT_ILLNESS |
|
en I-PRESENT_ILLNESS |
|
ambos I-PRESENT_ILLNESS |
|
ojos I-PRESENT_ILLNESS |
|
(AO), I-PRESENT_ILLNESS |
|
sin I-PRESENT_ILLNESS |
|
pérdida I-PRESENT_ILLNESS |
|
de I-PRESENT_ILLNESS |
|
agudeza I-PRESENT_ILLNESS |
|
visual I-PRESENT_ILLNESS |
|
(AV). I-PRESENT_ILLNESS |
|
Asimismo, I-PRESENT_ILLNESS |
|
comenta I-PRESENT_ILLNESS |
|
que I-PRESENT_ILLNESS |
|
lleva I-PRESENT_ILLNESS |
|
unos I-PRESENT_ILLNESS |
|
días I-PRESENT_ILLNESS |
|
notando I-PRESENT_ILLNESS |
|
molestias I-PRESENT_ILLNESS |
|
de I-PRESENT_ILLNESS |
|
manera I-PRESENT_ILLNESS |
|
alterna I-PRESENT_ILLNESS |
|
en I-PRESENT_ILLNESS |
|
uno I-PRESENT_ILLNESS |
|
y I-PRESENT_ILLNESS |
|
otro I-PRESENT_ILLNESS |
|
ojo. I-PRESENT_ILLNESS |
|
<EOS> B-FAMILY_HISTORY |
|
No I-FAMILY_HISTORY |
|
presenta I-FAMILY_HISTORY |
|
antecedentes I-FAMILY_HISTORY |
|
familiares I-FAMILY_HISTORY |
|
de I-FAMILY_HISTORY |
|
interés I-FAMILY_HISTORY |
|
y B-PAST_MEDICAL_HISTORY |
|
entre I-PAST_MEDICAL_HISTORY |
|
los I-PAST_MEDICAL_HISTORY |
|
personales I-PAST_MEDICAL_HISTORY |
|
destaca I-PAST_MEDICAL_HISTORY |
|
una I-PAST_MEDICAL_HISTORY |
|
cardiopatía I-PAST_MEDICAL_HISTORY |
|
isquémica I-PAST_MEDICAL_HISTORY |
|
hace I-PAST_MEDICAL_HISTORY |
|
3 I-PAST_MEDICAL_HISTORY |
|
años I-PAST_MEDICAL_HISTORY |
|
en I-PAST_MEDICAL_HISTORY |
|
tratamiento I-PAST_MEDICAL_HISTORY |
|
con: I-PAST_MEDICAL_HISTORY |
|
Pravastatina I-PAST_MEDICAL_HISTORY |
|
10 I-PAST_MEDICAL_HISTORY |
|
mg/24 I-PAST_MEDICAL_HISTORY |
|
horas, I-PAST_MEDICAL_HISTORY |
|
Atenolol I-PAST_MEDICAL_HISTORY |
|
50 I-PAST_MEDICAL_HISTORY |
|
mg/12 I-PAST_MEDICAL_HISTORY |
|
horas, I-PAST_MEDICAL_HISTORY |
|
Ranipril I-PAST_MEDICAL_HISTORY |
|
2, I-PAST_MEDICAL_HISTORY |
|
5 I-PAST_MEDICAL_HISTORY |
|
mg/12 I-PAST_MEDICAL_HISTORY |
|
horas, I-PAST_MEDICAL_HISTORY |
|
Acido I-PAST_MEDICAL_HISTORY |
|
acetilsalicílico I-PAST_MEDICAL_HISTORY |
|
100 I-PAST_MEDICAL_HISTORY |
|
mg/24 I-PAST_MEDICAL_HISTORY |
|
horas I-PAST_MEDICAL_HISTORY |
|
y I-PAST_MEDICAL_HISTORY |
|
Lorazepam I-PAST_MEDICAL_HISTORY |
|
1 I-PAST_MEDICAL_HISTORY |
|
mg/24 I-PAST_MEDICAL_HISTORY |
|
horas. I-PAST_MEDICAL_HISTORY |
|
<EOS> I-PAST_MEDICAL_HISTORY |
|
Como B-PRESENT_ILLNESS |
|
antecedente I-PRESENT_ILLNESS |
|
personal I-PRESENT_ILLNESS |
|
más I-PRESENT_ILLNESS |
|
próximo, I-PRESENT_ILLNESS |
|
señalar I-PRESENT_ILLNESS |
|
que I-PRESENT_ILLNESS |
|
dos I-PRESENT_ILLNESS |
|
semanas I-PRESENT_ILLNESS |
|
antes I-PRESENT_ILLNESS |
|
de I-PRESENT_ILLNESS |
|
empezar I-PRESENT_ILLNESS |
|
con I-PRESENT_ILLNESS |
|
los I-PRESENT_ILLNESS |
|
problemas I-PRESENT_ILLNESS |
|
oculares I-PRESENT_ILLNESS |
|
había I-PRESENT_ILLNESS |
|
sido I-PRESENT_ILLNESS |
|
ingresada I-PRESENT_ILLNESS |
|
en I-PRESENT_ILLNESS |
|
el I-PRESENT_ILLNESS |
|
servicio I-PRESENT_ILLNESS |
|
de I-PRESENT_ILLNESS |
|
medicina I-PRESENT_ILLNESS |
|
interna I-PRESENT_ILLNESS |
|
con I-PRESENT_ILLNESS |
|
el I-PRESENT_ILLNESS |
|
diagnóstico I-PRESENT_ILLNESS |
|
de I-PRESENT_ILLNESS |
|
Neumonía I-PRESENT_ILLNESS |
|
neumocócica I-PRESENT_ILLNESS |
|
en I-PRESENT_ILLNESS |
|
lóbulo I-PRESENT_ILLNESS |
|
superior I-PRESENT_ILLNESS |
|
derecho I-PRESENT_ILLNESS |
|
tratada I-PRESENT_ILLNESS |
|
con I-PRESENT_ILLNESS |
|
Moxifloxacino I-PRESENT_ILLNESS |
|
a I-PRESENT_ILLNESS |
|
dosis I-PRESENT_ILLNESS |
|
de I-PRESENT_ILLNESS |
|
400 I-PRESENT_ILLNESS |
|
mg/24 I-PRESENT_ILLNESS |
|
horas I-PRESENT_ILLNESS |
|
durante I-PRESENT_ILLNESS |
|
10 I-PRESENT_ILLNESS |
|
días, I-PRESENT_ILLNESS |
|
con I-PRESENT_ILLNESS |
|
buena I-PRESENT_ILLNESS |
|
respuesta. I-PRESENT_ILLNESS |
|
Tras I-PRESENT_ILLNESS |
|
el I-PRESENT_ILLNESS |
|
alta I-PRESENT_ILLNESS |
|
hospitalaria, I-PRESENT_ILLNESS |
|
ya I-PRESENT_ILLNESS |
|
sin I-PRESENT_ILLNESS |
|
tratamiento I-PRESENT_ILLNESS |
|
antibiótico, I-PRESENT_ILLNESS |
|
la I-PRESENT_ILLNESS |
|
paciente I-PRESENT_ILLNESS |
|
comienza I-PRESENT_ILLNESS |
|
a I-PRESENT_ILLNESS |
|
referir I-PRESENT_ILLNESS |
|
molestias I-PRESENT_ILLNESS |
|
oculares I-PRESENT_ILLNESS |
|
de I-PRESENT_ILLNESS |
|
manera I-PRESENT_ILLNESS |
|
alterna I-PRESENT_ILLNESS |
|
en I-PRESENT_ILLNESS |
|
AO. I-PRESENT_ILLNESS |
|
<EOS> I-PRESENT_ILLNESS |
|
En B-EXPLORATION |
|
la I-EXPLORATION |
|
exploración I-EXPLORATION |
|
oftalmológica I-EXPLORATION |
|
se I-EXPLORATION |
|
objetiva I-EXPLORATION |
|
una I-EXPLORATION |
|
AV I-EXPLORATION |
|
en I-EXPLORATION |
|
ojo I-EXPLORATION |
|
derecho I-EXPLORATION |
|
(OD) I-EXPLORATION |
|
de I-EXPLORATION |
|
0, I-EXPLORATION |
|
6 I-EXPLORATION |
|
que I-EXPLORATION |
|
mejora I-EXPLORATION |
|
a I-EXPLORATION |
|
0, I-EXPLORATION |
|
8 I-EXPLORATION |
|
con I-EXPLORATION |
|
corrección I-EXPLORATION |
|
y I-EXPLORATION |
|
en I-EXPLORATION |
|
el I-EXPLORATION |
|
ojo I-EXPLORATION |
|
izquierdo I-EXPLORATION |
|
(OI) I-EXPLORATION |
|
de I-EXPLORATION |
|
0, I-EXPLORATION |
|
3 I-EXPLORATION |
|
que I-EXPLORATION |
|
mejora I-EXPLORATION |
|
a I-EXPLORATION |
|
0, I-EXPLORATION |
|
6 I-EXPLORATION |
|
con I-EXPLORATION |
|
corrección. I-EXPLORATION |
|
<EOS> I-EXPLORATION |
|
En I-EXPLORATION |
|
el I-EXPLORATION |
|
segmento I-EXPLORATION |
|
anterior I-EXPLORATION |
|
destaca I-EXPLORATION |
|
una I-EXPLORATION |
|
reacción I-EXPLORATION |
|
inflamatoria I-EXPLORATION |
|
en I-EXPLORATION |
|
cámara I-EXPLORATION |
|
anterior I-EXPLORATION |
|
de I-EXPLORATION |
|
AO I-EXPLORATION |
|
(Fenómeno I-EXPLORATION |
|
de I-EXPLORATION |
|
tyndall I-EXPLORATION |
|
de I-EXPLORATION |
|
células I-EXPLORATION |
|
+1 I-EXPLORATION |
|
y I-EXPLORATION |
|
proteínas I-EXPLORATION |
|
+1), I-EXPLORATION |
|
y I-EXPLORATION |
|
una I-EXPLORATION |
|
fuerte I-EXPLORATION |
|
dispersión I-EXPLORATION |
|
de I-EXPLORATION |
|
pigmento I-EXPLORATION |
|
(+/++) I-EXPLORATION |
|
que I-EXPLORATION |
|
se I-EXPLORATION |
|
deposita I-EXPLORATION |
|
en I-EXPLORATION |
|
todas I-EXPLORATION |
|
las I-EXPLORATION |
|
estructuras: I-EXPLORATION |
|
en I-EXPLORATION |
|
el I-EXPLORATION |
|
endotelio I-EXPLORATION |
|
corneal I-EXPLORATION |
|
de I-EXPLORATION |
|
forma I-EXPLORATION |
|
difusa, I-EXPLORATION |
|
sobre I-EXPLORATION |
|
el I-EXPLORATION |
|
iris, I-EXPLORATION |
|
sinequias I-EXPLORATION |
|
posteriores I-EXPLORATION |
|
y I-EXPLORATION |
|
malla I-EXPLORATION |
|
trabecular. I-EXPLORATION |
|
<EOS> I-EXPLORATION |
|
La I-EXPLORATION |
|
tensión I-EXPLORATION |
|
ocular I-EXPLORATION |
|
era I-EXPLORATION |
|
de I-EXPLORATION |
|
9 I-EXPLORATION |
|
mm I-EXPLORATION |
|
Hg I-EXPLORATION |
|
en I-EXPLORATION |
|
OD I-EXPLORATION |
|
y I-EXPLORATION |
|
8 I-EXPLORATION |
|
mmHg I-EXPLORATION |
|
en I-EXPLORATION |
|
OI. I-EXPLORATION |
|
El I-EXPLORATION |
|
fondo I-EXPLORATION |
|
de I-EXPLORATION |
|
ojo, I-EXPLORATION |
|
bajo I-EXPLORATION |
|
midriasis I-EXPLORATION |
|
farmacológica, I-EXPLORATION |
|
era I-EXPLORATION |
|
normal, I-EXPLORATION |
|
y I-EXPLORATION |
|
no I-EXPLORATION |
|
se I-EXPLORATION |
|
apreció I-EXPLORATION |
|
reacción I-EXPLORATION |
|
inflamatoria I-EXPLORATION |
|
en I-EXPLORATION |
|
la I-EXPLORATION |
|
cámara I-EXPLORATION |
|
vítrea. I-EXPLORATION |
|
<EOS> I-EXPLORATION |
|
Se I-EXPLORATION |
|
realizó I-EXPLORATION |
|
una I-EXPLORATION |
|
historia I-EXPLORATION |
|
clínica, I-EXPLORATION |
|
dentro I-EXPLORATION |
|
del I-EXPLORATION |
|
protocolo I-EXPLORATION |
|
de I-EXPLORATION |
|
uveítis I-EXPLORATION |
|
seguido I-EXPLORATION |
|
en I-EXPLORATION |
|
nuestro I-EXPLORATION |
|
departamento, I-EXPLORATION |
|
que I-EXPLORATION |
|
incluyó I-EXPLORATION |
|
una I-EXPLORATION |
|
anamnesis I-EXPLORATION |
|
por I-EXPLORATION |
|
aparatos I-EXPLORATION |
|
y I-EXPLORATION |
|
la I-EXPLORATION |
|
solicitud I-EXPLORATION |
|
de I-EXPLORATION |
|
las I-EXPLORATION |
|
exploraciones I-EXPLORATION |
|
complementarias I-EXPLORATION |
|
dirigidas, I-EXPLORATION |
|
sistemático I-EXPLORATION |
|
de I-EXPLORATION |
|
sangre, I-EXPLORATION |
|
bioquímica, I-EXPLORATION |
|
VDRL, I-EXPLORATION |
|
FTA-abs I-EXPLORATION |
|
y I-EXPLORATION |
|
placa I-EXPLORATION |
|
de I-EXPLORATION |
|
tórax. I-EXPLORATION |
|
<EOS> I-EXPLORATION |
|
Se B-TREATMENT |
|
inició I-TREATMENT |
|
tratamiento I-TREATMENT |
|
con I-TREATMENT |
|
midriáticos I-TREATMENT |
|
y I-TREATMENT |
|
corticoides I-TREATMENT |
|
tópicos I-TREATMENT |
|
cediendo B-EXPLORATION |
|
el I-EXPLORATION |
|
cuadro I-EXPLORATION |
|
en I-EXPLORATION |
|
pocos I-EXPLORATION |
|
días, I-EXPLORATION |
|
manteniéndose, I-EXPLORATION |
|
en I-EXPLORATION |
|
las I-EXPLORATION |
|
sucesivas I-EXPLORATION |
|
revisiones, I-EXPLORATION |
|
la I-EXPLORATION |
|
presencia I-EXPLORATION |
|
de I-EXPLORATION |
|
pigmento I-EXPLORATION |
|
en I-EXPLORATION |
|
numerosas I-EXPLORATION |
|
estructuras I-EXPLORATION |
|
del I-EXPLORATION |
|
segmento I-EXPLORATION |
|
anterior I-EXPLORATION |
|
y I-EXPLORATION |
|
manteniendo I-EXPLORATION |
|
una I-EXPLORATION |
|
presión I-EXPLORATION |
|
intraocular I-EXPLORATION |
|
de I-EXPLORATION |
|
14 I-EXPLORATION |
|
mmHg I-EXPLORATION |
|
en I-EXPLORATION |
|
AO. I-EXPLORATION |
|
<EOS> I-EXPLORATION |
|
Las I-EXPLORATION |
|
exploraciones I-EXPLORATION |
|
complementarias I-EXPLORATION |
|
realizadas I-EXPLORATION |
|
no I-EXPLORATION |
|
detectaron I-EXPLORATION |
|
ninguna I-EXPLORATION |
|
alteración I-EXPLORATION |
|
significativa. I-EXPLORATION |
|
<EOS> I-EXPLORATION |
|
|
|
Mujer B-PRESENT_ILLNESS |
|
de I-PRESENT_ILLNESS |
|
18 I-PRESENT_ILLNESS |
|
años I-PRESENT_ILLNESS |
|
sin B-PAST_MEDICAL_HISTORY |
|
antecedentes I-PAST_MEDICAL_HISTORY |
|
personales I-PAST_MEDICAL_HISTORY |
|
de I-PAST_MEDICAL_HISTORY |
|
interés, I-PAST_MEDICAL_HISTORY |
|
que B-PRESENT_ILLNESS |
|
acudió I-PRESENT_ILLNESS |
|
a I-PRESENT_ILLNESS |
|
urgencias I-PRESENT_ILLNESS |
|
por I-PRESENT_ILLNESS |
|
cefalea I-PRESENT_ILLNESS |
|
holocraneal I-PRESENT_ILLNESS |
|
con I-PRESENT_ILLNESS |
|
fiebre I-PRESENT_ILLNESS |
|
y I-PRESENT_ILLNESS |
|
vómitos. I-PRESENT_ILLNESS |
|
<EOS> I-PRESENT_ILLNESS |
|
A B-EXPLORATION |
|
la I-EXPLORATION |
|
exploración I-EXPLORATION |
|
neurológica I-EXPLORATION |
|
presentaba I-EXPLORATION |
|
hipoestesia I-EXPLORATION |
|
de I-EXPLORATION |
|
miembro I-EXPLORATION |
|
superior I-EXPLORATION |
|
derecho I-EXPLORATION |
|
y I-EXPLORATION |
|
dudosa I-EXPLORATION |
|
rigidez I-EXPLORATION |
|
de I-EXPLORATION |
|
nuca, I-EXPLORATION |
|
sin I-EXPLORATION |
|
otros I-EXPLORATION |
|
signos I-EXPLORATION |
|
meníngeos. I-EXPLORATION |
|
<EOS> I-EXPLORATION |
|
La I-EXPLORATION |
|
tomografía I-EXPLORATION |
|
axial I-EXPLORATION |
|
computarizada I-EXPLORATION |
|
(TAC) I-EXPLORATION |
|
cerebral I-EXPLORATION |
|
era I-EXPLORATION |
|
normal, I-EXPLORATION |
|
el I-EXPLORATION |
|
análisis I-EXPLORATION |
|
del I-EXPLORATION |
|
líquido I-EXPLORATION |
|
cefalorraquídeo I-EXPLORATION |
|
(LCR) I-EXPLORATION |
|
mostró I-EXPLORATION |
|
hiperproteinorraquia, I-EXPLORATION |
|
hipoglucorraquia I-EXPLORATION |
|
y I-EXPLORATION |
|
pleocitosis I-EXPLORATION |
|
(98% I-EXPLORATION |
|
linfocitos). I-EXPLORATION |
|
Ante B-TREATMENT |
|
la I-TREATMENT |
|
sospecha I-TREATMENT |
|
de I-TREATMENT |
|
meningitis I-TREATMENT |
|
vírica I-TREATMENT |
|
o I-TREATMENT |
|
bacteriana I-TREATMENT |
|
decapitada, I-TREATMENT |
|
se I-TREATMENT |
|
instauró I-TREATMENT |
|
tratamiento I-TREATMENT |
|
intravenoso I-TREATMENT |
|
con I-TREATMENT |
|
aciclovir, I-TREATMENT |
|
ceftriaxona I-TREATMENT |
|
y I-TREATMENT |
|
ampicilina. I-TREATMENT |
|
<EOS> I-TREATMENT |
|
A B-EVOLUTION |
|
los I-EVOLUTION |
|
3 I-EVOLUTION |
|
días I-EVOLUTION |
|
presentó I-EVOLUTION |
|
disminución I-EVOLUTION |
|
de I-EVOLUTION |
|
conciencia, I-EVOLUTION |
|
midriasis I-EVOLUTION |
|
arreactiva I-EVOLUTION |
|
bilateral I-EVOLUTION |
|
y I-EVOLUTION |
|
parálisis I-EVOLUTION |
|
bilateral I-EVOLUTION |
|
de I-EVOLUTION |
|
los I-EVOLUTION |
|
pares I-EVOLUTION |
|
craneales I-EVOLUTION |
|
III, I-EVOLUTION |
|
IV, I-EVOLUTION |
|
VI, I-EVOLUTION |
|
VII, I-EVOLUTION |
|
IX I-EVOLUTION |
|
y I-EVOLUTION |
|
X. I-EVOLUTION |
|
La B-EXPLORATION |
|
resonancia I-EXPLORATION |
|
magnética I-EXPLORATION |
|
nuclear I-EXPLORATION |
|
(RMN) I-EXPLORATION |
|
mostró I-EXPLORATION |
|
realce I-EXPLORATION |
|
lepto I-EXPLORATION |
|
y I-EXPLORATION |
|
paquimeníngeo I-EXPLORATION |
|
e I-EXPLORATION |
|
hidrocefalia I-EXPLORATION |
|
tetraventricular. I-EXPLORATION |
|
A B-TREATMENT |
|
pesar I-TREATMENT |
|
de I-TREATMENT |
|
los I-TREATMENT |
|
resultados I-TREATMENT |
|
microbiológicos I-TREATMENT |
|
no I-TREATMENT |
|
concluyentes I-TREATMENT |
|
(hemocultivos, I-TREATMENT |
|
Mantoux, I-TREATMENT |
|
Tinción I-TREATMENT |
|
tinta I-TREATMENT |
|
china I-TREATMENT |
|
y I-TREATMENT |
|
Ziehl I-TREATMENT |
|
de I-TREATMENT |
|
LCR: I-TREATMENT |
|
todos I-TREATMENT |
|
negativos), I-TREATMENT |
|
y I-TREATMENT |
|
ante I-TREATMENT |
|
la I-TREATMENT |
|
sospecha I-TREATMENT |
|
de I-TREATMENT |
|
leptomeningitis I-TREATMENT |
|
tuberculosa I-TREATMENT |
|
se I-TREATMENT |
|
modificó I-TREATMENT |
|
el I-TREATMENT |
|
tratamiento, I-TREATMENT |
|
pautándose I-TREATMENT |
|
inicialmente I-TREATMENT |
|
isoniacida I-TREATMENT |
|
600 I-TREATMENT |
|
mg/día I-TREATMENT |
|
(más I-TREATMENT |
|
vitamina I-TREATMENT |
|
B6), I-TREATMENT |
|
etambutol I-TREATMENT |
|
22 I-TREATMENT |
|
mg/kg/día I-TREATMENT |
|
y I-TREATMENT |
|
rifampicina I-TREATMENT |
|
600 I-TREATMENT |
|
mg/día; I-TREATMENT |
|
a I-TREATMENT |
|
las I-TREATMENT |
|
48 I-TREATMENT |
|
horas I-TREATMENT |
|
se I-TREATMENT |
|
suspendió I-TREATMENT |
|
el I-TREATMENT |
|
etambutol I-TREATMENT |
|
y I-TREATMENT |
|
se I-TREATMENT |
|
añadió I-TREATMENT |
|
pirazinamida I-TREATMENT |
|
1, I-TREATMENT |
|
5 I-TREATMENT |
|
g/día, I-TREATMENT |
|
estreptomicina I-TREATMENT |
|
1g/día I-TREATMENT |
|
y I-TREATMENT |
|
dexametasona I-TREATMENT |
|
24 I-TREATMENT |
|
mg/día I-TREATMENT |
|
sustituyendo I-TREATMENT |
|
la I-TREATMENT |
|
ampicilina I-TREATMENT |
|
por I-TREATMENT |
|
cotrimoxazol. I-TREATMENT |
|
<EOS> I-TREATMENT |
|
A B-EVOLUTION |
|
los I-EVOLUTION |
|
12 I-EVOLUTION |
|
días I-EVOLUTION |
|
la I-EVOLUTION |
|
agudeza I-EVOLUTION |
|
visual I-EVOLUTION |
|
(AV) I-EVOLUTION |
|
bajó I-EVOLUTION |
|
a I-EVOLUTION |
|
amaurosis I-EVOLUTION |
|
bilateral I-EVOLUTION |
|
con I-EVOLUTION |
|
alucinaciones I-EVOLUTION |
|
visuales. I-EVOLUTION |
|
La B-EXPLORATION |
|
funduscopia I-EXPLORATION |
|
era I-EXPLORATION |
|
normal. I-EXPLORATION |
|
Los I-EXPLORATION |
|
potenciales I-EXPLORATION |
|
visuales I-EXPLORATION |
|
evocados I-EXPLORATION |
|
(PEV) I-EXPLORATION |
|
mostraron I-EXPLORATION |
|
una I-EXPLORATION |
|
onda I-EXPLORATION |
|
P100 I-EXPLORATION |
|
muy I-EXPLORATION |
|
degradada I-EXPLORATION |
|
con I-EXPLORATION |
|
latencia I-EXPLORATION |
|
muy I-EXPLORATION |
|
aumentada, I-EXPLORATION |
|
en I-EXPLORATION |
|
la I-EXPLORATION |
|
estimulación I-EXPLORATION |
|
mono I-EXPLORATION |
|
y I-EXPLORATION |
|
binocular. I-EXPLORATION |
|
<EOS> I-EXPLORATION |
|
El I-EXPLORATION |
|
diagnóstico I-EXPLORATION |
|
de I-EXPLORATION |
|
meningitis I-EXPLORATION |
|
tuberculosa I-EXPLORATION |
|
se I-EXPLORATION |
|
confirmó I-EXPLORATION |
|
mediante I-EXPLORATION |
|
cultivo I-EXPLORATION |
|
del I-EXPLORATION |
|
LCR I-EXPLORATION |
|
en I-EXPLORATION |
|
medio I-EXPLORATION |
|
Lowestein. I-EXPLORATION |
|
<EOS> I-EXPLORATION |
|
Durante B-TREATMENT |
|
6 I-TREATMENT |
|
meses I-TREATMENT |
|
se I-TREATMENT |
|
mantuvo I-TREATMENT |
|
el I-TREATMENT |
|
tratamiento I-TREATMENT |
|
tuberculostático I-TREATMENT |
|
(rifampicina I-TREATMENT |
|
y I-TREATMENT |
|
piridoxina) I-TREATMENT |
|
y I-TREATMENT |
|
dexametasona. I-TREATMENT |
|
<EOS> I-TREATMENT |
|
La B-EVOLUTION |
|
AV I-EVOLUTION |
|
mejoró I-EVOLUTION |
|
lentamente I-EVOLUTION |
|
y B-EXPLORATION |
|
al I-EXPLORATION |
|
año I-EXPLORATION |
|
presenta I-EXPLORATION |
|
la I-EXPLORATION |
|
siguiente I-EXPLORATION |
|
exploración: I-EXPLORATION |
|
AV I-EXPLORATION |
|
bilateral: I-EXPLORATION |
|
1/1, I-EXPLORATION |
|
leve I-EXPLORATION |
|
midriasis I-EXPLORATION |
|
reactiva, I-EXPLORATION |
|
sin I-EXPLORATION |
|
restricciones I-EXPLORATION |
|
en I-EXPLORATION |
|
la I-EXPLORATION |
|
motilidad I-EXPLORATION |
|
ocular I-EXPLORATION |
|
extrínseca I-EXPLORATION |
|
y I-EXPLORATION |
|
el I-EXPLORATION |
|
nervio I-EXPLORATION |
|
óptico I-EXPLORATION |
|
presenta I-EXPLORATION |
|
una I-EXPLORATION |
|
leve I-EXPLORATION |
|
palidez I-EXPLORATION |
|
papilar I-EXPLORATION |
|
sin I-EXPLORATION |
|
aumento I-EXPLORATION |
|
de I-EXPLORATION |
|
la I-EXPLORATION |
|
excavación. I-EXPLORATION |
|
<EOS> I-EXPLORATION |
|
La I-EXPLORATION |
|
perimetría I-EXPLORATION |
|
computarizada I-EXPLORATION |
|
en I-EXPLORATION |
|
ojo I-EXPLORATION |
|
derecho I-EXPLORATION |
|
muestra I-EXPLORATION |
|
una I-EXPLORATION |
|
reducción I-EXPLORATION |
|
concéntrica I-EXPLORATION |
|
con I-EXPLORATION |
|
respeto I-EXPLORATION |
|
de I-EXPLORATION |
|
los I-EXPLORATION |
|
10º I-EXPLORATION |
|
centrales, I-EXPLORATION |
|
y I-EXPLORATION |
|
en I-EXPLORATION |
|
ojo I-EXPLORATION |
|
izquierdo I-EXPLORATION |
|
una I-EXPLORATION |
|
reducción I-EXPLORATION |
|
concéntrica I-EXPLORATION |
|
en I-EXPLORATION |
|
hemicampo I-EXPLORATION |
|
temporal I-EXPLORATION |
|
y I-EXPLORATION |
|
parte I-EXPLORATION |
|
del I-EXPLORATION |
|
nasal. I-EXPLORATION |
|
Los I-EXPLORATION |
|
PVE I-EXPLORATION |
|
demuestran I-EXPLORATION |
|
una I-EXPLORATION |
|
notable I-EXPLORATION |
|
mejoría I-EXPLORATION |
|
de I-EXPLORATION |
|
la I-EXPLORATION |
|
onda I-EXPLORATION |
|
P100 I-EXPLORATION |
|
en I-EXPLORATION |
|
voltaje, I-EXPLORATION |
|
latencia I-EXPLORATION |
|
y I-EXPLORATION |
|
morfología. I-EXPLORATION |
|
<EOS> I-EXPLORATION |
|
|
|
Mujer B-PRESENT_ILLNESS |
|
de I-PRESENT_ILLNESS |
|
78 I-PRESENT_ILLNESS |
|
años, I-PRESENT_ILLNESS |
|
afáquica B-PAST_MEDICAL_HISTORY |
|
de I-PAST_MEDICAL_HISTORY |
|
ambos I-PAST_MEDICAL_HISTORY |
|
ojos I-PAST_MEDICAL_HISTORY |
|
tras I-PAST_MEDICAL_HISTORY |
|
haber I-PAST_MEDICAL_HISTORY |
|
sido I-PAST_MEDICAL_HISTORY |
|
intervenida I-PAST_MEDICAL_HISTORY |
|
de I-PAST_MEDICAL_HISTORY |
|
cataratas I-PAST_MEDICAL_HISTORY |
|
veinte I-PAST_MEDICAL_HISTORY |
|
años I-PAST_MEDICAL_HISTORY |
|
antes, I-PAST_MEDICAL_HISTORY |
|
que B-PRESENT_ILLNESS |
|
desarrolló I-PRESENT_ILLNESS |
|
un I-PRESENT_ILLNESS |
|
glaucoma I-PRESENT_ILLNESS |
|
secundario I-PRESENT_ILLNESS |
|
en I-PRESENT_ILLNESS |
|
ojo I-PRESENT_ILLNESS |
|
derecho I-PRESENT_ILLNESS |
|
(OD). I-PRESENT_ILLNESS |
|
Ante B-TREATMENT |
|
la I-TREATMENT |
|
falta I-TREATMENT |
|
de I-TREATMENT |
|
control I-TREATMENT |
|
de I-TREATMENT |
|
su I-TREATMENT |
|
presión I-TREATMENT |
|
intraocular I-TREATMENT |
|
con I-TREATMENT |
|
el I-TREATMENT |
|
tratamiento I-TREATMENT |
|
médico, I-TREATMENT |
|
se I-TREATMENT |
|
decidió I-TREATMENT |
|
la I-TREATMENT |
|
implantación I-TREATMENT |
|
de I-TREATMENT |
|
un I-TREATMENT |
|
dispositivo I-TREATMENT |
|
de I-TREATMENT |
|
drenaje I-TREATMENT |
|
valvulado I-TREATMENT |
|
de I-TREATMENT |
|
Ahmed, I-TREATMENT |
|
con I-TREATMENT |
|
parche I-TREATMENT |
|
de I-TREATMENT |
|
esclera I-TREATMENT |
|
recubriendo I-TREATMENT |
|
el I-TREATMENT |
|
trayecto I-TREATMENT |
|
extraocular I-TREATMENT |
|
del I-TREATMENT |
|
tubo I-TREATMENT |
|
y I-TREATMENT |
|
el I-TREATMENT |
|
extremo I-TREATMENT |
|
del I-TREATMENT |
|
mismo I-TREATMENT |
|
localizado I-TREATMENT |
|
en I-TREATMENT |
|
cámara I-TREATMENT |
|
anterior. I-TREATMENT |
|
El B-EVOLUTION |
|
postoperatorio I-EVOLUTION |
|
evolucionó I-EVOLUTION |
|
favorablemente. I-EVOLUTION |
|
La I-EVOLUTION |
|
agudeza I-EVOLUTION |
|
visual I-EVOLUTION |
|
(AV) I-EVOLUTION |
|
postoperatoria I-EVOLUTION |
|
era I-EVOLUTION |
|
de I-EVOLUTION |
|
0, I-EVOLUTION |
|
5 I-EVOLUTION |
|
en I-EVOLUTION |
|
OD I-EVOLUTION |
|
y I-EVOLUTION |
|
0, I-EVOLUTION |
|
2 I-EVOLUTION |
|
en I-EVOLUTION |
|
ojo I-EVOLUTION |
|
izquierdo I-EVOLUTION |
|
(OI). I-EVOLUTION |
|
La B-TREATMENT |
|
presión I-TREATMENT |
|
intraocular I-TREATMENT |
|
en I-TREATMENT |
|
OD I-TREATMENT |
|
era I-TREATMENT |
|
de I-TREATMENT |
|
12 I-TREATMENT |
|
mmHg I-TREATMENT |
|
en I-TREATMENT |
|
tratamiento I-TREATMENT |
|
con I-TREATMENT |
|
tartrato I-TREATMENT |
|
de I-TREATMENT |
|
brimonidina I-TREATMENT |
|
0, I-TREATMENT |
|
2%. I-TREATMENT |
|
El I-TREATMENT |
|
cuerpo I-TREATMENT |
|
valvular I-TREATMENT |
|
estaba I-TREATMENT |
|
situado I-TREATMENT |
|
en I-TREATMENT |
|
el I-TREATMENT |
|
cuadrante I-TREATMENT |
|
temporal I-TREATMENT |
|
superior I-TREATMENT |
|
y I-TREATMENT |
|
la I-TREATMENT |
|
ampolla I-TREATMENT |
|
era I-TREATMENT |
|
amplia I-TREATMENT |
|
y I-TREATMENT |
|
de I-TREATMENT |
|
paredes I-TREATMENT |
|
finas. I-TREATMENT |
|
El I-TREATMENT |
|
tubo I-TREATMENT |
|
quedaba I-TREATMENT |
|
situado I-TREATMENT |
|
en I-TREATMENT |
|
cámara I-TREATMENT |
|
anterior I-TREATMENT |
|
y I-TREATMENT |
|
libre I-TREATMENT |
|
de I-TREATMENT |
|
vítreo. I-TREATMENT |
|
Acudió B-EVOLUTION |
|
a I-EVOLUTION |
|
urgencias I-EVOLUTION |
|
nueve I-EVOLUTION |
|
meses I-EVOLUTION |
|
tras I-EVOLUTION |
|
la I-EVOLUTION |
|
cirugía I-EVOLUTION |
|
siendo I-EVOLUTION |
|
diagnosticada I-EVOLUTION |
|
de I-EVOLUTION |
|
conjuntivitis I-EVOLUTION |
|
aguda I-EVOLUTION |
|
en I-EVOLUTION |
|
el I-EVOLUTION |
|
OD, I-EVOLUTION |
|
se B-TREATMENT |
|
instauró I-TREATMENT |
|
tratamiento I-TREATMENT |
|
con I-TREATMENT |
|
medidas I-TREATMENT |
|
higiénicas I-TREATMENT |
|
y I-TREATMENT |
|
colirio I-TREATMENT |
|
de I-TREATMENT |
|
tobramicina I-TREATMENT |
|
1 I-TREATMENT |
|
gota/8 I-TREATMENT |
|
horas I-TREATMENT |
|
(Tobrex I-TREATMENT |
|
solución I-TREATMENT |
|
Gotas I-TREATMENT |
|
oft. I-TREATMENT |
|
0, I-TREATMENT |
|
3%; I-TREATMENT |
|
Alcon I-TREATMENT |
|
Cusi; I-TREATMENT |
|
Barcelona; I-TREATMENT |
|
España) I-TREATMENT |
|
y I-TREATMENT |
|
lágrimas I-TREATMENT |
|
artificiales I-TREATMENT |
|
a I-TREATMENT |
|
demanda. I-TREATMENT |
|
Cuatro B-EVOLUTION |
|
días I-EVOLUTION |
|
más I-EVOLUTION |
|
tarde I-EVOLUTION |
|
acudió I-EVOLUTION |
|
a I-EVOLUTION |
|
revisión I-EVOLUTION |
|
presentando I-EVOLUTION |
|
una I-EVOLUTION |
|
AV I-EVOLUTION |
|
de I-EVOLUTION |
|
movimiento I-EVOLUTION |
|
de I-EVOLUTION |
|
manos. I-EVOLUTION |
|
En B-EXPLORATION |
|
la I-EXPLORATION |
|
biomicroscopía I-EXPLORATION |
|
presentaba I-EXPLORATION |
|
hiperemia I-EXPLORATION |
|
3-4 I-EXPLORATION |
|
+, I-EXPLORATION |
|
blebitis, I-EXPLORATION |
|
no I-EXPLORATION |
|
seidel, I-EXPLORATION |
|
edema I-EXPLORATION |
|
corneal I-EXPLORATION |
|
difuso I-EXPLORATION |
|
de I-EXPLORATION |
|
3+, I-EXPLORATION |
|
tyndall I-EXPLORATION |
|
4+, I-EXPLORATION |
|
plastrón I-EXPLORATION |
|
de I-EXPLORATION |
|
fibrina I-EXPLORATION |
|
en I-EXPLORATION |
|
cámara I-EXPLORATION |
|
anterior, I-EXPLORATION |
|
no I-EXPLORATION |
|
hipopion I-EXPLORATION |
|
y I-EXPLORATION |
|
PIO I-EXPLORATION |
|
de I-EXPLORATION |
|
35 I-EXPLORATION |
|
mm I-EXPLORATION |
|
Hg. I-EXPLORATION |
|
La I-EXPLORATION |
|
conjuntiva I-EXPLORATION |
|
que I-EXPLORATION |
|
recubría I-EXPLORATION |
|
el I-EXPLORATION |
|
tubo I-EXPLORATION |
|
y I-EXPLORATION |
|
la I-EXPLORATION |
|
cápsula I-EXPLORATION |
|
filtrante I-EXPLORATION |
|
parecía I-EXPLORATION |
|
íntegra. I-EXPLORATION |
|
El I-EXPLORATION |
|
fondo I-EXPLORATION |
|
de I-EXPLORATION |
|
ojo I-EXPLORATION |
|
no I-EXPLORATION |
|
se I-EXPLORATION |
|
visualizaba I-EXPLORATION |
|
por I-EXPLORATION |
|
opacidad I-EXPLORATION |
|
de I-EXPLORATION |
|
medios. I-EXPLORATION |
|
En I-EXPLORATION |
|
la I-EXPLORATION |
|
ecografía I-EXPLORATION |
|
aparecían I-EXPLORATION |
|
ecos I-EXPLORATION |
|
de I-EXPLORATION |
|
baja I-EXPLORATION |
|
densidad, I-EXPLORATION |
|
sin I-EXPLORATION |
|
signos I-EXPLORATION |
|
de I-EXPLORATION |
|
desprendimiento I-EXPLORATION |
|
de I-EXPLORATION |
|
retina. I-EXPLORATION |
|
Ante B-TREATMENT |
|
el I-TREATMENT |
|
diagnóstico I-TREATMENT |
|
de I-TREATMENT |
|
una I-TREATMENT |
|
endoftalmitis I-TREATMENT |
|
aguda I-TREATMENT |
|
tardía, I-TREATMENT |
|
se I-TREATMENT |
|
decidió I-TREATMENT |
|
iniciar I-TREATMENT |
|
el I-TREATMENT |
|
protocolo I-TREATMENT |
|
existente I-TREATMENT |
|
en I-TREATMENT |
|
el I-TREATMENT |
|
hospital, I-TREATMENT |
|
con I-TREATMENT |
|
la I-TREATMENT |
|
obtención I-TREATMENT |
|
de I-TREATMENT |
|
muestras I-TREATMENT |
|
de I-TREATMENT |
|
humor I-TREATMENT |
|
acuoso I-TREATMENT |
|
y I-TREATMENT |
|
vítreo, I-TREATMENT |
|
y I-TREATMENT |
|
tratamiento I-TREATMENT |
|
intravenoso I-TREATMENT |
|
a I-TREATMENT |
|
base I-TREATMENT |
|
de I-TREATMENT |
|
ceftazidima I-TREATMENT |
|
1 I-TREATMENT |
|
gramo/8 I-TREATMENT |
|
horas I-TREATMENT |
|
y I-TREATMENT |
|
vancomicina I-TREATMENT |
|
1 I-TREATMENT |
|
gramo/12 I-TREATMENT |
|
horas, I-TREATMENT |
|
inyección I-TREATMENT |
|
intravítrea I-TREATMENT |
|
de I-TREATMENT |
|
ceftazidima I-TREATMENT |
|
2, I-TREATMENT |
|
25 I-TREATMENT |
|
mg/0, I-TREATMENT |
|
1 I-TREATMENT |
|
ml I-TREATMENT |
|
y I-TREATMENT |
|
vancomicina I-TREATMENT |
|
1 I-TREATMENT |
|
mg/0, I-TREATMENT |
|
1 I-TREATMENT |
|
ml I-TREATMENT |
|
y I-TREATMENT |
|
colirio I-TREATMENT |
|
tópico I-TREATMENT |
|
reforzado I-TREATMENT |
|
50 I-TREATMENT |
|
mg/ml I-TREATMENT |
|
de I-TREATMENT |
|
vancomicina I-TREATMENT |
|
y I-TREATMENT |
|
ceftazidima I-TREATMENT |
|
cada I-TREATMENT |
|
hora. I-TREATMENT |
|
A B-EXPLORATION |
|
las I-EXPLORATION |
|
48 I-EXPLORATION |
|
horas I-EXPLORATION |
|
el I-EXPLORATION |
|
resultado I-EXPLORATION |
|
del I-EXPLORATION |
|
cultivo I-EXPLORATION |
|
fue I-EXPLORATION |
|
Haemophilus I-EXPLORATION |
|
influenzae I-EXPLORATION |
|
resistente I-EXPLORATION |
|
a I-EXPLORATION |
|
vancomicina I-EXPLORATION |
|
y I-EXPLORATION |
|
sensible I-EXPLORATION |
|
a I-EXPLORATION |
|
betalactámicos, I-EXPLORATION |
|
quinolonas, I-EXPLORATION |
|
rifamicina, I-EXPLORATION |
|
aminoglicósidos I-EXPLORATION |
|
y I-EXPLORATION |
|
tetraciclinas I-EXPLORATION |
|
por B-TREATMENT |
|
lo I-TREATMENT |
|
que I-TREATMENT |
|
se I-TREATMENT |
|
suspendió I-TREATMENT |
|
el I-TREATMENT |
|
tratamiento I-TREATMENT |
|
con I-TREATMENT |
|
vancomicina I-TREATMENT |
|
y I-TREATMENT |
|
se I-TREATMENT |
|
añadió I-TREATMENT |
|
una I-TREATMENT |
|
quinolona I-TREATMENT |
|
intravenosa I-TREATMENT |
|
y I-TREATMENT |
|
tópica, I-TREATMENT |
|
además I-TREATMENT |
|
de I-TREATMENT |
|
una I-TREATMENT |
|
nueva I-TREATMENT |
|
inyección I-TREATMENT |
|
intravítrea I-TREATMENT |
|
de I-TREATMENT |
|
ceftazidima I-TREATMENT |
|
y I-TREATMENT |
|
decadrán. I-TREATMENT |
|
A I-TREATMENT |
|
las I-TREATMENT |
|
72 I-TREATMENT |
|
horas, I-TREATMENT |
|
y I-TREATMENT |
|
ante I-TREATMENT |
|
la I-TREATMENT |
|
mala I-TREATMENT |
|
evolución, I-TREATMENT |
|
se I-TREATMENT |
|
decidió I-TREATMENT |
|
la I-TREATMENT |
|
retirada I-TREATMENT |
|
del I-TREATMENT |
|
dispositivo I-TREATMENT |
|
de I-TREATMENT |
|
drenaje, I-TREATMENT |
|
lavado I-TREATMENT |
|
de I-TREATMENT |
|
la I-TREATMENT |
|
cámara I-TREATMENT |
|
anterior, I-TREATMENT |
|
e I-TREATMENT |
|
inyección I-TREATMENT |
|
de I-TREATMENT |
|
ceftazidima I-TREATMENT |
|
subconjuntival I-TREATMENT |
|
e I-TREATMENT |
|
intravítrea. I-TREATMENT |
|
La I-TREATMENT |
|
mala I-TREATMENT |
|
visualización I-TREATMENT |
|
desestimó I-TREATMENT |
|
la I-TREATMENT |
|
práctica I-TREATMENT |
|
de I-TREATMENT |
|
vitrectomía. I-TREATMENT |
|
A I-TREATMENT |
|
los I-TREATMENT |
|
cuatro I-TREATMENT |
|
días, I-TREATMENT |
|
la I-TREATMENT |
|
AV I-TREATMENT |
|
era I-TREATMENT |
|
de I-TREATMENT |
|
no I-TREATMENT |
|
percepción I-TREATMENT |
|
de I-TREATMENT |
|
luz I-TREATMENT |
|
por I-TREATMENT |
|
lo I-TREATMENT |
|
que I-TREATMENT |
|
se I-TREATMENT |
|
decidió I-TREATMENT |
|
eviscerar. I-TREATMENT |
|
<EOS> I-TREATMENT |
|
|
|
Varón B-PRESENT_ILLNESS |
|
de I-PRESENT_ILLNESS |
|
36 I-PRESENT_ILLNESS |
|
años I-PRESENT_ILLNESS |
|
de I-PRESENT_ILLNESS |
|
edad, I-PRESENT_ILLNESS |
|
con B-PAST_MEDICAL_HISTORY |
|
antecedente I-PAST_MEDICAL_HISTORY |
|
de I-PAST_MEDICAL_HISTORY |
|
ser I-PAST_MEDICAL_HISTORY |
|
bebedor I-PAST_MEDICAL_HISTORY |
|
de I-PAST_MEDICAL_HISTORY |
|
350 I-PAST_MEDICAL_HISTORY |
|
gr/alcohol/día, I-PAST_MEDICAL_HISTORY |
|
fumador I-PAST_MEDICAL_HISTORY |
|
de I-PAST_MEDICAL_HISTORY |
|
1 I-PAST_MEDICAL_HISTORY |
|
cajetilla/día, I-PAST_MEDICAL_HISTORY |
|
ExUDVP I-PAST_MEDICAL_HISTORY |
|
(heroína I-PAST_MEDICAL_HISTORY |
|
y I-PAST_MEDICAL_HISTORY |
|
cocaína), I-PAST_MEDICAL_HISTORY |
|
VHB I-PAST_MEDICAL_HISTORY |
|
+, I-PAST_MEDICAL_HISTORY |
|
VHC I-PAST_MEDICAL_HISTORY |
|
+, I-PAST_MEDICAL_HISTORY |
|
VIH I-PAST_MEDICAL_HISTORY |
|
-, I-PAST_MEDICAL_HISTORY |
|
y I-PAST_MEDICAL_HISTORY |
|
hepatitis I-PAST_MEDICAL_HISTORY |
|
crónica I-PAST_MEDICAL_HISTORY |
|
multifactorial I-PAST_MEDICAL_HISTORY |
|
en I-PAST_MEDICAL_HISTORY |
|
estadio I-PAST_MEDICAL_HISTORY |
|
A I-PAST_MEDICAL_HISTORY |
|
de I-PAST_MEDICAL_HISTORY |
|
Child I-PAST_MEDICAL_HISTORY |
|
sin I-PAST_MEDICAL_HISTORY |
|
datos I-PAST_MEDICAL_HISTORY |
|
de I-PAST_MEDICAL_HISTORY |
|
hipertensión I-PAST_MEDICAL_HISTORY |
|
portal. I-PAST_MEDICAL_HISTORY |
|
Acude B-PRESENT_ILLNESS |
|
al I-PRESENT_ILLNESS |
|
servicio I-PRESENT_ILLNESS |
|
de I-PRESENT_ILLNESS |
|
urgencias I-PRESENT_ILLNESS |
|
de I-PRESENT_ILLNESS |
|
nuestro I-PRESENT_ILLNESS |
|
hospital I-PRESENT_ILLNESS |
|
por I-PRESENT_ILLNESS |
|
una I-PRESENT_ILLNESS |
|
pérdida I-PRESENT_ILLNESS |
|
brusca I-PRESENT_ILLNESS |
|
e I-PRESENT_ILLNESS |
|
importante I-PRESENT_ILLNESS |
|
de I-PRESENT_ILLNESS |
|
la I-PRESENT_ILLNESS |
|
AV I-PRESENT_ILLNESS |
|
de I-PRESENT_ILLNESS |
|
varias I-PRESENT_ILLNESS |
|
horas I-PRESENT_ILLNESS |
|
de I-PRESENT_ILLNESS |
|
evolución. I-PRESENT_ILLNESS |
|
<EOS> I-PRESENT_ILLNESS |
|
El B-EXPLORATION |
|
estudio I-EXPLORATION |
|
oftalmológico I-EXPLORATION |
|
mostraba I-EXPLORATION |
|
una I-EXPLORATION |
|
AV I-EXPLORATION |
|
de I-EXPLORATION |
|
movimiento I-EXPLORATION |
|
de I-EXPLORATION |
|
manos I-EXPLORATION |
|
en I-EXPLORATION |
|
ambos I-EXPLORATION |
|
ojos I-EXPLORATION |
|
(AO), I-EXPLORATION |
|
con I-EXPLORATION |
|
un I-EXPLORATION |
|
fondo I-EXPLORATION |
|
de I-EXPLORATION |
|
ojo I-EXPLORATION |
|
con I-EXPLORATION |
|
infiltrados I-EXPLORATION |
|
en I-EXPLORATION |
|
polo I-EXPLORATION |
|
posterior I-EXPLORATION |
|
y I-EXPLORATION |
|
desprendimiento I-EXPLORATION |
|
seroso I-EXPLORATION |
|
macular. I-EXPLORATION |
|
El I-EXPLORATION |
|
resto I-EXPLORATION |
|
de I-EXPLORATION |
|
la I-EXPLORATION |
|
exploración I-EXPLORATION |
|
oftalmológica I-EXPLORATION |
|
era I-EXPLORATION |
|
normal. I-EXPLORATION |
|
Además I-EXPLORATION |
|
presentaba I-EXPLORATION |
|
fiebre I-EXPLORATION |
|
de I-EXPLORATION |
|
38, I-EXPLORATION |
|
4ºC I-EXPLORATION |
|
y I-EXPLORATION |
|
discreto I-EXPLORATION |
|
dolor I-EXPLORATION |
|
abdominal I-EXPLORATION |
|
a I-EXPLORATION |
|
la I-EXPLORATION |
|
palpación I-EXPLORATION |
|
con I-EXPLORATION |
|
hepatomegalia I-EXPLORATION |
|
de I-EXPLORATION |
|
dos I-EXPLORATION |
|
traveses I-EXPLORATION |
|
de I-EXPLORATION |
|
dedo. I-EXPLORATION |
|
<EOS> I-EXPLORATION |
|
Ante B-DERIVED_FROM/TO |
|
la I-DERIVED_FROM/TO |
|
sospecha I-DERIVED_FROM/TO |
|
de I-DERIVED_FROM/TO |
|
una I-DERIVED_FROM/TO |
|
pancreatitis I-DERIVED_FROM/TO |
|
aguda I-DERIVED_FROM/TO |
|
es I-DERIVED_FROM/TO |
|
derivado I-DERIVED_FROM/TO |
|
al I-DERIVED_FROM/TO |
|
Servicio I-DERIVED_FROM/TO |
|
de I-DERIVED_FROM/TO |
|
Medicina I-DERIVED_FROM/TO |
|
Interna, I-DERIVED_FROM/TO |
|
que B-EXPLORATION |
|
confirmada I-EXPLORATION |
|
el I-EXPLORATION |
|
diagnóstico I-EXPLORATION |
|
tras I-EXPLORATION |
|
los I-EXPLORATION |
|
estudios I-EXPLORATION |
|
de I-EXPLORATION |
|
laboratorio: I-EXPLORATION |
|
Leucocitos I-EXPLORATION |
|
12, I-EXPLORATION |
|
4 I-EXPLORATION |
|
(4, I-EXPLORATION |
|
8-10, I-EXPLORATION |
|
8 I-EXPLORATION |
|
x103 I-EXPLORATION |
|
ul); I-EXPLORATION |
|
Neutrófilos I-EXPLORATION |
|
88% I-EXPLORATION |
|
(42,2-75,2); I-EXPLORATION |
|
Volumen I-EXPLORATION |
|
Corpuscular I-EXPLORATION |
|
Medio I-EXPLORATION |
|
111 I-EXPLORATION |
|
fl I-EXPLORATION |
|
(85,9-95,9); I-EXPLORATION |
|
Bilirrubina I-EXPLORATION |
|
total I-EXPLORATION |
|
8, I-EXPLORATION |
|
23 I-EXPLORATION |
|
mg/dl I-EXPLORATION |
|
(0,2-1,0); I-EXPLORATION |
|
Amilasa I-EXPLORATION |
|
1.523 I-EXPLORATION |
|
u/l I-EXPLORATION |
|
(55-201); I-EXPLORATION |
|
GOT I-EXPLORATION |
|
200 I-EXPLORATION |
|
u/l I-EXPLORATION |
|
(5-45); I-EXPLORATION |
|
GPT I-EXPLORATION |
|
227 I-EXPLORATION |
|
u/l I-EXPLORATION |
|
(5-45); I-EXPLORATION |
|
GGT I-EXPLORATION |
|
1.346 I-EXPLORATION |
|
u/l I-EXPLORATION |
|
(3-52); I-EXPLORATION |
|
Fosfatasa I-EXPLORATION |
|
Alcalina I-EXPLORATION |
|
1.159 I-EXPLORATION |
|
u/l I-EXPLORATION |
|
(98-295); I-EXPLORATION |
|
Fibrinógeno I-EXPLORATION |
|
157 I-EXPLORATION |
|
mg/dl I-EXPLORATION |
|
(200-400) I-EXPLORATION |
|
y I-EXPLORATION |
|
de I-EXPLORATION |
|
imagen I-EXPLORATION |
|
[tomografía I-EXPLORATIONaxial I-EXPLORATIONcomputerizada I-EXPLORATION(TAC) I-EXPLORATIONy I-EXPLORATIONecografía I-EXPLORATIONabdominales I-EXPLORATIONque I-EXPLORATIONmuestran I-EXPLORATIONhepatopatía I-EXPLORATIONgrasa I-EXPLORATIONy I-EXPLORATIONinfiltración I-EXPLORATIONdel I-EXPLORATIONtejido I-EXPLORATIONperipancreático, I-EXPLORATIONespecialmente I-EXPLORATIONa I-EXPLORATIONla I-EXPLORATIONaltura I-EXPLORATIONde I-EXPLORATIONla I-EXPLORATIONcola I-EXPLORATIONdel I-EXPLORATIONpáncreas, I-EXPLORATIONdonde I-EXPLORATIONla I-EXPLORATIONinfiltración I-EXPLORATIONcontinúa I-EXPLORATIONpor I-EXPLORATIONel I-EXPLORATIONespacio I-EXPLORATIONpararrenal I-EXPLORATIONanterior I-EXPLORATIONizquierdo]. I-EXPLORATION |
|
La I-EXPLORATION |
|
angiografía I-EXPLORATION |
|
fluoresceínica I-EXPLORATION |
|
mostraba I-EXPLORATION |
|
inicialmente I-EXPLORATION |
|
áreas I-EXPLORATION |
|
de I-EXPLORATION |
|
no I-EXPLORATION |
|
perfusión I-EXPLORATION |
|
capilar, I-EXPLORATION |
|
que I-EXPLORATION |
|
se I-EXPLORATION |
|
correspondían I-EXPLORATION |
|
con I-EXPLORATION |
|
la I-EXPLORATION |
|
presencia I-EXPLORATION |
|
de I-EXPLORATION |
|
los I-EXPLORATION |
|
exudados, I-EXPLORATION |
|
seguidas I-EXPLORATION |
|
de I-EXPLORATION |
|
difusión I-EXPLORATION |
|
en I-EXPLORATION |
|
tiempos I-EXPLORATION |
|
tardíos I-EXPLORATION |
|
y I-EXPLORATION |
|
efectos I-EXPLORATION |
|
pantalla I-EXPLORATION |
|
provocados I-EXPLORATION |
|
por I-EXPLORATION |
|
las I-EXPLORATION |
|
hemorragias I-EXPLORATION |
|
retinianas. I-EXPLORATION |
|
La B-TREATMENT |
|
resolución I-TREATMENT |
|
del I-TREATMENT |
|
cuadro I-TREATMENT |
|
digestivo I-TREATMENT |
|
fue I-TREATMENT |
|
favorable I-TREATMENT |
|
con I-TREATMENT |
|
tratamiento I-TREATMENT |
|
médico I-TREATMENT |
|
mediante I-TREATMENT |
|
sueroterapia, I-TREATMENT |
|
dieta I-TREATMENT |
|
absoluta I-TREATMENT |
|
y I-TREATMENT |
|
antibioticoterapia, I-TREATMENT |
|
con B-EVOLUTION |
|
rápida I-EVOLUTION |
|
mejoría I-EVOLUTION |
|
de I-EVOLUTION |
|
la I-EVOLUTION |
|
sintomatología I-EVOLUTION |
|
clínica I-EVOLUTION |
|
e I-EVOLUTION |
|
importante I-EVOLUTION |
|
mejoría I-EVOLUTION |
|
de I-EVOLUTION |
|
la I-EVOLUTION |
|
analítica I-EVOLUTION |
|
a I-EVOLUTION |
|
los I-EVOLUTION |
|
dos I-EVOLUTION |
|
semanas, I-EVOLUTION |
|
aunque B-EXPLORATION |
|
un I-EXPLORATION |
|
mes I-EXPLORATION |
|
después I-EXPLORATION |
|
presenta I-EXPLORATION |
|
una I-EXPLORATION |
|
encefalopatía I-EXPLORATION |
|
de I-EXPLORATION |
|
Wernicke I-EXPLORATION |
|
con I-EXPLORATION |
|
una I-EXPLORATION |
|
TAC I-EXPLORATION |
|
craneal I-EXPLORATION |
|
normal. I-EXPLORATION |
|
<EOS> I-EXPLORATION |
|
A B-EVOLUTION |
|
los I-EVOLUTION |
|
dos I-EVOLUTION |
|
meses I-EVOLUTION |
|
el I-EVOLUTION |
|
paciente I-EVOLUTION |
|
había I-EVOLUTION |
|
recuperado I-EVOLUTION |
|
una I-EVOLUTION |
|
AV I-EVOLUTION |
|
de I-EVOLUTION |
|
1 I-EVOLUTION |
|
en I-EVOLUTION |
|
AO I-EVOLUTION |
|
y I-EVOLUTION |
|
el I-EVOLUTION |
|
estudio I-EVOLUTION |
|
de I-EVOLUTION |
|
fondo I-EVOLUTION |
|
de I-EVOLUTION |
|
ojo I-EVOLUTION |
|
solo I-EVOLUTION |
|
mostraba I-EVOLUTION |
|
algún I-EVOLUTION |
|
pigmento I-EVOLUTION |
|
residual. I-EVOLUTION |
|
<EOS> I-EVOLUTION |
|
|
|
Mujer B-PRESENT_ILLNESS |
|
de I-PRESENT_ILLNESS |
|
58 I-PRESENT_ILLNESS |
|
años I-PRESENT_ILLNESS |
|
que I-PRESENT_ILLNESS |
|
acude I-PRESENT_ILLNESS |
|
de I-PRESENT_ILLNESS |
|
urgencia I-PRESENT_ILLNESS |
|
a I-PRESENT_ILLNESS |
|
nuestras I-PRESENT_ILLNESS |
|
consultas I-PRESENT_ILLNESS |
|
por I-PRESENT_ILLNESS |
|
dolor I-PRESENT_ILLNESS |
|
ocular I-PRESENT_ILLNESS |
|
unilateral I-PRESENT_ILLNESS |
|
de I-PRESENT_ILLNESS |
|
unas I-PRESENT_ILLNESS |
|
horas I-PRESENT_ILLNESS |
|
de I-PRESENT_ILLNESS |
|
evolución I-PRESENT_ILLNESS |
|
acompañado I-PRESENT_ILLNESS |
|
de I-PRESENT_ILLNESS |
|
cierto I-PRESENT_ILLNESS |
|
grado I-PRESENT_ILLNESS |
|
de I-PRESENT_ILLNESS |
|
disminución I-PRESENT_ILLNESS |
|
de I-PRESENT_ILLNESS |
|
agudeza I-PRESENT_ILLNESS |
|
visual. I-PRESENT_ILLNESS |
|
A B-EXPLORATION |
|
la I-EXPLORATION |
|
exploración I-EXPLORATION |
|
presenta I-EXPLORATION |
|
inyección I-EXPLORATION |
|
ciliar, I-EXPLORATION |
|
midriasis I-EXPLORATION |
|
media I-EXPLORATION |
|
arreactiva I-EXPLORATION |
|
y I-EXPLORATION |
|
una I-EXPLORATION |
|
presión I-EXPLORATION |
|
intraocular I-EXPLORATION |
|
de I-EXPLORATION |
|
53 I-EXPLORATION |
|
mm I-EXPLORATION |
|
Hg. I-EXPLORATION |
|
Ante B-EVOLUTION |
|
este I-EVOLUTION |
|
cuadro I-EVOLUTION |
|
se I-EVOLUTION |
|
establece I-EVOLUTION |
|
el I-EVOLUTION |
|
diagnóstico I-EVOLUTION |
|
presuntivo I-EVOLUTION |
|
de I-EVOLUTION |
|
ataque I-EVOLUTION |
|
agudo I-EVOLUTION |
|
de I-EVOLUTION |
|
glaucoma I-EVOLUTION |
|
de I-EVOLUTION |
|
ángulo I-EVOLUTION |
|
estrecho I-EVOLUTION |
|
y I-EVOLUTION |
|
se I-EVOLUTION |
|
procede I-EVOLUTION |
|
a I-EVOLUTION |
|
la I-EVOLUTION |
|
toma I-EVOLUTION |
|
de I-EVOLUTION |
|
imágenes I-EVOLUTION |
|
mediante I-EVOLUTION |
|
BMU I-EVOLUTION |
|
y I-EVOLUTION |
|
OCT. I-EVOLUTION |
|
El B-EXPLORATION |
|
OCT I-EXPLORATION |
|
muestra I-EXPLORATION |
|
un I-EXPLORATION |
|
cierre I-EXPLORATION |
|
angular I-EXPLORATION |
|
con I-EXPLORATION |
|
contacto I-EXPLORATION |
|
entre I-EXPLORATION |
|
la I-EXPLORATION |
|
malla I-EXPLORATION |
|
trabecular I-EXPLORATION |
|
y I-EXPLORATION |
|
la I-EXPLORATION |
|
zona I-EXPLORATION |
|
más I-EXPLORATION |
|
periférica I-EXPLORATION |
|
del I-EXPLORATION |
|
iris I-EXPLORATION |
|
en I-EXPLORATION |
|
los I-EXPLORATION |
|
cuatro I-EXPLORATION |
|
cuadrantes. I-EXPLORATION |
|
De I-EXPLORATION |
|
igual I-EXPLORATION |
|
forma I-EXPLORATION |
|
la I-EXPLORATION |
|
BMU I-EXPLORATION |
|
muestra I-EXPLORATION |
|
una I-EXPLORATION |
|
disposición I-EXPLORATION |
|
similar I-EXPLORATION |
|
del I-EXPLORATION |
|
ángulo I-EXPLORATION |
|
en I-EXPLORATION |
|
los I-EXPLORATION |
|
360º. I-EXPLORATION |
|
Se B-TREATMENT |
|
instaura I-TREATMENT |
|
el I-TREATMENT |
|
tratamiento I-TREATMENT |
|
médico I-TREATMENT |
|
correspondiente I-TREATMENT |
|
para I-TREATMENT |
|
posteriormente I-TREATMENT |
|
realizar I-TREATMENT |
|
unas I-TREATMENT |
|
iridotomías I-TREATMENT |
|
bilaterales I-TREATMENT |
|
con I-TREATMENT |
|
láser I-TREATMENT |
|
YAG. I-TREATMENT |
|
Tras B-EXPLORATION |
|
las I-EXPLORATION |
|
iridotomías I-EXPLORATION |
|
se I-EXPLORATION |
|
realiza I-EXPLORATION |
|
un I-EXPLORATION |
|
OCT I-EXPLORATION |
|
de I-EXPLORATION |
|
cámara I-EXPLORATION |
|
anterior I-EXPLORATION |
|
que I-EXPLORATION |
|
nos I-EXPLORATION |
|
muestra I-EXPLORATION |
|
como I-EXPLORATION |
|
la I-EXPLORATION |
|
iridotomía I-EXPLORATION |
|
en I-EXPLORATION |
|
el I-EXPLORATION |
|
ojo I-EXPLORATION |
|
del I-EXPLORATION |
|
ataque I-EXPLORATION |
|
agudo I-EXPLORATION |
|
de I-EXPLORATION |
|
glaucoma I-EXPLORATION |
|
no I-EXPLORATION |
|
es I-EXPLORATION |
|
permeable, I-EXPLORATION |
|
siendo B-TREATMENT |
|
necesario I-TREATMENT |
|
retratar I-TREATMENT |
|
la I-TREATMENT |
|
zona I-TREATMENT |
|
con I-TREATMENT |
|
nuevos I-TREATMENT |
|
impactos. I-TREATMENT |
|
Tras B-EVOLUTION |
|
este I-EVOLUTION |
|
segundo I-EVOLUTION |
|
tratamiento I-EVOLUTION |
|
se I-EVOLUTION |
|
realiza I-EVOLUTION |
|
un I-EVOLUTION |
|
nuevo I-EVOLUTION |
|
OCT I-EVOLUTION |
|
que, I-EVOLUTION |
|
esta I-EVOLUTION |
|
vez I-EVOLUTION |
|
sí, I-EVOLUTION |
|
muestra I-EVOLUTION |
|
permeabilidad I-EVOLUTION |
|
de I-EVOLUTION |
|
la I-EVOLUTION |
|
iridotomía, I-EVOLUTION |
|
apertura I-EVOLUTION |
|
del I-EVOLUTION |
|
ángulo I-EVOLUTION |
|
y I-EVOLUTION |
|
profundización I-EVOLUTION |
|
de I-EVOLUTION |
|
la I-EVOLUTION |
|
cámara I-EVOLUTION |
|
anterior. I-EVOLUTION |
|
<EOS> I-EVOLUTION |
|
|
|
Una B-PRESENT_ILLNESS |
|
mujer I-PRESENT_ILLNESS |
|
de I-PRESENT_ILLNESS |
|
25 I-PRESENT_ILLNESS |
|
años I-PRESENT_ILLNESS |
|
de I-PRESENT_ILLNESS |
|
edad I-PRESENT_ILLNESS |
|
fue B-DERIVED_FROM/TO |
|
remitida I-DERIVED_FROM/TO |
|
a I-DERIVED_FROM/TO |
|
nuestro I-DERIVED_FROM/TO |
|
servicio I-DERIVED_FROM/TO |
|
para I-DERIVED_FROM/TO |
|
confirmar I-DERIVED_FROM/TO |
|
la I-DERIVED_FROM/TO |
|
presencia I-DERIVED_FROM/TO |
|
de I-DERIVED_FROM/TO |
|
un I-DERIVED_FROM/TO |
|
síndrome I-DERIVED_FROM/TO |
|
de I-DERIVED_FROM/TO |
|
Susac, I-DERIVED_FROM/TO |
|
debido I-DERIVED_FROM/TO |
|
a I-DERIVED_FROM/TO |
|
una I-DERIVED_FROM/TO |
|
pérdida I-DERIVED_FROM/TO |
|
visual I-DERIVED_FROM/TO |
|
bilateral. I-DERIVED_FROM/TO |
|
La B-PAST_MEDICAL_HISTORY |
|
paciente I-PAST_MEDICAL_HISTORY |
|
tenía I-PAST_MEDICAL_HISTORY |
|
una I-PAST_MEDICAL_HISTORY |
|
historia I-PAST_MEDICAL_HISTORY |
|
de I-PAST_MEDICAL_HISTORY |
|
alteraciones I-PAST_MEDICAL_HISTORY |
|
del I-PAST_MEDICAL_HISTORY |
|
equilibrio, I-PAST_MEDICAL_HISTORY |
|
ataxia, I-PAST_MEDICAL_HISTORY |
|
incontinencia I-PAST_MEDICAL_HISTORY |
|
fecal I-PAST_MEDICAL_HISTORY |
|
y I-PAST_MEDICAL_HISTORY |
|
urinaria, I-PAST_MEDICAL_HISTORY |
|
y I-PAST_MEDICAL_HISTORY |
|
pérdida I-PAST_MEDICAL_HISTORY |
|
auditiva I-PAST_MEDICAL_HISTORY |
|
izquierda I-PAST_MEDICAL_HISTORY |
|
desde I-PAST_MEDICAL_HISTORY |
|
hacía I-PAST_MEDICAL_HISTORY |
|
cuatro I-PAST_MEDICAL_HISTORY |
|
años, I-PAST_MEDICAL_HISTORY |
|
y I-PAST_MEDICAL_HISTORY |
|
estaba I-PAST_MEDICAL_HISTORY |
|
recibiendo I-PAST_MEDICAL_HISTORY |
|
corticoides, I-PAST_MEDICAL_HISTORY |
|
nimodipino I-PAST_MEDICAL_HISTORY |
|
y I-PAST_MEDICAL_HISTORY |
|
anticoagulantes. I-PAST_MEDICAL_HISTORY |
|
En B-EXPLORATION |
|
el I-EXPLORATION |
|
examen I-EXPLORATION |
|
neurológico I-EXPLORATION |
|
se I-EXPLORATION |
|
apreciaba I-EXPLORATION |
|
una I-EXPLORATION |
|
paraparesia I-EXPLORATION |
|
espástica, I-EXPLORATION |
|
hiperreflexia I-EXPLORATION |
|
tendinosa I-EXPLORATION |
|
y I-EXPLORATION |
|
disfunción I-EXPLORATION |
|
genitourinaria. I-EXPLORATION |
|
La I-EXPLORATION |
|
analítica I-EXPLORATION |
|
sanguínea I-EXPLORATION |
|
que I-EXPLORATION |
|
incluía I-EXPLORATION |
|
hemograma, I-EXPLORATION |
|
bioquímica I-EXPLORATION |
|
general, I-EXPLORATION |
|
velocidad I-EXPLORATION |
|
de I-EXPLORATION |
|
sedimentación I-EXPLORATION |
|
globular, I-EXPLORATION |
|
enzima I-EXPLORATION |
|
conversor I-EXPLORATION |
|
de I-EXPLORATION |
|
la I-EXPLORATION |
|
angiotensina I-EXPLORATION |
|
y I-EXPLORATION |
|
coagulación I-EXPLORATION |
|
resultaba I-EXPLORATION |
|
sin I-EXPLORATION |
|
alteraciones. I-EXPLORATION |
|
La I-EXPLORATION |
|
serología I-EXPLORATION |
|
de I-EXPLORATION |
|
lúes, I-EXPLORATION |
|
virus I-EXPLORATION |
|
de I-EXPLORATION |
|
la I-EXPLORATION |
|
inmunodeficiencia I-EXPLORATION |
|
humana, I-EXPLORATION |
|
herpes I-EXPLORATION |
|
simple, I-EXPLORATION |
|
hepatitis I-EXPLORATION |
|
B I-EXPLORATION |
|
y I-EXPLORATION |
|
C, I-EXPLORATION |
|
proteína I-EXPLORATION |
|
C I-EXPLORATION |
|
reactiva, I-EXPLORATION |
|
factor I-EXPLORATION |
|
reumatoide, I-EXPLORATION |
|
anticoagulante I-EXPLORATION |
|
lúpico, I-EXPLORATION |
|
anticuerpos I-EXPLORATION |
|
antinucleares, I-EXPLORATION |
|
anticardiolipina, I-EXPLORATION |
|
y I-EXPLORATION |
|
antifosfolípido I-EXPLORATION |
|
fue I-EXPLORATION |
|
negativa. I-EXPLORATION |
|
La I-EXPLORATION |
|
radiografía I-EXPLORATION |
|
de I-EXPLORATION |
|
tórax, I-EXPLORATION |
|
electrocardiograma, I-EXPLORATION |
|
ecocardiografía I-EXPLORATION |
|
y I-EXPLORATION |
|
tomografía I-EXPLORATION |
|
axial I-EXPLORATION |
|
computerizada I-EXPLORATION |
|
craneal I-EXPLORATION |
|
no I-EXPLORATION |
|
presentaban I-EXPLORATION |
|
alteraciones. I-EXPLORATION |
|
El I-EXPLORATION |
|
líquido I-EXPLORATION |
|
cefalorraquídeo I-EXPLORATION |
|
(LCR) I-EXPLORATION |
|
era I-EXPLORATION |
|
de I-EXPLORATION |
|
aspecto I-EXPLORATION |
|
claro I-EXPLORATION |
|
y I-EXPLORATION |
|
con I-EXPLORATION |
|
presión I-EXPLORATION |
|
de I-EXPLORATION |
|
apertura I-EXPLORATION |
|
normal, I-EXPLORATION |
|
con I-EXPLORATION |
|
ligero I-EXPLORATION |
|
aumento I-EXPLORATION |
|
de I-EXPLORATION |
|
proteínas, I-EXPLORATION |
|
y I-EXPLORATION |
|
resto I-EXPLORATION |
|
de I-EXPLORATION |
|
fórmula I-EXPLORATION |
|
normal. I-EXPLORATION |
|
La I-EXPLORATION |
|
serología I-EXPLORATION |
|
en I-EXPLORATION |
|
LCR I-EXPLORATION |
|
para I-EXPLORATION |
|
borrelia, I-EXPLORATION |
|
virus I-EXPLORATION |
|
de I-EXPLORATION |
|
Epstein-Barr, I-EXPLORATION |
|
citomegalovirus I-EXPLORATION |
|
y I-EXPLORATION |
|
lúes, I-EXPLORATION |
|
además I-EXPLORATION |
|
de I-EXPLORATION |
|
los I-EXPLORATION |
|
cultivos I-EXPLORATION |
|
habituales I-EXPLORATION |
|
resultaron I-EXPLORATION |
|
negativos. I-EXPLORATION |
|
La I-EXPLORATION |
|
detección I-EXPLORATION |
|
de I-EXPLORATION |
|
bandas I-EXPLORATION |
|
oligoclonales I-EXPLORATION |
|
en I-EXPLORATION |
|
el I-EXPLORATION |
|
mismo I-EXPLORATION |
|
también I-EXPLORATION |
|
resultó I-EXPLORATION |
|
negativa. I-EXPLORATION |
|
La I-EXPLORATION |
|
Resonancia I-EXPLORATION |
|
Magnética I-EXPLORATION |
|
Nuclear I-EXPLORATION |
|
(RMN) I-EXPLORATION |
|
cerebral I-EXPLORATION |
|
mostraba I-EXPLORATION |
|
múltiples I-EXPLORATION |
|
áreas I-EXPLORATION |
|
focales I-EXPLORATION |
|
de I-EXPLORATION |
|
hiperintensidad I-EXPLORATION |
|
en I-EXPLORATION |
|
la I-EXPLORATION |
|
sustancia I-EXPLORATION |
|
blanca I-EXPLORATION |
|
periventricular I-EXPLORATION |
|
y I-EXPLORATION |
|
pericallosa, I-EXPLORATION |
|
y I-EXPLORATION |
|
en I-EXPLORATION |
|
las I-EXPLORATION |
|
regiones I-EXPLORATION |
|
del I-EXPLORATION |
|
centro I-EXPLORATION |
|
semioval. I-EXPLORATION |
|
Los I-EXPLORATION |
|
tests I-EXPLORATION |
|
audiométricos I-EXPLORATION |
|
estándares I-EXPLORATION |
|
revelaron I-EXPLORATION |
|
pérdida I-EXPLORATION |
|
auditiva I-EXPLORATION |
|
neurosensorial, I-EXPLORATION |
|
asimétrica, I-EXPLORATION |
|
de I-EXPLORATION |
|
predominio I-EXPLORATION |
|
izquierdo, I-EXPLORATION |
|
para I-EXPLORATION |
|
las I-EXPLORATION |
|
bajas I-EXPLORATION |
|
frecuencias. I-EXPLORATION |
|
A I-EXPLORATION |
|
la I-EXPLORATION |
|
exploración I-EXPLORATION |
|
oftalmológica, I-EXPLORATION |
|
su I-EXPLORATION |
|
agudeza I-EXPLORATION |
|
visual I-EXPLORATION |
|
era I-EXPLORATION |
|
de I-EXPLORATION |
|
20/25 I-EXPLORATION |
|
en I-EXPLORATION |
|
ambos I-EXPLORATION |
|
ojos. I-EXPLORATION |
|
La I-EXPLORATION |
|
campimetría I-EXPLORATION |
|
de I-EXPLORATION |
|
Goldmann I-EXPLORATION |
|
(Haag-Streit, I-EXPLORATION |
|
Berna, I-EXPLORATION |
|
Suiza) I-EXPLORATION |
|
mostró I-EXPLORATION |
|
una I-EXPLORATION |
|
cuadrantanopsia I-EXPLORATION |
|
inferior I-EXPLORATION |
|
bitemporal. I-EXPLORATION |
|
En I-EXPLORATION |
|
la I-EXPLORATION |
|
biomicroscopía I-EXPLORATION |
|
del I-EXPLORATION |
|
segmento I-EXPLORATION |
|
anterior I-EXPLORATION |
|
no I-EXPLORATION |
|
se I-EXPLORATION |
|
apreciaban I-EXPLORATION |
|
hallazgos I-EXPLORATION |
|
destacables. I-EXPLORATION |
|
El I-EXPLORATION |
|
examen I-EXPLORATION |
|
funduscópico I-EXPLORATION |
|
reveló I-EXPLORATION |
|
una I-EXPLORATION |
|
microangiopatía I-EXPLORATION |
|
retiniana I-EXPLORATION |
|
periférica, I-EXPLORATION |
|
apreciándose I-EXPLORATION |
|
amputación I-EXPLORATION |
|
de I-EXPLORATION |
|
vasos I-EXPLORATION |
|
con I-EXPLORATION |
|
cúmulos I-EXPLORATION |
|
de I-EXPLORATION |
|
microaneurismas I-EXPLORATION |
|
en I-EXPLORATION |
|
ambos I-EXPLORATION |
|
ojos. I-EXPLORATION |
|
No I-EXPLORATION |
|
se I-EXPLORATION |
|
observaron I-EXPLORATION |
|
signos I-EXPLORATION |
|
de I-EXPLORATION |
|
inflamación I-EXPLORATION |
|
o I-EXPLORATION |
|
células I-EXPLORATION |
|
en I-EXPLORATION |
|
el I-EXPLORATION |
|
vítreo, I-EXPLORATION |
|
ni I-EXPLORATION |
|
envainamiento I-EXPLORATION |
|
de I-EXPLORATION |
|
los I-EXPLORATION |
|
vasos I-EXPLORATION |
|
retinianos. I-EXPLORATION |
|
La I-EXPLORATION |
|
angiografía I-EXPLORATION |
|
fluoresceínica I-EXPLORATION |
|
(AGF) I-EXPLORATION |
|
demostró I-EXPLORATION |
|
signos I-EXPLORATION |
|
de I-EXPLORATION |
|
isquemia I-EXPLORATION |
|
en I-EXPLORATION |
|
las I-EXPLORATION |
|
áreas I-EXPLORATION |
|
correspondientes I-EXPLORATION |
|
a I-EXPLORATION |
|
las I-EXPLORATION |
|
oclusiones I-EXPLORATION |
|
arteriolares. I-EXPLORATION |
|
El I-EXPLORATION |
|
diagnóstico I-EXPLORATION |
|
de I-EXPLORATION |
|
síndrome I-EXPLORATION |
|
de I-EXPLORATION |
|
Susac I-EXPLORATION |
|
se I-EXPLORATION |
|
basó I-EXPLORATION |
|
en I-EXPLORATION |
|
la I-EXPLORATION |
|
asociación I-EXPLORATION |
|
de I-EXPLORATION |
|
encefalopatía I-EXPLORATION |
|
con I-EXPLORATION |
|
hallazgos I-EXPLORATION |
|
típicos I-EXPLORATION |
|
en I-EXPLORATION |
|
la I-EXPLORATION |
|
RMN, I-EXPLORATION |
|
microangiopatía I-EXPLORATION |
|
retiniana I-EXPLORATION |
|
y I-EXPLORATION |
|
pérdida I-EXPLORATION |
|
auditiva I-EXPLORATION |
|
neurosensorial. I-EXPLORATION |
|
<EOS> I-EXPLORATION |
|
Debido B-TREATMENT |
|
a I-TREATMENT |
|
la I-TREATMENT |
|
evidente I-TREATMENT |
|
isquemia I-TREATMENT |
|
retiniana I-TREATMENT |
|
periférica I-TREATMENT |
|
apreciada I-TREATMENT |
|
en I-TREATMENT |
|
la I-TREATMENT |
|
AGF, I-TREATMENT |
|
se I-TREATMENT |
|
le I-TREATMENT |
|
realizó I-TREATMENT |
|
fotocoagulación I-TREATMENT |
|
retiniana I-TREATMENT |
|
con I-TREATMENT |
|
láser I-TREATMENT |
|
en I-TREATMENT |
|
las I-TREATMENT |
|
áreas I-TREATMENT |
|
isquémicas I-TREATMENT |
|
de I-TREATMENT |
|
forma I-TREATMENT |
|
profiláctica, I-TREATMENT |
|
manteniéndose I-TREATMENT |
|
estable I-TREATMENT |
|
el I-TREATMENT |
|
cuadro I-TREATMENT |
|
visual I-TREATMENT |
|
desde I-TREATMENT |
|
entonces. I-TREATMENT |
|
Al B-EVOLUTION |
|
cabo I-EVOLUTION |
|
de I-EVOLUTION |
|
dos I-EVOLUTION |
|
años I-EVOLUTION |
|
no I-EVOLUTION |
|
ha I-EVOLUTION |
|
habido I-EVOLUTION |
|
variaciones I-EVOLUTION |
|
significativas I-EVOLUTION |
|
tanto I-EVOLUTION |
|
en I-EVOLUTION |
|
el I-EVOLUTION |
|
estado I-EVOLUTION |
|
neurológico I-EVOLUTION |
|
como I-EVOLUTION |
|
auditivo. I-EVOLUTION |
|
<EOS> I-EVOLUTION |
|
|
|
Varón, B-PRESENT_ILLNESS |
|
hijo B-PAST_MEDICAL_HISTORY |
|
único, I-PAST_MEDICAL_HISTORY |
|
nacido I-PAST_MEDICAL_HISTORY |
|
a I-PAST_MEDICAL_HISTORY |
|
las I-PAST_MEDICAL_HISTORY |
|
cuarenta I-PAST_MEDICAL_HISTORY |
|
semanas I-PAST_MEDICAL_HISTORY |
|
de I-PAST_MEDICAL_HISTORY |
|
gestación I-PAST_MEDICAL_HISTORY |
|
por I-PAST_MEDICAL_HISTORY |
|
cesárea. I-PAST_MEDICAL_HISTORY |
|
Como B-FAMILY_HISTORY |
|
antecedentes I-FAMILY_HISTORY |
|
familiares I-FAMILY_HISTORY |
|
destacar I-FAMILY_HISTORY |
|
que I-FAMILY_HISTORY |
|
su I-FAMILY_HISTORY |
|
madre I-FAMILY_HISTORY |
|
presentaba I-FAMILY_HISTORY |
|
diabetes I-FAMILY_HISTORY |
|
mellitus I-FAMILY_HISTORY |
|
no I-FAMILY_HISTORY |
|
insulinodependiente I-FAMILY_HISTORY |
|
desde I-FAMILY_HISTORY |
|
los I-FAMILY_HISTORY |
|
17 I-FAMILY_HISTORY |
|
años I-FAMILY_HISTORY |
|
y I-FAMILY_HISTORY |
|
no I-FAMILY_HISTORY |
|
existir I-FAMILY_HISTORY |
|
consaguinidad I-FAMILY_HISTORY |
|
entre I-FAMILY_HISTORY |
|
los I-FAMILY_HISTORY |
|
padres. I-FAMILY_HISTORY |
|
<EOS> I-FAMILY_HISTORY |
|
A B-PRESENT_ILLNESS |
|
los I-PRESENT_ILLNESS |
|
cuatro I-PRESENT_ILLNESS |
|
meses I-PRESENT_ILLNESS |
|
de I-PRESENT_ILLNESS |
|
vida, I-PRESENT_ILLNESS |
|
sufre I-PRESENT_ILLNESS |
|
una I-PRESENT_ILLNESS |
|
parada I-PRESENT_ILLNESS |
|
cardiorrespiratoria, I-PRESENT_ILLNESS |
|
(diagnosticado I-PRESENT_ILLNESS |
|
de I-PRESENT_ILLNESS |
|
cardiomiopatía I-PRESENT_ILLNESS |
|
dilatada) I-PRESENT_ILLNESS |
|
(1). I-PRESENT_ILLNESS |
|
Durante B-EVOLUTION |
|
su I-EVOLUTION |
|
ingreso I-EVOLUTION |
|
hospitalario I-EVOLUTION |
|
comienza I-EVOLUTION |
|
con I-EVOLUTION |
|
fotofobia I-EVOLUTION |
|
y I-EVOLUTION |
|
nistagmus I-EVOLUTION |
|
intermitente, I-EVOLUTION |
|
y B-EXPLORATION |
|
se I-EXPLORATION |
|
recomienda I-EXPLORATION |
|
revisión I-EXPLORATION |
|
oftalmológica I-EXPLORATION |
|
en I-EXPLORATION |
|
su I-EXPLORATION |
|
lugar I-EXPLORATION |
|
de I-EXPLORATION |
|
origen. I-EXPLORATION |
|
<EOS> I-EXPLORATION |
|
El I-EXPLORATION |
|
niño I-EXPLORATION |
|
presenta I-EXPLORATION |
|
un I-EXPLORATION |
|
retraso I-EXPLORATION |
|
psicomotor I-EXPLORATION |
|
por I-EXPLORATION |
|
lo I-EXPLORATION |
|
que I-EXPLORATION |
|
se I-EXPLORATION |
|
solicita I-EXPLORATION |
|
una I-EXPLORATION |
|
Resonancia I-EXPLORATION |
|
Magnética I-EXPLORATION |
|
Nuclear I-EXPLORATION |
|
(RMN) I-EXPLORATION |
|
y B-TREATMENT |
|
comienza I-TREATMENT |
|
desde I-TREATMENT |
|
el I-TREATMENT |
|
año I-TREATMENT |
|
de I-TREATMENT |
|
vida I-TREATMENT |
|
con I-TREATMENT |
|
tratamiento I-TREATMENT |
|
de I-TREATMENT |
|
estimulación I-TREATMENT |
|
precoz, I-TREATMENT |
|
consiguiendo I-TREATMENT |
|
en I-TREATMENT |
|
ocho I-TREATMENT |
|
meses I-TREATMENT |
|
los I-TREATMENT |
|
objetivos I-TREATMENT |
|
propuestos. I-TREATMENT |
|
En B-EXPLORATION |
|
la I-EXPLORATION |
|
RMN I-EXPLORATION |
|
se I-EXPLORATION |
|
observan I-EXPLORATION |
|
pequeñas I-EXPLORATION |
|
áreas I-EXPLORATION |
|
de I-EXPLORATION |
|
aumento I-EXPLORATION |
|
de I-EXPLORATION |
|
señal I-EXPLORATION |
|
en I-EXPLORATION |
|
T2 I-EXPLORATION |
|
y I-EXPLORATION |
|
FLAIR I-EXPLORATION |
|
en I-EXPLORATION |
|
las I-EXPLORATION |
|
regiones I-EXPLORATION |
|
periatriales I-EXPLORATION |
|
y I-EXPLORATION |
|
sustancia I-EXPLORATION |
|
blanca I-EXPLORATION |
|
temporal. I-EXPLORATION |
|
<EOS> I-EXPLORATION |
|
A B-DERIVED_FROM/TO |
|
los I-DERIVED_FROM/TO |
|
dos I-DERIVED_FROM/TO |
|
años I-DERIVED_FROM/TO |
|
es I-DERIVED_FROM/TO |
|
remitido I-DERIVED_FROM/TO |
|
a I-DERIVED_FROM/TO |
|
nuestro I-DERIVED_FROM/TO |
|
Hospital I-DERIVED_FROM/TO |
|
para I-DERIVED_FROM/TO |
|
estudio I-DERIVED_FROM/TO |
|
ecográfico I-DERIVED_FROM/TO |
|
y I-DERIVED_FROM/TO |
|
oftalmológico. I-DERIVED_FROM/TO |
|
Se B-EXPLORATION |
|
solicita I-EXPLORATION |
|
un I-EXPLORATION |
|
ERG I-EXPLORATION |
|
que I-EXPLORATION |
|
muestra I-EXPLORATION |
|
ausencia I-EXPLORATION |
|
de I-EXPLORATION |
|
respuestas, I-EXPLORATION |
|
y I-EXPLORATION |
|
Potenciales I-EXPLORATION |
|
Evocados I-EXPLORATION |
|
Visuales I-EXPLORATION |
|
(PEV) I-EXPLORATION |
|
normales. I-EXPLORATION |
|
Oftalmoscópicamente I-EXPLORATION |
|
muestra I-EXPLORATION |
|
nistagmus I-EXPLORATION |
|
con I-EXPLORATION |
|
fotofobia I-EXPLORATION |
|
intensa. I-EXPLORATION |
|
El I-EXPLORATION |
|
segmento I-EXPLORATION |
|
anterior I-EXPLORATION |
|
y I-EXPLORATION |
|
el I-EXPLORATION |
|
fondo I-EXPLORATION |
|
de I-EXPLORATION |
|
ojo I-EXPLORATION |
|
son I-EXPLORATION |
|
normales. I-EXPLORATION |
|
<EOS> I-EXPLORATION |
|
Como I-EXPLORATION |
|
el I-EXPLORATION |
|
diagnóstico I-EXPLORATION |
|
clínico I-EXPLORATION |
|
es I-EXPLORATION |
|
sugestivo I-EXPLORATION |
|
de I-EXPLORATION |
|
Síndrome I-EXPLORATION |
|
de I-EXPLORATION |
|
Alström, I-EXPLORATION |
|
se I-EXPLORATION |
|
solicita I-EXPLORATION |
|
un I-EXPLORATION |
|
estudio I-EXPLORATION |
|
genético I-EXPLORATION |
|
en I-EXPLORATION |
|
el I-EXPLORATION |
|
que I-EXPLORATION |
|
tras I-EXPLORATION |
|
analizar I-EXPLORATION |
|
los I-EXPLORATION |
|
exones I-EXPLORATION |
|
10, I-EXPLORATION |
|
16 I-EXPLORATION |
|
y I-EXPLORATION |
|
un I-EXPLORATION |
|
segmento I-EXPLORATION |
|
del I-EXPLORATION |
|
exón I-EXPLORATION |
|
8 I-EXPLORATION |
|
del I-EXPLORATION |
|
gen I-EXPLORATION |
|
ALMS-1 I-EXPLORATION |
|
(3) I-EXPLORATION |
|
donde I-EXPLORATION |
|
se I-EXPLORATION |
|
encuentran I-EXPLORATION |
|
las I-EXPLORATION |
|
mutaciones I-EXPLORATION |
|
descritas I-EXPLORATION |
|
hasta I-EXPLORATION |
|
el I-EXPLORATION |
|
momento, I-EXPLORATION |
|
amplificado I-EXPLORATION |
|
por I-EXPLORATION |
|
PCR I-EXPLORATION |
|
y I-EXPLORATION |
|
secuenciación I-EXPLORATION |
|
automatizada, I-EXPLORATION |
|
no I-EXPLORATION |
|
se I-EXPLORATION |
|
detectan I-EXPLORATION |
|
mutaciones, I-EXPLORATION |
|
sin I-EXPLORATION |
|
embargo, I-EXPLORATION |
|
estos I-EXPLORATION |
|
resultados I-EXPLORATION |
|
no I-EXPLORATION |
|
excluyen I-EXPLORATION |
|
el I-EXPLORATION |
|
diagnóstico. I-EXPLORATION |
|
<EOS> I-EXPLORATION |
|
|
|
Mujer B-PRESENT_ILLNESS |
|
de I-PRESENT_ILLNESS |
|
28 I-PRESENT_ILLNESS |
|
años, I-PRESENT_ILLNESS |
|
con B-PAST_MEDICAL_HISTORY |
|
antecedentes I-PAST_MEDICAL_HISTORY |
|
de I-PAST_MEDICAL_HISTORY |
|
«Síndrome I-PAST_MEDICAL_HISTORY |
|
de I-PAST_MEDICAL_HISTORY |
|
múltiples I-PAST_MEDICAL_HISTORY |
|
puntos I-PAST_MEDICAL_HISTORY |
|
blancos I-PAST_MEDICAL_HISTORY |
|
evanescentes» I-PAST_MEDICAL_HISTORY |
|
en I-PAST_MEDICAL_HISTORY |
|
ambos I-PAST_MEDICAL_HISTORY |
|
ojos I-PAST_MEDICAL_HISTORY |
|
hace I-PAST_MEDICAL_HISTORY |
|
7 I-PAST_MEDICAL_HISTORY |
|
años I-PAST_MEDICAL_HISTORY |
|
y I-PAST_MEDICAL_HISTORY |
|
buena I-PAST_MEDICAL_HISTORY |
|
respuesta I-PAST_MEDICAL_HISTORY |
|
a I-PAST_MEDICAL_HISTORY |
|
corticoterapia I-PAST_MEDICAL_HISTORY |
|
oral. I-PAST_MEDICAL_HISTORY |
|
Acude B-PRESENT_ILLNESS |
|
a I-PRESENT_ILLNESS |
|
urgencias I-PRESENT_ILLNESS |
|
de I-PRESENT_ILLNESS |
|
nuestro I-PRESENT_ILLNESS |
|
hospital I-PRESENT_ILLNESS |
|
por I-PRESENT_ILLNESS |
|
disminución I-PRESENT_ILLNESS |
|
de I-PRESENT_ILLNESS |
|
agudeza I-PRESENT_ILLNESS |
|
visual I-PRESENT_ILLNESS |
|
bilateral I-PRESENT_ILLNESS |
|
y I-PRESENT_ILLNESS |
|
cefalea I-PRESENT_ILLNESS |
|
de I-PRESENT_ILLNESS |
|
15 I-PRESENT_ILLNESS |
|
días I-PRESENT_ILLNESS |
|
de I-PRESENT_ILLNESS |
|
evolución. I-PRESENT_ILLNESS |
|
A B-EXPLORATION |
|
la I-EXPLORATION |
|
exploración I-EXPLORATION |
|
oftalmológica I-EXPLORATION |
|
presenta I-EXPLORATION |
|
una I-EXPLORATION |
|
agudeza I-EXPLORATION |
|
visual I-EXPLORATION |
|
de I-EXPLORATION |
|
3/10 I-EXPLORATION |
|
con I-EXPLORATION |
|
reacción I-EXPLORATION |
|
inflamatoria I-EXPLORATION |
|
en I-EXPLORATION |
|
cámara I-EXPLORATION |
|
anterior I-EXPLORATION |
|
y I-EXPLORATION |
|
desprendimiento I-EXPLORATION |
|
de I-EXPLORATION |
|
retina I-EXPLORATION |
|
exudativo I-EXPLORATION |
|
bilateral. I-EXPLORATION |
|
Se B-TREATMENT |
|
inicia I-TREATMENT |
|
tratamiento I-TREATMENT |
|
corticoideo I-TREATMENT |
|
oral I-TREATMENT |
|
a I-TREATMENT |
|
altas I-TREATMENT |
|
dosis I-TREATMENT |
|
(80 I-TREATMENT |
|
mg I-TREATMENT |
|
de I-TREATMENT |
|
prednisona), I-TREATMENT |
|
constatándose I-TREATMENT |
|
una I-TREATMENT |
|
buena I-TREATMENT |
|
respuesta I-TREATMENT |
|
inicial. I-TREATMENT |
|
Al B-EVOLUTION |
|
mes I-EVOLUTION |
|
del I-EVOLUTION |
|
tratamiento I-EVOLUTION |
|
se I-EVOLUTION |
|
observa I-EVOLUTION |
|
una I-EVOLUTION |
|
recidiva I-EVOLUTION |
|
del I-EVOLUTION |
|
desprendimiento I-EVOLUTION |
|
de I-EVOLUTION |
|
retina I-EVOLUTION |
|
foveal I-EVOLUTION |
|
en I-EVOLUTION |
|
el I-EVOLUTION |
|
ojo I-EVOLUTION |
|
izquierdo, I-EVOLUTION |
|
por I-EVOLUTION |
|
lo I-EVOLUTION |
|
que I-EVOLUTION |
|
se I-EVOLUTION |
|
asocia I-EVOLUTION |
|
a I-EVOLUTION |
|
su I-EVOLUTION |
|
tratamiento I-EVOLUTION |
|
CyA I-EVOLUTION |
|
(dosis I-EVOLUTION |
|
inicial I-EVOLUTION |
|
de I-EVOLUTION |
|
4 I-EVOLUTION |
|
mg/kg/día). I-EVOLUTION |
|
Tras I-EVOLUTION |
|
nueve I-EVOLUTION |
|
meses I-EVOLUTION |
|
de I-EVOLUTION |
|
seguimiento, I-EVOLUTION |
|
presenta I-EVOLUTION |
|
una I-EVOLUTION |
|
agudeza I-EVOLUTION |
|
visual I-EVOLUTION |
|
de I-EVOLUTION |
|
unidad I-EVOLUTION |
|
en I-EVOLUTION |
|
el I-EVOLUTION |
|
ojo I-EVOLUTION |
|
derecho I-EVOLUTION |
|
y I-EVOLUTION |
|
de I-EVOLUTION |
|
8/10 I-EVOLUTION |
|
en I-EVOLUTION |
|
el I-EVOLUTION |
|
ojo I-EVOLUTION |
|
izquierdo I-EVOLUTION |
|
con I-EVOLUTION |
|
movilización I-EVOLUTION |
|
pigmentaria I-EVOLUTION |
|
en I-EVOLUTION |
|
cuatro I-EVOLUTION |
|
cuadrantes I-EVOLUTION |
|
y I-EVOLUTION |
|
fibrosis I-EVOLUTION |
|
subretiniana. I-EVOLUTION |
|
<EOS> I-EVOLUTION |
|
|
|
Mujer B-PRESENT_ILLNESS |
|
de I-PRESENT_ILLNESS |
|
67 I-PRESENT_ILLNESS |
|
años I-PRESENT_ILLNESS |
|
remitida B-DERIVED_FROM/TO |
|
de I-DERIVED_FROM/TO |
|
otro I-DERIVED_FROM/TO |
|
centro I-DERIVED_FROM/TO |
|
para I-DERIVED_FROM/TO |
|
tratamiento I-DERIVED_FROM/TO |
|
de I-DERIVED_FROM/TO |
|
carcinoma I-DERIVED_FROM/TO |
|
de I-DERIVED_FROM/TO |
|
células I-DERIVED_FROM/TO |
|
sebáceas I-DERIVED_FROM/TO |
|
de I-DERIVED_FROM/TO |
|
ojo I-DERIVED_FROM/TO |
|
derecho I-DERIVED_FROM/TO |
|
intervenido I-DERIVED_FROM/TO |
|
en I-DERIVED_FROM/TO |
|
seis I-DERIVED_FROM/TO |
|
ocasiones. I-DERIVED_FROM/TO |
|
Debutó B-PRESENT_ILLNESS |
|
como I-PRESENT_ILLNESS |
|
una I-PRESENT_ILLNESS |
|
lesión I-PRESENT_ILLNESS |
|
pediculada I-PRESENT_ILLNESS |
|
en I-PRESENT_ILLNESS |
|
conjuntiva I-PRESENT_ILLNESS |
|
tarsal I-PRESENT_ILLNESS |
|
superior. I-PRESENT_ILLNESS |
|
La B-EXPLORATION |
|
biopsia I-EXPLORATION |
|
realizada I-EXPLORATION |
|
se I-EXPLORATION |
|
informó I-EXPLORATION |
|
como I-EXPLORATION |
|
carcinoma I-EXPLORATION |
|
sebáceo. I-EXPLORATION |
|
Se B-TREATMENT |
|
hicieron I-TREATMENT |
|
varias I-TREATMENT |
|
ampliaciones I-TREATMENT |
|
de I-TREATMENT |
|
márgenes I-TREATMENT |
|
quirúrgicos I-TREATMENT |
|
de I-TREATMENT |
|
lamela I-TREATMENT |
|
posterior I-TREATMENT |
|
de I-TREATMENT |
|
párpado I-TREATMENT |
|
superior I-TREATMENT |
|
derecho, I-TREATMENT |
|
hasta I-TREATMENT |
|
encontrar I-TREATMENT |
|
límites I-TREATMENT |
|
libre I-TREATMENT |
|
de I-TREATMENT |
|
tumor. I-TREATMENT |
|
Las B-EXPLORATION |
|
piezas I-EXPLORATION |
|
se I-EXPLORATION |
|
informaron I-EXPLORATION |
|
como I-EXPLORATION |
|
carcinoma I-EXPLORATION |
|
sebáceo I-EXPLORATION |
|
con I-EXPLORATION |
|
diseminación I-EXPLORATION |
|
pagetoide. I-EXPLORATION |
|
<EOS> I-EXPLORATION |
|
La B-EVOLUTION |
|
paciente I-EVOLUTION |
|
refería I-EVOLUTION |
|
inflamación I-EVOLUTION |
|
crónica I-EVOLUTION |
|
palpebral I-EVOLUTION |
|
y I-EVOLUTION |
|
conjuntival. I-EVOLUTION |
|
A B-EXPLORATION |
|
la I-EXPLORATION |
|
exploración I-EXPLORATION |
|
destacaba I-EXPLORATION |
|
leve I-EXPLORATION |
|
engrosamiento I-EXPLORATION |
|
de I-EXPLORATION |
|
tercio I-EXPLORATION |
|
externo I-EXPLORATION |
|
del I-EXPLORATION |
|
borde I-EXPLORATION |
|
libre I-EXPLORATION |
|
de I-EXPLORATION |
|
párpado I-EXPLORATION |
|
superior I-EXPLORATION |
|
derecho. I-EXPLORATION |
|
En I-EXPLORATION |
|
la I-EXPLORATION |
|
biomicroscopía I-EXPLORATION |
|
presentaba: I-EXPLORATION |
|
conjuntiva I-EXPLORATION |
|
bulbar I-EXPLORATION |
|
superior I-EXPLORATION |
|
irregular I-EXPLORATION |
|
y I-EXPLORATION |
|
muy I-EXPLORATION |
|
eritematosa, I-EXPLORATION |
|
área I-EXPLORATION |
|
de I-EXPLORATION |
|
6 I-EXPLORATION |
|
mm I-EXPLORATION |
|
de I-EXPLORATION |
|
amplitud I-EXPLORATION |
|
en I-EXPLORATION |
|
la I-EXPLORATION |
|
que I-EXPLORATION |
|
se I-EXPLORATION |
|
observaba I-EXPLORATION |
|
una I-EXPLORATION |
|
desestructuración I-EXPLORATION |
|
de I-EXPLORATION |
|
la I-EXPLORATION |
|
arquitectura I-EXPLORATION |
|
limbar, I-EXPLORATION |
|
con I-EXPLORATION |
|
infiltración I-EXPLORATION |
|
de I-EXPLORATION |
|
las I-EXPLORATION |
|
empalizadas I-EXPLORATION |
|
de I-EXPLORATION |
|
Vogt I-EXPLORATION |
|
por I-EXPLORATION |
|
cordones I-EXPLORATION |
|
amarillentos I-EXPLORATION |
|
de I-EXPLORATION |
|
aspecto I-EXPLORATION |
|
sebáceo I-EXPLORATION |
|
y I-EXPLORATION |
|
conjuntivalización I-EXPLORATION |
|
del I-EXPLORATION |
|
epitelio I-EXPLORATION |
|
corneal I-EXPLORATION |
|
superior, I-EXPLORATION |
|
acortamiento I-EXPLORATION |
|
de I-EXPLORATION |
|
fórnix I-EXPLORATION |
|
superior I-EXPLORATION |
|
y I-EXPLORATION |
|
simbléfaron I-EXPLORATION |
|
en I-EXPLORATION |
|
zona I-EXPLORATION |
|
del I-EXPLORATION |
|
canto I-EXPLORATION |
|
externo. I-EXPLORATION |
|
No I-EXPLORATION |
|
se I-EXPLORATION |
|
observó I-EXPLORATION |
|
afectación I-EXPLORATION |
|
ganglionar I-EXPLORATION |
|
a I-EXPLORATION |
|
la I-EXPLORATION |
|
palpación. I-EXPLORATION |
|
La I-EXPLORATION |
|
TC I-EXPLORATION |
|
de I-EXPLORATION |
|
cráneo, I-EXPLORATION |
|
abdomen I-EXPLORATION |
|
y I-EXPLORATION |
|
tórax I-EXPLORATION |
|
era I-EXPLORATION |
|
normal. I-EXPLORATION |
|
La I-EXPLORATION |
|
gammagrafía I-EXPLORATION |
|
ósea I-EXPLORATION |
|
era I-EXPLORATION |
|
normal. I-EXPLORATION |
|
<EOS> I-EXPLORATION |
|
Se B-TREATMENT |
|
realizó I-TREATMENT |
|
blefarectomía I-TREATMENT |
|
en I-TREATMENT |
|
cuña I-TREATMENT |
|
de I-TREATMENT |
|
la I-TREATMENT |
|
zona I-TREATMENT |
|
engrosada I-TREATMENT |
|
del I-TREATMENT |
|
párpado I-TREATMENT |
|
superior I-TREATMENT |
|
derecho I-TREATMENT |
|
y I-TREATMENT |
|
mapeo I-TREATMENT |
|
de I-TREATMENT |
|
biopsias I-TREATMENT |
|
conjuntivales. I-TREATMENT |
|
La B-EXPLORATION |
|
pieza I-EXPLORATION |
|
principal I-EXPLORATION |
|
se I-EXPLORATION |
|
informó I-EXPLORATION |
|
como I-EXPLORATION |
|
carcinoma I-EXPLORATION |
|
sebáceo. I-EXPLORATION |
|
Las I-EXPLORATION |
|
muestras I-EXPLORATION |
|
conjuntivales I-EXPLORATION |
|
estaban I-EXPLORATION |
|
libres I-EXPLORATION |
|
de I-EXPLORATION |
|
tumor. I-EXPLORATION |
|
<EOS> I-EXPLORATION |
|
Ampliamos B-TREATMENT |
|
la I-TREATMENT |
|
blefarectomía I-TREATMENT |
|
y I-TREATMENT |
|
esperamos I-TREATMENT |
|
a I-TREATMENT |
|
poder I-TREATMENT |
|
instaurar I-TREATMENT |
|
tratamiento I-TREATMENT |
|
de I-TREATMENT |
|
la I-TREATMENT |
|
superficie I-TREATMENT |
|
ocular I-TREATMENT |
|
con I-TREATMENT |
|
colirio I-TREATMENT |
|
de I-TREATMENT |
|
mitomicina I-TREATMENT |
|
C. I-TREATMENT |
|
No B-EVOLUTION |
|
se I-EVOLUTION |
|
pudo I-EVOLUTION |
|
seguir I-EVOLUTION |
|
la I-EVOLUTION |
|
evolución I-EVOLUTION |
|
del I-EVOLUTION |
|
caso I-EVOLUTION |
|
ya I-EVOLUTION |
|
que I-EVOLUTION |
|
la I-EVOLUTION |
|
paciente I-EVOLUTION |
|
decidió I-EVOLUTION |
|
seguir I-EVOLUTION |
|
con I-EVOLUTION |
|
el I-EVOLUTION |
|
tratamiento I-EVOLUTION |
|
en I-EVOLUTION |
|
su I-EVOLUTION |
|
ciudad I-EVOLUTION |
|
de I-EVOLUTION |
|
residencia. I-EVOLUTION |
|
<EOS> I-EVOLUTION |
|
|
|
Un B-PRESENT_ILLNESS |
|
varón I-PRESENT_ILLNESS |
|
de I-PRESENT_ILLNESS |
|
58 I-PRESENT_ILLNESS |
|
años I-PRESENT_ILLNESS |
|
acudió I-PRESENT_ILLNESS |
|
a I-PRESENT_ILLNESS |
|
Urgencias I-PRESENT_ILLNESS |
|
por I-PRESENT_ILLNESS |
|
una I-PRESENT_ILLNESS |
|
diplopía I-PRESENT_ILLNESS |
|
binocular I-PRESENT_ILLNESS |
|
de I-PRESENT_ILLNESS |
|
instauración I-PRESENT_ILLNESS |
|
subaguda I-PRESENT_ILLNESS |
|
de I-PRESENT_ILLNESS |
|
al I-PRESENT_ILLNESS |
|
menos I-PRESENT_ILLNESS |
|
3 I-PRESENT_ILLNESS |
|
meses I-PRESENT_ILLNESS |
|
de I-PRESENT_ILLNESS |
|
evolución I-PRESENT_ILLNESS |
|
atribuida I-PRESENT_ILLNESS |
|
inicialmente I-PRESENT_ILLNESS |
|
a I-PRESENT_ILLNESS |
|
los I-PRESENT_ILLNESS |
|
efectos I-PRESENT_ILLNESS |
|
secundarios I-PRESENT_ILLNESS |
|
de I-PRESENT_ILLNESS |
|
quimioterapia. I-PRESENT_ILLNESS |
|
El B-PAST_MEDICAL_HISTORY |
|
paciente I-PAST_MEDICAL_HISTORY |
|
había I-PAST_MEDICAL_HISTORY |
|
sido I-PAST_MEDICAL_HISTORY |
|
tratado I-PAST_MEDICAL_HISTORY |
|
con I-PAST_MEDICAL_HISTORY |
|
ciclos I-PAST_MEDICAL_HISTORY |
|
de I-PAST_MEDICAL_HISTORY |
|
carboxiplatino/taxol I-PAST_MEDICAL_HISTORY |
|
y I-PAST_MEDICAL_HISTORY |
|
radioterapia I-PAST_MEDICAL_HISTORY |
|
concomitante I-PAST_MEDICAL_HISTORY |
|
por I-PAST_MEDICAL_HISTORY |
|
un I-PAST_MEDICAL_HISTORY |
|
carcinoma I-PAST_MEDICAL_HISTORY |
|
pulmonar I-PAST_MEDICAL_HISTORY |
|
de I-PAST_MEDICAL_HISTORY |
|
células I-PAST_MEDICAL_HISTORY |
|
grandes I-PAST_MEDICAL_HISTORY |
|
en I-PAST_MEDICAL_HISTORY |
|
estadio I-PAST_MEDICAL_HISTORY |
|
T2N3M0 I-PAST_MEDICAL_HISTORY |
|
diagnosticado I-PAST_MEDICAL_HISTORY |
|
hacía I-PAST_MEDICAL_HISTORY |
|
7 I-PAST_MEDICAL_HISTORY |
|
meses. I-PAST_MEDICAL_HISTORY |
|
En B-EXPLORATION |
|
la I-EXPLORATION |
|
exploración I-EXPLORATION |
|
oftalmológica, I-EXPLORATION |
|
la I-EXPLORATION |
|
AV I-EXPLORATION |
|
mejor I-EXPLORATION |
|
corregida I-EXPLORATION |
|
era I-EXPLORATION |
|
de I-EXPLORATION |
|
0, I-EXPLORATION |
|
9 I-EXPLORATION |
|
en I-EXPLORATION |
|
ojo I-EXPLORATION |
|
derecho I-EXPLORATION |
|
(OD) I-EXPLORATION |
|
y I-EXPLORATION |
|
de I-EXPLORATION |
|
0, I-EXPLORATION |
|
8 I-EXPLORATION |
|
en I-EXPLORATION |
|
ojo I-EXPLORATION |
|
izquierdo I-EXPLORATION |
|
(OI). I-EXPLORATION |
|
Ambas I-EXPLORATION |
|
pupilas I-EXPLORATION |
|
estaban I-EXPLORATION |
|
en I-EXPLORATION |
|
midriasis I-EXPLORATION |
|
media I-EXPLORATION |
|
con I-EXPLORATION |
|
escasa I-EXPLORATION |
|
reactividad I-EXPLORATION |
|
a I-EXPLORATION |
|
la I-EXPLORATION |
|
luz I-EXPLORATION |
|
y I-EXPLORATION |
|
convergencia. I-EXPLORATION |
|
Respecto I-EXPLORATION |
|
a I-EXPLORATION |
|
la I-EXPLORATION |
|
motilidad I-EXPLORATION |
|
ocular I-EXPLORATION |
|
extrínseca, I-EXPLORATION |
|
se I-EXPLORATION |
|
objetivaba I-EXPLORATION |
|
una I-EXPLORATION |
|
exotropía I-EXPLORATION |
|
de I-EXPLORATION |
|
-50 I-EXPLORATION |
|
dp I-EXPLORATION |
|
(dioptrías I-EXPLORATION |
|
prismátricas) I-EXPLORATION |
|
con I-EXPLORATION |
|
dominancia I-EXPLORATION |
|
OD I-EXPLORATION |
|
pero I-EXPLORATION |
|
con I-EXPLORATION |
|
capacidad I-EXPLORATION |
|
de I-EXPLORATION |
|
fijación I-EXPLORATION |
|
alternante. I-EXPLORATION |
|
En I-EXPLORATION |
|
el I-EXPLORATION |
|
OD I-EXPLORATION |
|
se I-EXPLORATION |
|
observaba I-EXPLORATION |
|
una I-EXPLORATION |
|
limitación I-EXPLORATION |
|
de I-EXPLORATION |
|
las I-EXPLORATION |
|
supraducciones I-EXPLORATION |
|
(+++) I-EXPLORATION |
|
y I-EXPLORATION |
|
de I-EXPLORATION |
|
la I-EXPLORATION |
|
aducción I-EXPLORATION |
|
(++) I-EXPLORATION |
|
pero I-EXPLORATION |
|
con I-EXPLORATION |
|
conservación I-EXPLORATION |
|
de I-EXPLORATION |
|
la I-EXPLORATION |
|
abducción. I-EXPLORATION |
|
El I-EXPLORATION |
|
OI I-EXPLORATION |
|
presentaba I-EXPLORATION |
|
un I-EXPLORATION |
|
ptosis I-EXPLORATION |
|
palpebral I-EXPLORATION |
|
casi I-EXPLORATION |
|
total I-EXPLORATION |
|
y I-EXPLORATION |
|
una I-EXPLORATION |
|
severa I-EXPLORATION |
|
limitación I-EXPLORATION |
|
de I-EXPLORATION |
|
las I-EXPLORATION |
|
supraducciones I-EXPLORATION |
|
(+++), I-EXPLORATION |
|
de I-EXPLORATION |
|
la I-EXPLORATION |
|
aducción I-EXPLORATION |
|
(++) I-EXPLORATION |
|
y I-EXPLORATION |
|
de I-EXPLORATION |
|
las I-EXPLORATION |
|
infraducciones I-EXPLORATION |
|
(+++) I-EXPLORATION |
|
con I-EXPLORATION |
|
conservación I-EXPLORATION |
|
de I-EXPLORATION |
|
la I-EXPLORATION |
|
abducción. I-EXPLORATION |
|
La I-EXPLORATION |
|
biomicroscopía I-EXPLORATION |
|
del I-EXPLORATION |
|
segmento I-EXPLORATION |
|
anterior I-EXPLORATION |
|
era I-EXPLORATION |
|
normal I-EXPLORATION |
|
así I-EXPLORATION |
|
como I-EXPLORATION |
|
la I-EXPLORATION |
|
tensión I-EXPLORATION |
|
ocular I-EXPLORATION |
|
de I-EXPLORATION |
|
ambos I-EXPLORATION |
|
ojos I-EXPLORATION |
|
(AO). I-EXPLORATION |
|
En I-EXPLORATION |
|
el I-EXPLORATION |
|
fondo I-EXPLORATION |
|
de I-EXPLORATION |
|
ojo I-EXPLORATION |
|
tampoco I-EXPLORATION |
|
se I-EXPLORATION |
|
hallaron I-EXPLORATION |
|
alteraciones I-EXPLORATION |
|
patológicas. I-EXPLORATION |
|
En I-EXPLORATION |
|
la I-EXPLORATION |
|
exploración I-EXPLORATION |
|
neurológica I-EXPLORATION |
|
el I-EXPLORATION |
|
paciente I-EXPLORATION |
|
no I-EXPLORATION |
|
mostraba I-EXPLORATION |
|
ninguna I-EXPLORATION |
|
alteración I-EXPLORATION |
|
clínica. I-EXPLORATION |
|
<EOS> I-EXPLORATION |
|
Se I-EXPLORATION |
|
le I-EXPLORATION |
|
realizó I-EXPLORATION |
|
una I-EXPLORATION |
|
resonancia I-EXPLORATION |
|
magnética I-EXPLORATION |
|
(RM) I-EXPLORATION |
|
cerebral I-EXPLORATION |
|
que I-EXPLORATION |
|
evidenció I-EXPLORATION |
|
la I-EXPLORATION |
|
existencia I-EXPLORATION |
|
una I-EXPLORATION |
|
lesión I-EXPLORATION |
|
solitaria I-EXPLORATION |
|
en I-EXPLORATION |
|
la I-EXPLORATION |
|
región I-EXPLORATION |
|
posterior I-EXPLORATION |
|
del I-EXPLORATION |
|
suelo I-EXPLORATION |
|
del I-EXPLORATION |
|
III I-EXPLORATION |
|
ventrículo. I-EXPLORATION |
|
Dicha I-EXPLORATION |
|
lesión I-EXPLORATION |
|
tenía I-EXPLORATION |
|
un I-EXPLORATION |
|
aspecto I-EXPLORATION |
|
anular I-EXPLORATION |
|
hiperintenso, I-EXPLORATION |
|
con I-EXPLORATION |
|
una I-EXPLORATION |
|
porción I-EXPLORATION |
|
central I-EXPLORATION |
|
hipointensa I-EXPLORATION |
|
sugestiva I-EXPLORATION |
|
de I-EXPLORATION |
|
necrosis, I-EXPLORATION |
|
y I-EXPLORATION |
|
afectaba I-EXPLORATION |
|
bilateralmente I-EXPLORATION |
|
a I-EXPLORATION |
|
los I-EXPLORATION |
|
núcleos I-EXPLORATION |
|
y I-EXPLORATION |
|
fascículos I-EXPLORATION |
|
del I-EXPLORATION |
|
III I-EXPLORATION |
|
nervio I-EXPLORATION |
|
craneal I-EXPLORATION |
|
en I-EXPLORATION |
|
el I-EXPLORATION |
|
mesencéfalo I-EXPLORATION |
|
central. I-EXPLORATION |
|
<EOS> I-EXPLORATION |
|
|
|
Mujer B-PRESENT_ILLNESS |
|
hispana I-PRESENT_ILLNESS |
|
de I-PRESENT_ILLNESS |
|
33 I-PRESENT_ILLNESS |
|
años I-PRESENT_ILLNESS |
|
de I-PRESENT_ILLNESS |
|
edad, I-PRESENT_ILLNESS |
|
sin B-PAST_MEDICAL_HISTORY |
|
antecedentes I-PAST_MEDICAL_HISTORY |
|
de I-PAST_MEDICAL_HISTORY |
|
interés, I-PAST_MEDICAL_HISTORY |
|
que B-PRESENT_ILLNESS |
|
queja I-PRESENT_ILLNESS |
|
una I-PRESENT_ILLNESS |
|
disminución I-PRESENT_ILLNESS |
|
progresiva I-PRESENT_ILLNESS |
|
de I-PRESENT_ILLNESS |
|
visión I-PRESENT_ILLNESS |
|
en I-PRESENT_ILLNESS |
|
el I-PRESENT_ILLNESS |
|
ojo I-PRESENT_ILLNESS |
|
izquierdo I-PRESENT_ILLNESS |
|
(OI). I-PRESENT_ILLNESS |
|
<EOS> I-PRESENT_ILLNESS |
|
En B-EXPLORATION |
|
la I-EXPLORATION |
|
exploración I-EXPLORATION |
|
destaca I-EXPLORATION |
|
una I-EXPLORATION |
|
agudeza I-EXPLORATION |
|
visual I-EXPLORATION |
|
(AV) I-EXPLORATION |
|
de I-EXPLORATION |
|
0, I-EXPLORATION |
|
05 I-EXPLORATION |
|
en I-EXPLORATION |
|
OI. I-EXPLORATION |
|
En I-EXPLORATION |
|
el I-EXPLORATION |
|
fondo I-EXPLORATION |
|
de I-EXPLORATION |
|
ojo I-EXPLORATION |
|
(FO) I-EXPLORATION |
|
del I-EXPLORATION |
|
OI I-EXPLORATION |
|
se I-EXPLORATION |
|
observa I-EXPLORATION |
|
una I-EXPLORATION |
|
masa I-EXPLORATION |
|
papilar I-EXPLORATION |
|
elevada, I-EXPLORATION |
|
polipoidea, I-EXPLORATION |
|
intensamente I-EXPLORATION |
|
pigmentada I-EXPLORATION |
|
así I-EXPLORATION |
|
como I-EXPLORATION |
|
ristras I-EXPLORATION |
|
de I-EXPLORATION |
|
pigmento I-EXPLORATION |
|
móvil I-EXPLORATION |
|
en I-EXPLORATION |
|
la I-EXPLORATION |
|
cavidad I-EXPLORATION |
|
vítrea. I-EXPLORATION |
|
El I-EXPLORATION |
|
resto I-EXPLORATION |
|
de I-EXPLORATION |
|
la I-EXPLORATION |
|
exploración I-EXPLORATION |
|
oftalmológica I-EXPLORATION |
|
es I-EXPLORATION |
|
normal. I-EXPLORATION |
|
<EOS> I-EXPLORATION |
|
En I-EXPLORATION |
|
la I-EXPLORATION |
|
angiofluoresceingrafía I-EXPLORATION |
|
(AFG) I-EXPLORATION |
|
se I-EXPLORATION |
|
apreció I-EXPLORATION |
|
un I-EXPLORATION |
|
efecto I-EXPLORATION |
|
pantalla. I-EXPLORATION |
|
<EOS> I-EXPLORATION |
|
La I-EXPLORATION |
|
ecografía I-EXPLORATION |
|
mostró I-EXPLORATION |
|
una I-EXPLORATION |
|
lesión I-EXPLORATION |
|
sólida. I-EXPLORATION |
|
En I-EXPLORATION |
|
modo I-EXPLORATION |
|
A I-EXPLORATION |
|
se I-EXPLORATION |
|
observó I-EXPLORATION |
|
una I-EXPLORATION |
|
reflectividad I-EXPLORATION |
|
interna I-EXPLORATION |
|
muy I-EXPLORATION |
|
elevada I-EXPLORATION |
|
sin I-EXPLORATION |
|
movimiento I-EXPLORATION |
|
vascular I-EXPLORATION |
|
espontáneo. I-EXPLORATION |
|
<EOS> I-EXPLORATION |
|
En I-EXPLORATION |
|
aquel I-EXPLORATION |
|
momento I-EXPLORATION |
|
fueron I-EXPLORATION |
|
consultados I-EXPLORATION |
|
varios I-EXPLORATION |
|
expertos. I-EXPLORATION |
|
Unos I-EXPLORATION |
|
se I-EXPLORATION |
|
inclinaron I-EXPLORATION |
|
por I-EXPLORATION |
|
un I-EXPLORATION |
|
diagnóstico I-EXPLORATION |
|
de I-EXPLORATION |
|
melanoma I-EXPLORATION |
|
maligno I-EXPLORATION |
|
y I-EXPLORATION |
|
otros I-EXPLORATION |
|
por I-EXPLORATION |
|
melanocitoma. I-EXPLORATION |
|
<EOS> I-EXPLORATION |
|
La B-TREATMENT |
|
decisión I-TREATMENT |
|
adoptada I-TREATMENT |
|
fue I-TREATMENT |
|
seguir I-TREATMENT |
|
observando I-TREATMENT |
|
a I-TREATMENT |
|
la I-TREATMENT |
|
paciente. I-TREATMENT |
|
A B-EVOLUTION |
|
lo I-EVOLUTION |
|
largo I-EVOLUTION |
|
de I-EVOLUTION |
|
diecinueve I-EVOLUTION |
|
años I-EVOLUTION |
|
la I-EVOLUTION |
|
lesión I-EVOLUTION |
|
aumentó I-EVOLUTION |
|
paulatinamente I-EVOLUTION |
|
de I-EVOLUTION |
|
tamaño I-EVOLUTION |
|
sin I-EVOLUTION |
|
cambios I-EVOLUTION |
|
rápidos I-EVOLUTION |
|
en I-EVOLUTION |
|
su I-EVOLUTION |
|
configuración I-EVOLUTION |
|
por I-EVOLUTION |
|
lo I-EVOLUTION |
|
que I-EVOLUTION |
|
el I-EVOLUTION |
|
diagnóstico I-EVOLUTION |
|
de I-EVOLUTION |
|
melanocitoma I-EVOLUTION |
|
seguía I-EVOLUTION |
|
siendo I-EVOLUTION |
|
el I-EVOLUTION |
|
más I-EVOLUTION |
|
apropiado. I-EVOLUTION |
|
La I-EVOLUTION |
|
paciente I-EVOLUTION |
|
acabó I-EVOLUTION |
|
por I-EVOLUTION |
|
perder I-EVOLUTION |
|
completamente I-EVOLUTION |
|
la I-EVOLUTION |
|
visión I-EVOLUTION |
|
del I-EVOLUTION |
|
OI I-EVOLUTION |
|
y I-EVOLUTION |
|
la I-EVOLUTION |
|
funduscopia I-EVOLUTION |
|
llegó I-EVOLUTION |
|
a I-EVOLUTION |
|
ser I-EVOLUTION |
|
impracticable, I-EVOLUTION |
|
al I-EVOLUTION |
|
principio I-EVOLUTION |
|
a I-EVOLUTION |
|
causa I-EVOLUTION |
|
del I-EVOLUTION |
|
pigmento I-EVOLUTION |
|
vítreo I-EVOLUTION |
|
y I-EVOLUTION |
|
posteriormente I-EVOLUTION |
|
por I-EVOLUTION |
|
una I-EVOLUTION |
|
catarata. I-EVOLUTION |
|
<EOS> I-EVOLUTION |
|
A I-EVOLUTION |
|
los I-EVOLUTION |
|
19 I-EVOLUTION |
|
años I-EVOLUTION |
|
de I-EVOLUTION |
|
la I-EVOLUTION |
|
primera I-EVOLUTION |
|
visita I-EVOLUTION |
|
la I-EVOLUTION |
|
paciente I-EVOLUTION |
|
empezó I-EVOLUTION |
|
a I-EVOLUTION |
|
aquejar I-EVOLUTION |
|
intenso I-EVOLUTION |
|
dolor I-EVOLUTION |
|
debido I-EVOLUTION |
|
a I-EVOLUTION |
|
un I-EVOLUTION |
|
glaucoma I-EVOLUTION |
|
agudo I-EVOLUTION |
|
con I-EVOLUTION |
|
inflamación I-EVOLUTION |
|
en I-EVOLUTION |
|
cámara I-EVOLUTION |
|
anterior I-EVOLUTION |
|
y I-EVOLUTION |
|
seclusión I-EVOLUTION |
|
pupilar I-EVOLUTION |
|
sin I-EVOLUTION |
|
rubeosis I-EVOLUTION |
|
por B-TREATMENT |
|
lo I-TREATMENT |
|
que I-TREATMENT |
|
se I-TREATMENT |
|
decidió I-TREATMENT |
|
la I-TREATMENT |
|
enucleación. I-TREATMENT |
|
<EOS> I-TREATMENT |
|
En B-EXPLORATION |
|
el I-EXPLORATION |
|
examen I-EXPLORATION |
|
anatomopatológico I-EXPLORATION |
|
del I-EXPLORATION |
|
globo I-EXPLORATION |
|
ocular I-EXPLORATION |
|
: I-EXPLORATION |
|
el I-EXPLORATION |
|
ángulo I-EXPLORATION |
|
camerular I-EXPLORATION |
|
está I-EXPLORATION |
|
abierto, I-EXPLORATION |
|
contiene I-EXPLORATION |
|
abundantes I-EXPLORATION |
|
macrófagos I-EXPLORATION |
|
llenos I-EXPLORATION |
|
de I-EXPLORATION |
|
pigmento I-EXPLORATION |
|
que I-EXPLORATION |
|
infiltran I-EXPLORATION |
|
la I-EXPLORATION |
|
malla I-EXPLORATION |
|
trabecular, I-EXPLORATION |
|
rodean I-EXPLORATION |
|
el I-EXPLORATION |
|
canal I-EXPLORATION |
|
de I-EXPLORATION |
|
Schlemm, I-EXPLORATION |
|
tapizan I-EXPLORATION |
|
la I-EXPLORATION |
|
superficie I-EXPLORATION |
|
anterior I-EXPLORATION |
|
del I-EXPLORATION |
|
iris, I-EXPLORATION |
|
y I-EXPLORATION |
|
aparecen I-EXPLORATION |
|
sobre I-EXPLORATION |
|
la I-EXPLORATION |
|
cápsula I-EXPLORATION |
|
posterior I-EXPLORATION |
|
del I-EXPLORATION |
|
cristalino, I-EXPLORATION |
|
entre I-EXPLORATION |
|
los I-EXPLORATION |
|
procesos I-EXPLORATION |
|
ciliares I-EXPLORATION |
|
y I-EXPLORATION |
|
en I-EXPLORATION |
|
el I-EXPLORATION |
|
vítreo I-EXPLORATION |
|
anterior. I-EXPLORATION |
|
El I-EXPLORATION |
|
cristalino I-EXPLORATION |
|
es I-EXPLORATION |
|
cataratoso. I-EXPLORATION |
|
Emergiendo I-EXPLORATION |
|
de I-EXPLORATION |
|
la I-EXPLORATION |
|
cabeza I-EXPLORATION |
|
del I-EXPLORATION |
|
nervio I-EXPLORATION |
|
óptico I-EXPLORATION |
|
y I-EXPLORATION |
|
extendiéndose I-EXPLORATION |
|
por I-EXPLORATION |
|
la I-EXPLORATION |
|
retina I-EXPLORATION |
|
yuxtapapilar I-EXPLORATION |
|
se I-EXPLORATION |
|
aprecia I-EXPLORATION |
|
un I-EXPLORATION |
|
tumor I-EXPLORATION |
|
densamente I-EXPLORATION |
|
pigmentado I-EXPLORATION |
|
compuesto I-EXPLORATION |
|
por I-EXPLORATION |
|
células I-EXPLORATION |
|
grandes I-EXPLORATION |
|
poliédricas I-EXPLORATION |
|
con I-EXPLORATION |
|
citoplasma I-EXPLORATION |
|
abundante I-EXPLORATION |
|
y I-EXPLORATION |
|
núcleos I-EXPLORATION |
|
picnóticos I-EXPLORATION |
|
pequeños. I-EXPLORATION |
|
La I-EXPLORATION |
|
mayoría I-EXPLORATION |
|
de I-EXPLORATION |
|
las I-EXPLORATION |
|
células I-EXPLORATION |
|
son I-EXPLORATION |
|
anucleoladas I-EXPLORATION |
|
pero I-EXPLORATION |
|
unas I-EXPLORATION |
|
pocas I-EXPLORATION |
|
tienen I-EXPLORATION |
|
nucléolos I-EXPLORATION |
|
pequeños. I-EXPLORATION |
|
El I-EXPLORATION |
|
tumor I-EXPLORATION |
|
muestra I-EXPLORATION |
|
focos I-EXPLORATION |
|
de I-EXPLORATION |
|
necrosis I-EXPLORATION |
|
en I-EXPLORATION |
|
su I-EXPLORATION |
|
superficie, I-EXPLORATION |
|
con I-EXPLORATION |
|
siembra I-EXPLORATION |
|
de I-EXPLORATION |
|
macrófagos I-EXPLORATION |
|
llenos I-EXPLORATION |
|
de I-EXPLORATION |
|
pigmento I-EXPLORATION |
|
sobre I-EXPLORATION |
|
la I-EXPLORATION |
|
membrana I-EXPLORATION |
|
limitante I-EXPLORATION |
|
interna I-EXPLORATION |
|
y I-EXPLORATION |
|
en I-EXPLORATION |
|
el I-EXPLORATION |
|
vítreo. I-EXPLORATION |
|
En I-EXPLORATION |
|
algunas I-EXPLORATION |
|
áreas I-EXPLORATION |
|
se I-EXPLORATION |
|
observan I-EXPLORATION |
|
células I-EXPLORATION |
|
fusiformes I-EXPLORATION |
|
intensamente I-EXPLORATION |
|
pigmentadas. I-EXPLORATION |
|
Las I-EXPLORATION |
|
células I-EXPLORATION |
|
pigmentadas I-EXPLORATION |
|
en I-EXPLORATION |
|
muchas I-EXPLORATION |
|
áreas I-EXPLORATION |
|
se I-EXPLORATION |
|
extienden I-EXPLORATION |
|
a I-EXPLORATION |
|
lo I-EXPLORATION |
|
largo I-EXPLORATION |
|
de I-EXPLORATION |
|
la I-EXPLORATION |
|
membrana I-EXPLORATION |
|
limitante I-EXPLORATION |
|
interna I-EXPLORATION |
|
de I-EXPLORATION |
|
la I-EXPLORATION |
|
retina I-EXPLORATION |
|
llegando I-EXPLORATION |
|
hasta I-EXPLORATION |
|
la I-EXPLORATION |
|
ora I-EXPLORATION |
|
serrata. I-EXPLORATION |
|
Las I-EXPLORATION |
|
preparaciones I-EXPLORATION |
|
decoloradas I-EXPLORATION |
|
del I-EXPLORATION |
|
tumor I-EXPLORATION |
|
muestran I-EXPLORATION |
|
características I-EXPLORATION |
|
citológicas I-EXPLORATION |
|
benignas I-EXPLORATION |
|
propias I-EXPLORATION |
|
de I-EXPLORATION |
|
las I-EXPLORATION |
|
células I-EXPLORATION |
|
del I-EXPLORATION |
|
melanocitoma. I-EXPLORATION |
|
El I-EXPLORATION |
|
tumor I-EXPLORATION |
|
no I-EXPLORATION |
|
revela I-EXPLORATION |
|
actividad I-EXPLORATION |
|
mitótica, I-EXPLORATION |
|
no I-EXPLORATION |
|
se I-EXPLORATION |
|
observa I-EXPLORATION |
|
evidencia I-EXPLORATION |
|
de I-EXPLORATION |
|
melanoma I-EXPLORATION |
|
maligno I-EXPLORATION |
|
ni I-EXPLORATION |
|
de I-EXPLORATION |
|
extensión I-EXPLORATION |
|
extraocular. I-EXPLORATION |
|
<EOS> I-EXPLORATION |
|
|
|
Varón B-PRESENT_ILLNESS |
|
de I-PRESENT_ILLNESS |
|
70 I-PRESENT_ILLNESS |
|
años I-PRESENT_ILLNESS |
|
remitido I-PRESENT_ILLNESS |
|
por I-PRESENT_ILLNESS |
|
disminución I-PRESENT_ILLNESS |
|
progresiva I-PRESENT_ILLNESS |
|
de I-PRESENT_ILLNESS |
|
visión I-PRESENT_ILLNESS |
|
en I-PRESENT_ILLNESS |
|
ojo I-PRESENT_ILLNESS |
|
derecho I-PRESENT_ILLNESS |
|
(OD) I-PRESENT_ILLNESS |
|
y I-PRESENT_ILLNESS |
|
escotoma I-PRESENT_ILLNESS |
|
central I-PRESENT_ILLNESS |
|
relativo, I-PRESENT_ILLNESS |
|
de I-PRESENT_ILLNESS |
|
6 I-PRESENT_ILLNESS |
|
meses I-PRESENT_ILLNESS |
|
de I-PRESENT_ILLNESS |
|
evolución. I-PRESENT_ILLNESS |
|
Sin B-PAST_MEDICAL_HISTORY |
|
antecedentes I-PAST_MEDICAL_HISTORY |
|
oftalmológicos I-PAST_MEDICAL_HISTORY |
|
personales I-PAST_MEDICAL_HISTORY |
|
ni I-PAST_MEDICAL_HISTORY |
|
familiares I-PAST_MEDICAL_HISTORY |
|
conocidos. I-PAST_MEDICAL_HISTORY |
|
Diabetes I-PAST_MEDICAL_HISTORY |
|
mellitus I-PAST_MEDICAL_HISTORY |
|
tipo I-PAST_MEDICAL_HISTORY |
|
2, I-PAST_MEDICAL_HISTORY |
|
de I-PAST_MEDICAL_HISTORY |
|
tres I-PAST_MEDICAL_HISTORY |
|
años I-PAST_MEDICAL_HISTORY |
|
de I-PAST_MEDICAL_HISTORY |
|
evolución, I-PAST_MEDICAL_HISTORY |
|
con I-PAST_MEDICAL_HISTORY |
|
buen I-PAST_MEDICAL_HISTORY |
|
control I-PAST_MEDICAL_HISTORY |
|
metabólico, I-PAST_MEDICAL_HISTORY |
|
e I-PAST_MEDICAL_HISTORY |
|
hipertensión I-PAST_MEDICAL_HISTORY |
|
arterial I-PAST_MEDICAL_HISTORY |
|
en I-PAST_MEDICAL_HISTORY |
|
tratamiento. I-PAST_MEDICAL_HISTORY |
|
<EOS> I-PAST_MEDICAL_HISTORY |
|
La B-EXPLORATION |
|
mejor I-EXPLORATION |
|
agudeza I-EXPLORATION |
|
visual I-EXPLORATION |
|
con I-EXPLORATION |
|
corrección I-EXPLORATION |
|
en I-EXPLORATION |
|
la I-EXPLORATION |
|
exploración I-EXPLORATION |
|
inicial I-EXPLORATION |
|
era I-EXPLORATION |
|
de I-EXPLORATION |
|
4/10 I-EXPLORATION |
|
en I-EXPLORATION |
|
OD I-EXPLORATION |
|
(+1, I-EXPLORATION |
|
75; I-EXPLORATION |
|
-1.00×95o) I-EXPLORATION |
|
y I-EXPLORATION |
|
8/10 I-EXPLORATION |
|
en I-EXPLORATION |
|
ojo I-EXPLORATION |
|
izquierdo I-EXPLORATION |
|
(OI) I-EXPLORATION |
|
(+1, I-EXPLORATION |
|
75; I-EXPLORATION |
|
-1, I-EXPLORATION |
|
50×85o). I-EXPLORATION |
|
La I-EXPLORATION |
|
biomicroscopia I-EXPLORATION |
|
del I-EXPLORATION |
|
polo I-EXPLORATION |
|
anterior I-EXPLORATION |
|
era I-EXPLORATION |
|
normal. I-EXPLORATION |
|
En I-EXPLORATION |
|
el I-EXPLORATION |
|
fondo I-EXPLORATION |
|
de I-EXPLORATION |
|
ojo I-EXPLORATION |
|
se I-EXPLORATION |
|
observaba I-EXPLORATION |
|
la I-EXPLORATION |
|
presencia I-EXPLORATION |
|
de I-EXPLORATION |
|
una I-EXPLORATION |
|
lesión I-EXPLORATION |
|
amarillenta, I-EXPLORATION |
|
sobreelevada I-EXPLORATION |
|
en I-EXPLORATION |
|
el I-EXPLORATION |
|
área I-EXPLORATION |
|
macular I-EXPLORATION |
|
del I-EXPLORATION |
|
OD I-EXPLORATION |
|
y I-EXPLORATION |
|
alteración I-EXPLORATION |
|
pigmentaria I-EXPLORATION |
|
macular I-EXPLORATION |
|
en I-EXPLORATION |
|
el I-EXPLORATION |
|
OI. I-EXPLORATION |
|
No I-EXPLORATION |
|
se I-EXPLORATION |
|
encontraron I-EXPLORATION |
|
signos I-EXPLORATION |
|
de I-EXPLORATION |
|
retinopatía I-EXPLORATION |
|
diabética I-EXPLORATION |
|
en I-EXPLORATION |
|
ninguno I-EXPLORATION |
|
de I-EXPLORATION |
|
los I-EXPLORATION |
|
ojos. I-EXPLORATION |
|
La I-EXPLORATION |
|
tomografía I-EXPLORATION |
|
de I-EXPLORATION |
|
coherencia I-EXPLORATION |
|
óptica I-EXPLORATION |
|
(OCT) I-EXPLORATION |
|
mostraba, I-EXPLORATION |
|
en I-EXPLORATION |
|
el I-EXPLORATION |
|
área I-EXPLORATION |
|
macular I-EXPLORATION |
|
del I-EXPLORATION |
|
OD, I-EXPLORATION |
|
la I-EXPLORATION |
|
presencia I-EXPLORATION |
|
de I-EXPLORATION |
|
una I-EXPLORATION |
|
masa I-EXPLORATION |
|
de I-EXPLORATION |
|
reflectividad I-EXPLORATION |
|
media, I-EXPLORATION |
|
por I-EXPLORATION |
|
encima I-EXPLORATION |
|
de I-EXPLORATION |
|
la I-EXPLORATION |
|
banda I-EXPLORATION |
|
del I-EXPLORATION |
|
epitelio I-EXPLORATION |
|
pigmentario, I-EXPLORATION |
|
con I-EXPLORATION |
|
levantamiento I-EXPLORATION |
|
de I-EXPLORATION |
|
la I-EXPLORATION |
|
retina I-EXPLORATION |
|
neurosensorial, I-EXPLORATION |
|
sin I-EXPLORATION |
|
evidencia I-EXPLORATION |
|
de I-EXPLORATION |
|
fluido I-EXPLORATION |
|
intrarretiniano I-EXPLORATION |
|
ni I-EXPLORATION |
|
subretiniano. I-EXPLORATION |
|
En I-EXPLORATION |
|
la I-EXPLORATION |
|
angiografía I-EXPLORATION |
|
fluoresceínica I-EXPLORATION |
|
(AGF) I-EXPLORATION |
|
podía I-EXPLORATION |
|
comprobarse I-EXPLORATION |
|
la I-EXPLORATION |
|
presencia I-EXPLORATION |
|
de I-EXPLORATION |
|
una I-EXPLORATION |
|
lesión I-EXPLORATION |
|
hiperfluorescente I-EXPLORATION |
|
con I-EXPLORATION |
|
centro I-EXPLORATION |
|
de I-EXPLORATION |
|
hipofluorescencia, I-EXPLORATION |
|
que I-EXPLORATION |
|
aumentaba I-EXPLORATION |
|
de I-EXPLORATION |
|
intensidad I-EXPLORATION |
|
en I-EXPLORATION |
|
fases I-EXPLORATION |
|
tardías I-EXPLORATION |
|
pero I-EXPLORATION |
|
sin I-EXPLORATION |
|
difusión I-EXPLORATION |
|
del I-EXPLORATION |
|
contraste, I-EXPLORATION |
|
que I-EXPLORATION |
|
confirmaría I-EXPLORATION |
|
el I-EXPLORATION |
|
diagnóstico I-EXPLORATION |
|
de I-EXPLORATION |
|
DFVA. I-EXPLORATION |
|
Las I-EXPLORATION |
|
pruebas I-EXPLORATION |
|
electrofisiológicas, I-EXPLORATION |
|
tanto I-EXPLORATION |
|
el I-EXPLORATION |
|
electrorretinograma I-EXPLORATION |
|
como I-EXPLORATION |
|
el I-EXPLORATION |
|
electrooculograma, I-EXPLORATION |
|
fueron I-EXPLORATION |
|
normales. I-EXPLORATION |
|
<EOS> I-EXPLORATION |
|
A I-EXPLORATION |
|
partir I-EXPLORATION |
|
de I-EXPLORATION |
|
ese I-EXPLORATION |
|
momento I-EXPLORATION |
|
se I-EXPLORATION |
|
establecieron I-EXPLORATION |
|
controles I-EXPLORATION |
|
oftalmológicos I-EXPLORATION |
|
periódicos, I-EXPLORATION |
|
en I-EXPLORATION |
|
los I-EXPLORATION |
|
que I-EXPLORATION |
|
se I-EXPLORATION |
|
evidenció I-EXPLORATION |
|
la I-EXPLORATION |
|
regresión I-EXPLORATION |
|
progresiva I-EXPLORATION |
|
de I-EXPLORATION |
|
la I-EXPLORATION |
|
lesión I-EXPLORATION |
|
viteliforme I-EXPLORATION |
|
y I-EXPLORATION |
|
la I-EXPLORATION |
|
evolución I-EXPLORATION |
|
hacia I-EXPLORATION |
|
la I-EXPLORATION |
|
atrofia I-EXPLORATION |
|
del I-EXPLORATION |
|
epitelio I-EXPLORATION |
|
pigmentario I-EXPLORATION |
|
macular I-EXPLORATION |
|
en I-EXPLORATION |
|
el I-EXPLORATION |
|
OD. I-EXPLORATION |
|
La I-EXPLORATION |
|
visión I-EXPLORATION |
|
en I-EXPLORATION |
|
el I-EXPLORATION |
|
OI I-EXPLORATION |
|
se I-EXPLORATION |
|
mantuvo I-EXPLORATION |
|
estable I-EXPLORATION |
|
(7/10), I-EXPLORATION |
|
a I-EXPLORATION |
|
pesar I-EXPLORATION |
|
de I-EXPLORATION |
|
que I-EXPLORATION |
|
las I-EXPLORATION |
|
alteraciones I-EXPLORATION |
|
pigmentarias I-EXPLORATION |
|
maculares I-EXPLORATION |
|
eran I-EXPLORATION |
|
cada I-EXPLORATION |
|
vez I-EXPLORATION |
|
más I-EXPLORATION |
|
evidentes. I-EXPLORATION |
|
<EOS> I-EXPLORATION |
|
Dos B-EVOLUTION |
|
años I-EVOLUTION |
|
y I-EVOLUTION |
|
medio I-EVOLUTION |
|
después I-EVOLUTION |
|
de I-EVOLUTION |
|
la I-EVOLUTION |
|
primera I-EVOLUTION |
|
visita, I-EVOLUTION |
|
el I-EVOLUTION |
|
paciente I-EVOLUTION |
|
consulta I-EVOLUTION |
|
por I-EVOLUTION |
|
disminución I-EVOLUTION |
|
brusca I-EVOLUTION |
|
de I-EVOLUTION |
|
visión I-EVOLUTION |
|
en I-EVOLUTION |
|
el I-EVOLUTION |
|
OI I-EVOLUTION |
|
(2/10), I-EVOLUTION |
|
coincidiendo I-EVOLUTION |
|
con I-EVOLUTION |
|
la I-EVOLUTION |
|
aparición I-EVOLUTION |
|
de I-EVOLUTION |
|
un I-EVOLUTION |
|
desprendimiento I-EVOLUTION |
|
macular I-EVOLUTION |
|
serohemorrágico I-EVOLUTION |
|
en I-EVOLUTION |
|
dicho I-EVOLUTION |
|
ojo. I-EVOLUTION |
|
La B-EXPLORATION |
|
OCT I-EXPLORATION |
|
mostraba I-EXPLORATION |
|
un I-EXPLORATION |
|
importante I-EXPLORATION |
|
levantamiento I-EXPLORATION |
|
macular I-EXPLORATION |
|
con I-EXPLORATION |
|
desprendimiento I-EXPLORATION |
|
del I-EXPLORATION |
|
epitelio I-EXPLORATION |
|
pigmentario, I-EXPLORATION |
|
quistes I-EXPLORATION |
|
intrarretinianos I-EXPLORATION |
|
y I-EXPLORATION |
|
presencia I-EXPLORATION |
|
de I-EXPLORATION |
|
líquido I-EXPLORATION |
|
subretiniano I-EXPLORATION |
|
(LSR) I-EXPLORATION |
|
en I-EXPLORATION |
|
los I-EXPLORATION |
|
bordes I-EXPLORATION |
|
de I-EXPLORATION |
|
la I-EXPLORATION |
|
lesión. I-EXPLORATION |
|
Mediante I-EXPLORATION |
|
AGF I-EXPLORATION |
|
se I-EXPLORATION |
|
comprobó I-EXPLORATION |
|
la I-EXPLORATION |
|
existencia I-EXPLORATION |
|
de I-EXPLORATION |
|
una I-EXPLORATION |
|
membrana I-EXPLORATION |
|
neovascular I-EXPLORATION |
|
oculta I-EXPLORATION |
|
con I-EXPLORATION |
|
difusión I-EXPLORATION |
|
tardía I-EXPLORATION |
|
del I-EXPLORATION |
|
colorante. I-EXPLORATION |
|
En B-TREATMENT |
|
este I-TREATMENT |
|
momento I-TREATMENT |
|
se I-TREATMENT |
|
decidió I-TREATMENT |
|
realizar I-TREATMENT |
|
tratamiento I-TREATMENT |
|
en I-TREATMENT |
|
el I-TREATMENT |
|
OI I-TREATMENT |
|
con I-TREATMENT |
|
ranibizumab I-TREATMENT |
|
intravítreo, I-TREATMENT |
|
a I-TREATMENT |
|
la I-TREATMENT |
|
dosis I-TREATMENT |
|
habitualmente I-TREATMENT |
|
utilizada I-TREATMENT |
|
para I-TREATMENT |
|
el I-TREATMENT |
|
tratamiento I-TREATMENT |
|
de I-TREATMENT |
|
la I-TREATMENT |
|
degeneración I-TREATMENT |
|
macular I-TREATMENT |
|
exudativa I-TREATMENT |
|
(0,5mg/0,05ml). I-TREATMENT |
|
<EOS> I-TREATMENT |
|
A B-EVOLUTION |
|
las I-EVOLUTION |
|
4 I-EVOLUTION |
|
semanas I-EVOLUTION |
|
de I-EVOLUTION |
|
la I-EVOLUTION |
|
inyección I-EVOLUTION |
|
la I-EVOLUTION |
|
agudeza I-EVOLUTION |
|
visual I-EVOLUTION |
|
había I-EVOLUTION |
|
mejorado I-EVOLUTION |
|
a I-EVOLUTION |
|
3/10 I-EVOLUTION |
|
en I-EVOLUTION |
|
el I-EVOLUTION |
|
OI, I-EVOLUTION |
|
con I-EVOLUTION |
|
reabsorción I-EVOLUTION |
|
prácticamente I-EVOLUTION |
|
completa I-EVOLUTION |
|
de I-EVOLUTION |
|
la I-EVOLUTION |
|
hemorragia I-EVOLUTION |
|
macular, I-EVOLUTION |
|
apreciándose I-EVOLUTION |
|
una I-EVOLUTION |
|
mínima I-EVOLUTION |
|
cantidad I-EVOLUTION |
|
de I-EVOLUTION |
|
LSR I-EVOLUTION |
|
en I-EVOLUTION |
|
la I-EVOLUTION |
|
tomografía. I-EVOLUTION |
|
Tras I-EVOLUTION |
|
8 I-EVOLUTION |
|
semanas, I-EVOLUTION |
|
la I-EVOLUTION |
|
AV I-EVOLUTION |
|
era I-EVOLUTION |
|
de I-EVOLUTION |
|
4/10, I-EVOLUTION |
|
comprobándose I-EVOLUTION |
|
en I-EVOLUTION |
|
la I-EVOLUTION |
|
OCT I-EVOLUTION |
|
una I-EVOLUTION |
|
disminución I-EVOLUTION |
|
importante I-EVOLUTION |
|
del I-EVOLUTION |
|
grosor I-EVOLUTION |
|
macular I-EVOLUTION |
|
central I-EVOLUTION |
|
con I-EVOLUTION |
|
mínima I-EVOLUTION |
|
fibrosis I-EVOLUTION |
|
subretiniana. I-EVOLUTION |
|
En I-EVOLUTION |
|
el I-EVOLUTION |
|
control I-EVOLUTION |
|
de I-EVOLUTION |
|
los I-EVOLUTION |
|
3 I-EVOLUTION |
|
meses, I-EVOLUTION |
|
la I-EVOLUTION |
|
visión I-EVOLUTION |
|
en I-EVOLUTION |
|
el I-EVOLUTION |
|
OI I-EVOLUTION |
|
había I-EVOLUTION |
|
descendido I-EVOLUTION |
|
(2/10), I-EVOLUTION |
|
evidenciándose I-EVOLUTION |
|
en I-EVOLUTION |
|
la I-EVOLUTION |
|
OCT I-EVOLUTION |
|
un I-EVOLUTION |
|
aumento I-EVOLUTION |
|
del I-EVOLUTION |
|
espesor I-EVOLUTION |
|
macular I-EVOLUTION |
|
superior I-EVOLUTION |
|
a I-EVOLUTION |
|
100micras, I-EVOLUTION |
|
con I-EVOLUTION |
|
presencia I-EVOLUTION |
|
de I-EVOLUTION |
|
líquido I-EVOLUTION |
|
subretiniano, I-EVOLUTION |
|
por B-TREATMENT |
|
lo I-TREATMENT |
|
que I-TREATMENT |
|
se I-TREATMENT |
|
decide I-TREATMENT |
|
realizar I-TREATMENT |
|
segunda I-TREATMENT |
|
inyección I-TREATMENT |
|
de I-TREATMENT |
|
ranibizumab. I-TREATMENT |
|
La B-EVOLUTION |
|
respuesta I-EVOLUTION |
|
a I-EVOLUTION |
|
esta I-EVOLUTION |
|
segunda I-EVOLUTION |
|
inyección I-EVOLUTION |
|
fue I-EVOLUTION |
|
favorable, I-EVOLUTION |
|
y I-EVOLUTION |
|
a I-EVOLUTION |
|
las I-EVOLUTION |
|
12 I-EVOLUTION |
|
semanas I-EVOLUTION |
|
se I-EVOLUTION |
|
pudo I-EVOLUTION |
|
comprobar I-EVOLUTION |
|
la I-EVOLUTION |
|
reabsorción I-EVOLUTION |
|
completa I-EVOLUTION |
|
del I-EVOLUTION |
|
fluido I-EVOLUTION |
|
subretiniano, I-EVOLUTION |
|
quedando I-EVOLUTION |
|
una I-EVOLUTION |
|
mínima I-EVOLUTION |
|
fibrosis I-EVOLUTION |
|
subretiniana I-EVOLUTION |
|
como I-EVOLUTION |
|
resultado I-EVOLUTION |
|
del I-EVOLUTION |
|
cierre I-EVOLUTION |
|
de I-EVOLUTION |
|
la I-EVOLUTION |
|
membrana I-EVOLUTION |
|
neovascular. I-EVOLUTION |
|
<EOS> I-EVOLUTION |
|
Doce I-EVOLUTION |
|
meses I-EVOLUTION |
|
después I-EVOLUTION |
|
de I-EVOLUTION |
|
la I-EVOLUTION |
|
última I-EVOLUTION |
|
inyección I-EVOLUTION |
|
la I-EVOLUTION |
|
agudeza I-EVOLUTION |
|
visual I-EVOLUTION |
|
se I-EVOLUTION |
|
mantiene I-EVOLUTION |
|
estable I-EVOLUTION |
|
en I-EVOLUTION |
|
el I-EVOLUTION |
|
OI I-EVOLUTION |
|
(6/10), I-EVOLUTION |
|
sin I-EVOLUTION |
|
signos I-EVOLUTION |
|
de I-EVOLUTION |
|
reactivación I-EVOLUTION |
|
de I-EVOLUTION |
|
la I-EVOLUTION |
|
membrana I-EVOLUTION |
|
y I-EVOLUTION |
|
sin I-EVOLUTION |
|
complicaciones I-EVOLUTION |
|
derivadas I-EVOLUTION |
|
del I-EVOLUTION |
|
tratamiento I-EVOLUTION |
|
intravítreo. I-EVOLUTION |
|
<EOS> I-EVOLUTION |
|
|
|
Embarazada B-PRESENT_ILLNESS |
|
de I-PRESENT_ILLNESS |
|
40 I-PRESENT_ILLNESS |
|
años I-PRESENT_ILLNESS |
|
multípara B-PAST_MEDICAL_HISTORY |
|
de I-PAST_MEDICAL_HISTORY |
|
tres, I-PAST_MEDICAL_HISTORY |
|
serología I-PAST_MEDICAL_HISTORY |
|
VIH I-PAST_MEDICAL_HISTORY |
|
negativo, I-PAST_MEDICAL_HISTORY |
|
cursó I-PAST_MEDICAL_HISTORY |
|
con I-PAST_MEDICAL_HISTORY |
|
sífilis I-PAST_MEDICAL_HISTORY |
|
latente I-PAST_MEDICAL_HISTORY |
|
precoz I-PAST_MEDICAL_HISTORY |
|
diagnosticada I-PAST_MEDICAL_HISTORY |
|
en I-PAST_MEDICAL_HISTORY |
|
la I-PAST_MEDICAL_HISTORY |
|
semana I-PAST_MEDICAL_HISTORY |
|
28 I-PAST_MEDICAL_HISTORY |
|
de I-PAST_MEDICAL_HISTORY |
|
embarazo I-PAST_MEDICAL_HISTORY |
|
(VDRL I-PAST_MEDICAL_HISTORY |
|
no I-PAST_MEDICAL_HISTORY |
|
reactivo I-PAST_MEDICAL_HISTORY |
|
a I-PAST_MEDICAL_HISTORY |
|
las I-PAST_MEDICAL_HISTORY |
|
12 I-PAST_MEDICAL_HISTORY |
|
semanas I-PAST_MEDICAL_HISTORY |
|
de I-PAST_MEDICAL_HISTORY |
|
gestación, I-PAST_MEDICAL_HISTORY |
|
VDRL I-PAST_MEDICAL_HISTORY |
|
1: I-PAST_MEDICAL_HISTORY |
|
128 I-PAST_MEDICAL_HISTORY |
|
a I-PAST_MEDICAL_HISTORY |
|
las I-PAST_MEDICAL_HISTORY |
|
28 I-PAST_MEDICAL_HISTORY |
|
semanas I-PAST_MEDICAL_HISTORY |
|
y I-PAST_MEDICAL_HISTORY |
|
VDRL I-PAST_MEDICAL_HISTORY |
|
1: I-PAST_MEDICAL_HISTORY |
|
32 I-PAST_MEDICAL_HISTORY |
|
a I-PAST_MEDICAL_HISTORY |
|
las I-PAST_MEDICAL_HISTORY |
|
31 I-PAST_MEDICAL_HISTORY |
|
semanas, I-PAST_MEDICAL_HISTORY |
|
MHA-TP I-PAST_MEDICAL_HISTORY |
|
(microhemagglutination-Treponema I-PAST_MEDICAL_HISTORY |
|
pallidum I-PAST_MEDICAL_HISTORY |
|
test) I-PAST_MEDICAL_HISTORY |
|
positivo. I-PAST_MEDICAL_HISTORY |
|
Tratada I-PAST_MEDICAL_HISTORY |
|
junto I-PAST_MEDICAL_HISTORY |
|
a I-PAST_MEDICAL_HISTORY |
|
su I-PAST_MEDICAL_HISTORY |
|
pareja I-PAST_MEDICAL_HISTORY |
|
3 I-PAST_MEDICAL_HISTORY |
|
semanas I-PAST_MEDICAL_HISTORY |
|
antes I-PAST_MEDICAL_HISTORY |
|
del I-PAST_MEDICAL_HISTORY |
|
inicio I-PAST_MEDICAL_HISTORY |
|
del I-PAST_MEDICAL_HISTORY |
|
trabajo I-PAST_MEDICAL_HISTORY |
|
de I-PAST_MEDICAL_HISTORY |
|
parto. I-PAST_MEDICAL_HISTORY |
|
Sin I-PAST_MEDICAL_HISTORY |
|
historia I-PAST_MEDICAL_HISTORY |
|
de I-PAST_MEDICAL_HISTORY |
|
sífilis I-PAST_MEDICAL_HISTORY |
|
en I-PAST_MEDICAL_HISTORY |
|
embarazos I-PAST_MEDICAL_HISTORY |
|
previos I-PAST_MEDICAL_HISTORY |
|
y I-PAST_MEDICAL_HISTORY |
|
pareja I-PAST_MEDICAL_HISTORY |
|
estable I-PAST_MEDICAL_HISTORY |
|
hace I-PAST_MEDICAL_HISTORY |
|
más I-PAST_MEDICAL_HISTORY |
|
de I-PAST_MEDICAL_HISTORY |
|
2 I-PAST_MEDICAL_HISTORY |
|
años. I-PAST_MEDICAL_HISTORY |
|
Ingresó B-PRESENT_ILLNESS |
|
al I-PRESENT_ILLNESS |
|
Servicio I-PRESENT_ILLNESS |
|
de I-PRESENT_ILLNESS |
|
Urgencia I-PRESENT_ILLNESS |
|
por I-PRESENT_ILLNESS |
|
rotura I-PRESENT_ILLNESS |
|
prematura I-PRESENT_ILLNESS |
|
ovular I-PRESENT_ILLNESS |
|
de I-PRESENT_ILLNESS |
|
30 I-PRESENT_ILLNESS |
|
h I-PRESENT_ILLNESS |
|
de I-PRESENT_ILLNESS |
|
evolución I-PRESENT_ILLNESS |
|
administrándose B-TREATMENT |
|
corticoides I-TREATMENT |
|
y I-TREATMENT |
|
6 I-TREATMENT |
|
dosis I-TREATMENT |
|
de I-TREATMENT |
|
ampicilina. I-TREATMENT |
|
Se B-EXPLORATION |
|
realizó I-EXPLORATION |
|
RPR I-EXPLORATION |
|
en I-EXPLORATION |
|
parto I-EXPLORATION |
|
que I-EXPLORATION |
|
resultó I-EXPLORATION |
|
no I-EXPLORATION |
|
reactivo I-EXPLORATION |
|
(no I-EXPLORATION |
|
se I-EXPLORATION |
|
realizó I-EXPLORATION |
|
VDRL). I-EXPLORATION |
|
<EOS> I-EXPLORATION |
|
Nació B-EVOLUTION |
|
RN I-EVOLUTION |
|
por I-EVOLUTION |
|
parto I-EVOLUTION |
|
vaginal I-EVOLUTION |
|
de I-EVOLUTION |
|
34 I-EVOLUTION |
|
semanas, I-EVOLUTION |
|
pequeño I-EVOLUTION |
|
para I-EVOLUTION |
|
la I-EVOLUTION |
|
edad I-EVOLUTION |
|
gestacional I-EVOLUTION |
|
(PEG) I-EVOLUTION |
|
peso I-EVOLUTION |
|
de I-EVOLUTION |
|
1.920 I-EVOLUTION |
|
g, I-EVOLUTION |
|
con I-EVOLUTION |
|
cianosis I-EVOLUTION |
|
generalizada, I-EVOLUTION |
|
sin I-EVOLUTION |
|
esfuerzo I-EVOLUTION |
|
respiratorio, I-EVOLUTION |
|
APGAR I-EVOLUTION |
|
6-8, I-EVOLUTION |
|
requiriendo B-TREATMENT |
|
ventilación I-TREATMENT |
|
a I-TREATMENT |
|
presión I-TREATMENT |
|
positiva. I-TREATMENT |
|
Cursó I-TREATMENT |
|
con I-TREATMENT |
|
enfermedad I-TREATMENT |
|
de I-TREATMENT |
|
membrana I-TREATMENT |
|
hialina I-TREATMENT |
|
(EMH) I-TREATMENT |
|
administrándose I-TREATMENT |
|
surfactante, I-TREATMENT |
|
sin I-TREATMENT |
|
embargo, I-TREATMENT |
|
por I-TREATMENT |
|
compromiso I-TREATMENT |
|
respiratorio I-TREATMENT |
|
progresivo I-TREATMENT |
|
debió I-TREATMENT |
|
conectarse I-TREATMENT |
|
a I-TREATMENT |
|
ventilación I-TREATMENT |
|
mecánica. I-TREATMENT |
|
Evolucionó B-EVOLUTION |
|
grave I-EVOLUTION |
|
con I-EVOLUTION |
|
altos I-EVOLUTION |
|
requerimientos I-EVOLUTION |
|
de I-EVOLUTION |
|
oxígeno, I-EVOLUTION |
|
con I-EVOLUTION |
|
deterioro I-EVOLUTION |
|
del I-EVOLUTION |
|
estado I-EVOLUTION |
|
general, I-EVOLUTION |
|
se I-EVOLUTION |
|
agregó I-EVOLUTION |
|
ictericia I-EVOLUTION |
|
generalizada, I-EVOLUTION |
|
petequias I-EVOLUTION |
|
múltiples, I-EVOLUTION |
|
sangrado I-EVOLUTION |
|
en I-EVOLUTION |
|
sitios I-EVOLUTION |
|
de I-EVOLUTION |
|
punción I-EVOLUTION |
|
e I-EVOLUTION |
|
hipertensión I-EVOLUTION |
|
pulmonar I-EVOLUTION |
|
por B-TREATMENT |
|
lo I-TREATMENT |
|
que I-TREATMENT |
|
debió I-TREATMENT |
|
iniciarse I-TREATMENT |
|
drogas I-TREATMENT |
|
vasoactivas. I-TREATMENT |
|
Al B-EXPLORATION |
|
examen I-EXPLORATION |
|
físico I-EXPLORATION |
|
destacaba: I-EXPLORATION |
|
abdomen I-EXPLORATION |
|
globuloso, I-EXPLORATION |
|
hepato-esplenomegalia I-EXPLORATION |
|
(ambos I-EXPLORATION |
|
en I-EXPLORATION |
|
3 I-EXPLORATION |
|
cm I-EXPLORATION |
|
bajo I-EXPLORATION |
|
reborde I-EXPLORATION |
|
costal), I-EXPLORATION |
|
petequias, I-EXPLORATION |
|
edema I-EXPLORATION |
|
de I-EXPLORATION |
|
pared I-EXPLORATION |
|
abdominal I-EXPLORATION |
|
y I-EXPLORATION |
|
extremidades, I-EXPLORATION |
|
y I-EXPLORATION |
|
descamación I-EXPLORATION |
|
palmo-plantar. I-EXPLORATION |
|
Inició B-TREATMENT |
|
tratamiento I-TREATMENT |
|
con I-TREATMENT |
|
penicilina I-TREATMENT |
|
sódica I-TREATMENT |
|
y I-TREATMENT |
|
gentamicina I-TREATMENT |
|
i.v. I-TREATMENT |
|
por I-TREATMENT |
|
sospecha I-TREATMENT |
|
de I-TREATMENT |
|
sepsis I-TREATMENT |
|
precoz. I-TREATMENT |
|
<EOS> I-TREATMENT |
|
Se B-EXPLORATION |
|
recibió I-EXPLORATION |
|
resultado I-EXPLORATION |
|
del I-EXPLORATION |
|
VDRL I-EXPLORATION |
|
en I-EXPLORATION |
|
sangre I-EXPLORATION |
|
del I-EXPLORATION |
|
RN I-EXPLORATION |
|
1: I-EXPLORATION |
|
64, I-EXPLORATION |
|
no I-EXPLORATION |
|
se I-EXPLORATION |
|
realizó I-EXPLORATION |
|
punción I-EXPLORATION |
|
lumbar I-EXPLORATION |
|
(PL) I-EXPLORATION |
|
en I-EXPLORATION |
|
ese I-EXPLORATION |
|
momento I-EXPLORATION |
|
por I-EXPLORATION |
|
gravedad I-EXPLORATION |
|
y I-EXPLORATION |
|
trombocitopenia I-EXPLORATION |
|
marcada. I-EXPLORATION |
|
Los I-EXPLORATION |
|
exámenes I-EXPLORATION |
|
de I-EXPLORATION |
|
laboratorio I-EXPLORATION |
|
iniciales I-EXPLORATION |
|
se I-EXPLORATION |
|
muestran I-EXPLORATION |
|
en I-EXPLORATION |
|
la I-EXPLORATION |
|
tabla I-EXPLORATION |
|
1. I-EXPLORATION |
|
<EOS> I-EXPLORATION |
|
Se I-EXPLORATION |
|
asumió I-EXPLORATION |
|
diagnóstico I-EXPLORATION |
|
probable I-EXPLORATION |
|
de I-EXPLORATION |
|
sífilis I-EXPLORATION |
|
congénita I-EXPLORATION |
|
y I-EXPLORATION |
|
sepsis I-EXPLORATION |
|
precoz, I-EXPLORATION |
|
se I-EXPLORATION |
|
decidió I-EXPLORATION |
|
completar I-EXPLORATION |
|
estudio I-EXPLORATION |
|
para I-EXPLORATION |
|
pesquisa I-EXPLORATION |
|
de I-EXPLORATION |
|
daño I-EXPLORATION |
|
multisistémico. I-EXPLORATION |
|
Se I-EXPLORATION |
|
realizó I-EXPLORATION |
|
ecocardiografía, I-EXPLORATION |
|
ecografía I-EXPLORATION |
|
abdominal I-EXPLORATION |
|
y I-EXPLORATION |
|
ecografía I-EXPLORATION |
|
cerebral I-EXPLORATION |
|
que I-EXPLORATION |
|
resultaron I-EXPLORATION |
|
normales. I-EXPLORATION |
|
Los I-EXPLORATION |
|
hemocultivos I-EXPLORATION |
|
fueron I-EXPLORATION |
|
negativos. I-EXPLORATION |
|
Completó B-EVOLUTION |
|
tratamiento I-EVOLUTION |
|
antibiótico I-EVOLUTION |
|
con I-EVOLUTION |
|
7 I-EVOLUTION |
|
días I-EVOLUTION |
|
de I-EVOLUTION |
|
gentamicina I-EVOLUTION |
|
iv I-EVOLUTION |
|
y I-EVOLUTION |
|
14 I-EVOLUTION |
|
de I-EVOLUTION |
|
penicilina I-EVOLUTION |
|
sódica I-EVOLUTION |
|
iv., I-EVOLUTION |
|
lográndose I-EVOLUTION |
|
disminuir I-EVOLUTION |
|
progresivamente I-EVOLUTION |
|
las I-EVOLUTION |
|
drogas I-EVOLUTION |
|
vasoactivas I-EVOLUTION |
|
hasta I-EVOLUTION |
|
su I-EVOLUTION |
|
suspensión. I-EVOLUTION |
|
<EOS> I-EVOLUTION |
|
En B-EXPLORATION |
|
contexto I-EXPLORATION |
|
de I-EXPLORATION |
|
transaminasas I-EXPLORATION |
|
elevadas I-EXPLORATION |
|
y I-EXPLORATION |
|
hepatomegalia I-EXPLORATION |
|
se I-EXPLORATION |
|
completó I-EXPLORATION |
|
estudio I-EXPLORATION |
|
con I-EXPLORATION |
|
serología I-EXPLORATION |
|
para I-EXPLORATION |
|
Hepatitis I-EXPLORATION |
|
B I-EXPLORATION |
|
y I-EXPLORATION |
|
C I-EXPLORATION |
|
que I-EXPLORATION |
|
resultaron I-EXPLORATION |
|
negativas. I-EXPLORATION |
|
No I-EXPLORATION |
|
se I-EXPLORATION |
|
realizó I-EXPLORATION |
|
estudio I-EXPLORATION |
|
de I-EXPLORATION |
|
citomegalovirus I-EXPLORATION |
|
(CMV). I-EXPLORATION |
|
Se I-EXPLORATION |
|
logró I-EXPLORATION |
|
realizar I-EXPLORATION |
|
PL I-EXPLORATION |
|
a I-EXPLORATION |
|
los I-EXPLORATION |
|
28 I-EXPLORATION |
|
días I-EXPLORATION |
|
de I-EXPLORATION |
|
vida, I-EXPLORATION |
|
resultando I-EXPLORATION |
|
citoquímico I-EXPLORATION |
|
de I-EXPLORATION |
|
líquido I-EXPLORATION |
|
cefalorraquídeo I-EXPLORATION |
|
(LCR) I-EXPLORATION |
|
normal I-EXPLORATION |
|
y I-EXPLORATION |
|
VDRL I-EXPLORATION |
|
no I-EXPLORATION |
|
reactivo, I-EXPLORATION |
|
con I-EXPLORATION |
|
VDRL I-EXPLORATION |
|
en I-EXPLORATION |
|
sangre I-EXPLORATION |
|
de I-EXPLORATION |
|
1: I-EXPLORATION |
|
32. I-EXPLORATION |
|
Radiografía I-EXPLORATION |
|
de I-EXPLORATION |
|
huesos I-EXPLORATION |
|
largos I-EXPLORATION |
|
y I-EXPLORATION |
|
fondo I-EXPLORATION |
|
de I-EXPLORATION |
|
ojo I-EXPLORATION |
|
no I-EXPLORATION |
|
mostraron I-EXPLORATION |
|
alteraciones. I-EXPLORATION |
|
Durante B-EVOLUTION |
|
el I-EVOLUTION |
|
primer I-EVOLUTION |
|
mes I-EVOLUTION |
|
de I-EVOLUTION |
|
hospitalización I-EVOLUTION |
|
evolucionó I-EVOLUTION |
|
favorablemente I-EVOLUTION |
|
del I-EVOLUTION |
|
punto I-EVOLUTION |
|
de I-EVOLUTION |
|
vista I-EVOLUTION |
|
clínico, I-EVOLUTION |
|
con I-EVOLUTION |
|
mejoría I-EVOLUTION |
|
de I-EVOLUTION |
|
pruebas I-EVOLUTION |
|
hepáticas I-EVOLUTION |
|
pero I-EVOLUTION |
|
con I-EVOLUTION |
|
mal I-EVOLUTION |
|
incremento I-EVOLUTION |
|
ponderal. I-EVOLUTION |
|
<EOS> I-EVOLUTION |
|
|
|
Adolescente B-PRESENT_ILLNESS |
|
de I-PRESENT_ILLNESS |
|
16 I-PRESENT_ILLNESS |
|
años I-PRESENT_ILLNESS |
|
procedente B-PAST_MEDICAL_HISTORY |
|
de I-PAST_MEDICAL_HISTORY |
|
zona I-PAST_MEDICAL_HISTORY |
|
rural I-PAST_MEDICAL_HISTORY |
|
lejana, I-PAST_MEDICAL_HISTORY |
|
con I-PAST_MEDICAL_HISTORY |
|
altura I-PAST_MEDICAL_HISTORY |
|
superior I-PAST_MEDICAL_HISTORY |
|
a I-PAST_MEDICAL_HISTORY |
|
2.500 I-PAST_MEDICAL_HISTORY |
|
m I-PAST_MEDICAL_HISTORY |
|
sobre I-PAST_MEDICAL_HISTORY |
|
el I-PAST_MEDICAL_HISTORY |
|
nivel I-PAST_MEDICAL_HISTORY |
|
del I-PAST_MEDICAL_HISTORY |
|
mar, I-PAST_MEDICAL_HISTORY |
|
en I-PAST_MEDICAL_HISTORY |
|
el I-PAST_MEDICAL_HISTORY |
|
Departamento I-PAST_MEDICAL_HISTORY |
|
de I-PAST_MEDICAL_HISTORY |
|
Nariño-Colombia, I-PAST_MEDICAL_HISTORY |
|
con B-PRESENT_ILLNESS |
|
cuadro I-PRESENT_ILLNESS |
|
clínico I-PRESENT_ILLNESS |
|
de I-PRESENT_ILLNESS |
|
3 I-PRESENT_ILLNESS |
|
meses I-PRESENT_ILLNESS |
|
de I-PRESENT_ILLNESS |
|
evolución I-PRESENT_ILLNESS |
|
consistente I-PRESENT_ILLNESS |
|
en I-PRESENT_ILLNESS |
|
aparición I-PRESENT_ILLNESS |
|
de I-PRESENT_ILLNESS |
|
masa I-PRESENT_ILLNESS |
|
abdominal I-PRESENT_ILLNESS |
|
en I-PRESENT_ILLNESS |
|
hipocondrio I-PRESENT_ILLNESS |
|
izquierdo. I-PRESENT_ILLNESS |
|
El B-EXPLORATION |
|
paciente I-EXPLORATION |
|
nunca I-EXPLORATION |
|
antes I-EXPLORATION |
|
había I-EXPLORATION |
|
tenido I-EXPLORATION |
|
contacto I-EXPLORATION |
|
con I-EXPLORATION |
|
un I-EXPLORATION |
|
servicio I-EXPLORATION |
|
de I-EXPLORATION |
|
salud. I-EXPLORATION |
|
<EOS> I-EXPLORATION |
|
Ingresó I-EXPLORATION |
|
al I-EXPLORATION |
|
Hospital I-EXPLORATION |
|
con I-EXPLORATION |
|
disnea I-EXPLORATION |
|
de I-EXPLORATION |
|
pequeños I-EXPLORATION |
|
esfuerzos, I-EXPLORATION |
|
cianosis I-EXPLORATION |
|
peribucal, I-EXPLORATION |
|
conjuntivas I-EXPLORATION |
|
hipercrómicas I-EXPLORATION |
|
y I-EXPLORATION |
|
soplo I-EXPLORATION |
|
holosistólico I-EXPLORATION |
|
en I-EXPLORATION |
|
todos I-EXPLORATION |
|
los I-EXPLORATION |
|
focos I-EXPLORATION |
|
grado I-EXPLORATION |
|
IV/VI, I-EXPLORATION |
|
de I-EXPLORATION |
|
predominio I-EXPLORATION |
|
tricuspídeo, I-EXPLORATION |
|
con I-EXPLORATION |
|
reforzamiento I-EXPLORATION |
|
de I-EXPLORATION |
|
segundo I-EXPLORATION |
|
ruido. I-EXPLORATION |
|
En I-EXPLORATION |
|
abdomen, I-EXPLORATION |
|
masa I-EXPLORATION |
|
no I-EXPLORATION |
|
móvil, I-EXPLORATION |
|
con I-EXPLORATION |
|
bordes I-EXPLORATION |
|
definidos, I-EXPLORATION |
|
con I-EXPLORATION |
|
diámetro I-EXPLORATION |
|
de I-EXPLORATION |
|
14 I-EXPLORATION |
|
x I-EXPLORATION |
|
15 I-EXPLORATION |
|
cm, I-EXPLORATION |
|
indolora, I-EXPLORATION |
|
localizada I-EXPLORATION |
|
en I-EXPLORATION |
|
dorso I-EXPLORATION |
|
izquierdo I-EXPLORATION |
|
llegando I-EXPLORATION |
|
hasta I-EXPLORATION |
|
hipogastrio. I-EXPLORATION |
|
Dedos I-EXPLORATION |
|
en I-EXPLORATION |
|
palillo I-EXPLORATION |
|
de I-EXPLORATION |
|
tambor I-EXPLORATION |
|
y I-EXPLORATION |
|
extremidades I-EXPLORATION |
|
inferiores I-EXPLORATION |
|
con I-EXPLORATION |
|
edema I-EXPLORATION |
|
grado I-EXPLORATION |
|
I. I-EXPLORATION |
|
<EOS> I-EXPLORATION |
|
Se I-EXPLORATION |
|
decidió I-EXPLORATION |
|
hospitalizar I-EXPLORATION |
|
para I-EXPLORATION |
|
estudio I-EXPLORATION |
|
de I-EXPLORATION |
|
la I-EXPLORATION |
|
masa I-EXPLORATION |
|
abdominal, I-EXPLORATION |
|
diagnóstico I-EXPLORATION |
|
y I-EXPLORATION |
|
compensación I-EXPLORATION |
|
de I-EXPLORATION |
|
patología I-EXPLORATION |
|
cardiovascular. I-EXPLORATION |
|
<EOS> I-EXPLORATION |
|
El I-EXPLORATION |
|
hemograma I-EXPLORATION |
|
de I-EXPLORATION |
|
ingreso I-EXPLORATION |
|
mostró I-EXPLORATION |
|
marcado I-EXPLORATION |
|
aumento I-EXPLORATION |
|
de I-EXPLORATION |
|
glóbulos I-EXPLORATION |
|
rojos I-EXPLORATION |
|
(9.320.000/mm3), I-EXPLORATION |
|
hemoglobina I-EXPLORATION |
|
de I-EXPLORATION |
|
19, I-EXPLORATION |
|
9 I-EXPLORATION |
|
g/dL, I-EXPLORATION |
|
hematocrito I-EXPLORATION |
|
de I-EXPLORATION |
|
66%, I-EXPLORATION |
|
glóbulos I-EXPLORATION |
|
blancos I-EXPLORATION |
|
3.500/mm3, I-EXPLORATION |
|
plaquetas I-EXPLORATION |
|
48.000/mm3, I-EXPLORATION |
|
ácido I-EXPLORATION |
|
úrico I-EXPLORATION |
|
10, I-EXPLORATION |
|
5 I-EXPLORATION |
|
mg/dL. I-EXPLORATION |
|
<EOS> I-EXPLORATION |
|
El I-EXPLORATION |
|
ecocardiograma I-EXPLORATION |
|
reportó I-EXPLORATION |
|
dilatación I-EXPLORATION |
|
severa I-EXPLORATION |
|
de I-EXPLORATION |
|
cavidades I-EXPLORATION |
|
derechas, I-EXPLORATION |
|
insuficiencia I-EXPLORATION |
|
tricuspídea I-EXPLORATION |
|
e I-EXPLORATION |
|
hipertensión I-EXPLORATION |
|
pulmonar I-EXPLORATION |
|
(HTP) I-EXPLORATION |
|
severa I-EXPLORATION |
|
a I-EXPLORATION |
|
nivel I-EXPLORATION |
|
suprasistémico, I-EXPLORATION |
|
(presión I-EXPLORATION |
|
sistólica I-EXPLORATION |
|
arterial I-EXPLORATION |
|
pulmonar- I-EXPLORATION |
|
PSAP: I-EXPLORATION |
|
115 I-EXPLORATION |
|
mmHg). I-EXPLORATION |
|
<EOS> I-EXPLORATION |
|
Se I-EXPLORATION |
|
realizó I-EXPLORATION |
|
tomografía I-EXPLORATION |
|
computarizada I-EXPLORATION |
|
(TC) I-EXPLORATION |
|
de I-EXPLORATION |
|
abdomen I-EXPLORATION |
|
con I-EXPLORATION |
|
medio I-EXPLORATION |
|
de I-EXPLORATION |
|
contraste I-EXPLORATION |
|
endovenoso, I-EXPLORATION |
|
que I-EXPLORATION |
|
mostró I-EXPLORATION |
|
grandes I-EXPLORATION |
|
masa I-EXPLORATION |
|
tumoral I-EXPLORATION |
|
intrarrenales I-EXPLORATION |
|
bilaterales, I-EXPLORATION |
|
de I-EXPLORATION |
|
mayor I-EXPLORATION |
|
tamaño I-EXPLORATION |
|
gran I-EXPLORATION |
|
tamaño I-EXPLORATION |
|
y I-EXPLORATION |
|
de I-EXPLORATION |
|
crecimiento I-EXPLORATION |
|
exofítico I-EXPLORATION |
|
a I-EXPLORATION |
|
izquierda I-EXPLORATION |
|
y I-EXPLORATION |
|
con I-EXPLORATION |
|
marcado I-EXPLORATION |
|
adelgazamiento I-EXPLORATION |
|
del I-EXPLORATION |
|
parénquima I-EXPLORATION |
|
en I-EXPLORATION |
|
ambos I-EXPLORATION |
|
riñones. I-EXPLORATION |
|
El I-EXPLORATION |
|
examen I-EXPLORATION |
|
mostró I-EXPLORATION |
|
además I-EXPLORATION |
|
adenopatías I-EXPLORATION |
|
retroperitoneales I-EXPLORATION |
|
múltiples I-EXPLORATION |
|
y I-EXPLORATION |
|
lesiones I-EXPLORATION |
|
osteolíticas I-EXPLORATION |
|
vertebrales. I-EXPLORATION |
|
La I-EXPLORATION |
|
TC I-EXPLORATION |
|
de I-EXPLORATION |
|
tórax I-EXPLORATION |
|
no I-EXPLORATION |
|
mostró I-EXPLORATION |
|
alteraciones I-EXPLORATION |
|
en I-EXPLORATION |
|
el I-EXPLORATION |
|
parénquima I-EXPLORATION |
|
pulmonar. I-EXPLORATION |
|
<EOS> I-EXPLORATION |
|
Por B-TREATMENT |
|
sospecha I-TREATMENT |
|
de I-TREATMENT |
|
HTP I-TREATMENT |
|
severa I-TREATMENT |
|
con I-TREATMENT |
|
signos I-TREATMENT |
|
clínicos I-TREATMENT |
|
de I-TREATMENT |
|
hipoxia I-TREATMENT |
|
crónica, I-TREATMENT |
|
se I-TREATMENT |
|
le I-TREATMENT |
|
administró I-TREATMENT |
|
sildenafil I-TREATMENT |
|
y I-TREATMENT |
|
oxígeno I-TREATMENT |
|
como I-TREATMENT |
|
vasodilatadores I-TREATMENT |
|
pulmonares, I-TREATMENT |
|
furosemida I-TREATMENT |
|
para I-TREATMENT |
|
manejo I-TREATMENT |
|
de I-TREATMENT |
|
su I-TREATMENT |
|
sobrecarga I-TREATMENT |
|
hídrica I-TREATMENT |
|
y I-TREATMENT |
|
alopurinol I-TREATMENT |
|
como I-TREATMENT |
|
tratamiento I-TREATMENT |
|
de I-TREATMENT |
|
hiperuricemia I-TREATMENT |
|
para I-TREATMENT |
|
prevenir I-TREATMENT |
|
lesión I-TREATMENT |
|
renal. I-TREATMENT |
|
<EOS> I-TREATMENT |
|
La B-EXPLORATION |
|
biopsia I-EXPLORATION |
|
de I-EXPLORATION |
|
médula I-EXPLORATION |
|
ósea I-EXPLORATION |
|
reportó I-EXPLORATION |
|
hiperplasia I-EXPLORATION |
|
eritroide I-EXPLORATION |
|
sin I-EXPLORATION |
|
evidencia I-EXPLORATION |
|
de I-EXPLORATION |
|
infiltración, I-EXPLORATION |
|
por I-EXPLORATION |
|
lo I-EXPLORATION |
|
que I-EXPLORATION |
|
se I-EXPLORATION |
|
descartó I-EXPLORATION |
|
linfoma. I-EXPLORATION |
|
Por I-EXPLORATION |
|
riesgo I-EXPLORATION |
|
anestésico, I-EXPLORATION |
|
secundario I-EXPLORATION |
|
a I-EXPLORATION |
|
HTP, I-EXPLORATION |
|
se I-EXPLORATION |
|
realizó I-EXPLORATION |
|
biopsia I-EXPLORATION |
|
renal I-EXPLORATION |
|
con I-EXPLORATION |
|
Trucut I-EXPLORATION |
|
guiada I-EXPLORATION |
|
por I-EXPLORATION |
|
Ecografía, I-EXPLORATION |
|
cuyo I-EXPLORATION |
|
reporte I-EXPLORATION |
|
de I-EXPLORATION |
|
patología I-EXPLORATION |
|
confirmó I-EXPLORATION |
|
diagnóstico I-EXPLORATION |
|
de I-EXPLORATION |
|
HEM. I-EXPLORATION |
|
<EOS> I-EXPLORATION |
|
Se B-EVOLUTION |
|
ha I-EVOLUTION |
|
realizado I-EVOLUTION |
|
seguimiento I-EVOLUTION |
|
durante I-EVOLUTION |
|
8 I-EVOLUTION |
|
meses, I-EVOLUTION |
|
sin I-EVOLUTION |
|
cambios I-EVOLUTION |
|
significativos I-EVOLUTION |
|
en I-EVOLUTION |
|
su I-EVOLUTION |
|
evolución. I-EVOLUTION |
|
<EOS> I-EVOLUTION |
|
|
|
Paciente B-PRESENT_ILLNESS |
|
femenino I-PRESENT_ILLNESS |
|
de I-PRESENT_ILLNESS |
|
6 I-PRESENT_ILLNESS |
|
años I-PRESENT_ILLNESS |
|
de I-PRESENT_ILLNESS |
|
edad I-PRESENT_ILLNESS |
|
con B-PAST_MEDICAL_HISTORY |
|
antecedentes I-PAST_MEDICAL_HISTORY |
|
de I-PAST_MEDICAL_HISTORY |
|
epilepsia I-PAST_MEDICAL_HISTORY |
|
secundaria I-PAST_MEDICAL_HISTORY |
|
a I-PAST_MEDICAL_HISTORY |
|
extensa I-PAST_MEDICAL_HISTORY |
|
alteración I-PAST_MEDICAL_HISTORY |
|
del I-PAST_MEDICAL_HISTORY |
|
desarrollo I-PAST_MEDICAL_HISTORY |
|
cortical I-PAST_MEDICAL_HISTORY |
|
hemisférico I-PAST_MEDICAL_HISTORY |
|
derecho. I-PAST_MEDICAL_HISTORY |
|
Presentó B-PRESENT_ILLNESS |
|
estatus I-PRESENT_ILLNESS |
|
epiléptico I-PRESENT_ILLNESS |
|
refractario I-PRESENT_ILLNESS |
|
que B-TREATMENT |
|
re I-TREATMENT |
|
quirió I-TREATMENT |
|
ingreso I-TREATMENT |
|
a I-TREATMENT |
|
Unidad I-TREATMENT |
|
de I-TREATMENT |
|
Cuidados I-TREATMENT |
|
Intensivos I-TREATMENT |
|
para I-TREATMENT |
|
soporte I-TREATMENT |
|
vital I-TREATMENT |
|
y I-TREATMENT |
|
tratamiento, I-TREATMENT |
|
el I-TREATMENT |
|
que I-TREATMENT |
|
incluyó I-TREATMENT |
|
como I-TREATMENT |
|
terapia I-TREATMENT |
|
de I-TREATMENT |
|
tercera I-TREATMENT |
|
línea I-TREATMENT |
|
infusión I-TREATMENT |
|
intravenosa I-TREATMENT |
|
continua I-TREATMENT |
|
de I-TREATMENT |
|
propofol I-TREATMENT |
|
en I-TREATMENT |
|
dosis I-TREATMENT |
|
progresivas I-TREATMENT |
|
hasta I-TREATMENT |
|
alcanzar I-TREATMENT |
|
una I-TREATMENT |
|
tasa I-TREATMENT |
|
10 I-TREATMENT |
|
mg/kg/h. I-TREATMENT |
|
Cursó B-EVOLUTION |
|
con I-EVOLUTION |
|
compromiso I-EVOLUTION |
|
hemodinámico I-EVOLUTION |
|
y I-EVOLUTION |
|
a I-EVOLUTION |
|
las I-EVOLUTION |
|
24 I-EVOLUTION |
|
h I-EVOLUTION |
|
de I-EVOLUTION |
|
iniciado I-EVOLUTION |
|
el I-EVOLUTION |
|
tratamiento I-EVOLUTION |
|
se I-EVOLUTION |
|
observó I-EVOLUTION |
|
alza I-EVOLUTION |
|
de I-EVOLUTION |
|
la I-EVOLUTION |
|
creatinifosfokinasa I-EVOLUTION |
|
(CK), I-EVOLUTION |
|
acidosis I-EVOLUTION |
|
metabólica I-EVOLUTION |
|
y I-EVOLUTION |
|
lactacidemia I-EVOLUTION |
|
elevada, I-EVOLUTION |
|
y B-TREATMENT |
|
luego I-TREATMENT |
|
de I-TREATMENT |
|
descartar I-TREATMENT |
|
otras I-TREATMENT |
|
causas I-TREATMENT |
|
se I-TREATMENT |
|
planteó I-TREATMENT |
|
el I-TREATMENT |
|
dianóstico I-TREATMENT |
|
de I-TREATMENT |
|
SIP I-TREATMENT |
|
por I-TREATMENT |
|
lo I-TREATMENT |
|
que I-TREATMENT |
|
se I-TREATMENT |
|
suspendió I-TREATMENT |
|
la I-TREATMENT |
|
droga, I-TREATMENT |
|
logrando B-EVOLUTION |
|
esta I-EVOLUTION |
|
bilización I-EVOLUTION |
|
hemodinámica I-EVOLUTION |
|
a I-EVOLUTION |
|
las I-EVOLUTION |
|
24 I-EVOLUTION |
|
h. I-EVOLUTION |
|
<EOS> I-EVOLUTION |
|
|
|
Mujer B-PRESENT_ILLNESS |
|
de I-PRESENT_ILLNESS |
|
58 I-PRESENT_ILLNESS |
|
años I-PRESENT_ILLNESS |
|
que B-PAST_MEDICAL_HISTORY |
|
presentaba I-PAST_MEDICAL_HISTORY |
|
como I-PAST_MEDICAL_HISTORY |
|
enfermedad I-PAST_MEDICAL_HISTORY |
|
de I-PAST_MEDICAL_HISTORY |
|
base I-PAST_MEDICAL_HISTORY |
|
leucemia I-PAST_MEDICAL_HISTORY |
|
de I-PAST_MEDICAL_HISTORY |
|
4 I-PAST_MEDICAL_HISTORY |
|
años I-PAST_MEDICAL_HISTORY |
|
de I-PAST_MEDICAL_HISTORY |
|
evolución, I-PAST_MEDICAL_HISTORY |
|
que I-PAST_MEDICAL_HISTORY |
|
precisaba I-PAST_MEDICAL_HISTORY |
|
de I-PAST_MEDICAL_HISTORY |
|
transfusiones I-PAST_MEDICAL_HISTORY |
|
de I-PAST_MEDICAL_HISTORY |
|
derivados I-PAST_MEDICAL_HISTORY |
|
hemáticos I-PAST_MEDICAL_HISTORY |
|
con I-PAST_MEDICAL_HISTORY |
|
cierta I-PAST_MEDICAL_HISTORY |
|
frecuencia. I-PAST_MEDICAL_HISTORY |
|
Tras B-PRESENT_ILLNESS |
|
presentar I-PRESENT_ILLNESS |
|
una I-PRESENT_ILLNESS |
|
síndrome I-PRESENT_ILLNESS |
|
constitucional I-PRESENT_ILLNESS |
|
en I-PRESENT_ILLNESS |
|
los I-PRESENT_ILLNESS |
|
últimos I-PRESENT_ILLNESS |
|
meses, I-PRESENT_ILLNESS |
|
se I-PRESENT_ILLNESS |
|
le I-PRESENT_ILLNESS |
|
había I-PRESENT_ILLNESS |
|
detectado I-PRESENT_ILLNESS |
|
una I-PRESENT_ILLNESS |
|
masa I-PRESENT_ILLNESS |
|
en I-PRESENT_ILLNESS |
|
pared I-PRESENT_ILLNESS |
|
costal I-PRESENT_ILLNESS |
|
derecha I-PRESENT_ILLNESS |
|
de I-PRESENT_ILLNESS |
|
4 I-PRESENT_ILLNESS |
|
cm I-PRESENT_ILLNESS |
|
de I-PRESENT_ILLNESS |
|
diámetro, I-PRESENT_ILLNESS |
|
que I-PRESENT_ILLNESS |
|
fue I-PRESENT_ILLNESS |
|
diagnosticada I-PRESENT_ILLNESS |
|
de I-PRESENT_ILLNESS |
|
múcor. I-PRESENT_ILLNESS |
|
<EOS> I-PRESENT_ILLNESS |
|
Planteamos B-TREATMENT |
|
intervención I-TREATMENT |
|
quirúrgica I-TREATMENT |
|
para I-TREATMENT |
|
resecar I-TREATMENT |
|
la I-TREATMENT |
|
lesión I-TREATMENT |
|
con I-TREATMENT |
|
3 I-TREATMENT |
|
cm I-TREATMENT |
|
de I-TREATMENT |
|
margen. I-TREATMENT |
|
Al I-TREATMENT |
|
estar I-TREATMENT |
|
situada I-TREATMENT |
|
en I-TREATMENT |
|
la I-TREATMENT |
|
proximidad I-TREATMENT |
|
de I-TREATMENT |
|
la I-TREATMENT |
|
línea I-TREATMENT |
|
axilar I-TREATMENT |
|
anterior, I-TREATMENT |
|
llevamos I-TREATMENT |
|
a I-TREATMENT |
|
cabo I-TREATMENT |
|
la I-TREATMENT |
|
reconstrucción I-TREATMENT |
|
con I-TREATMENT |
|
un I-TREATMENT |
|
colgajo I-TREATMENT |
|
de I-TREATMENT |
|
músculo I-TREATMENT |
|
dorsal I-TREATMENT |
|
ancho I-TREATMENT |
|
con I-TREATMENT |
|
isla I-TREATMENT |
|
de I-TREATMENT |
|
piel I-TREATMENT |
|
desepidermizada I-TREATMENT |
|
de I-TREATMENT |
|
8 I-TREATMENT |
|
por I-TREATMENT |
|
12 I-TREATMENT |
|
cm I-TREATMENT |
|
; I-TREATMENT |
|
se I-TREATMENT |
|
anclaron I-TREATMENT |
|
puntos I-TREATMENT |
|
de I-TREATMENT |
|
sutura I-TREATMENT |
|
desde I-TREATMENT |
|
los I-TREATMENT |
|
bordes I-TREATMENT |
|
costales I-TREATMENT |
|
hasta I-TREATMENT |
|
la I-TREATMENT |
|
dermis I-TREATMENT |
|
del I-TREATMENT |
|
colgajo, I-TREATMENT |
|
para I-TREATMENT |
|
así I-TREATMENT |
|
dar I-TREATMENT |
|
continuidad I-TREATMENT |
|
a I-TREATMENT |
|
la I-TREATMENT |
|
propia I-TREATMENT |
|
pared I-TREATMENT |
|
costal. I-TREATMENT |
|
La B-EVOLUTION |
|
paciente I-EVOLUTION |
|
recibió I-EVOLUTION |
|
el I-EVOLUTION |
|
alta I-EVOLUTION |
|
hospitalaria I-EVOLUTION |
|
una I-EVOLUTION |
|
semana I-EVOLUTION |
|
más I-EVOLUTION |
|
tarde, I-EVOLUTION |
|
sin I-EVOLUTION |
|
problemas I-EVOLUTION |
|
ventilatorios I-EVOLUTION |
|
ni I-EVOLUTION |
|
respiración I-EVOLUTION |
|
paradójica. I-EVOLUTION |
|
No I-EVOLUTION |
|
han I-EVOLUTION |
|
aparecido I-EVOLUTION |
|
recidivas I-EVOLUTION |
|
ni I-EVOLUTION |
|
complicaciones I-EVOLUTION |
|
tras I-EVOLUTION |
|
24 I-EVOLUTION |
|
meses I-EVOLUTION |
|
de I-EVOLUTION |
|
seguimiento I-EVOLUTION |
|
postoperatorio. I-EVOLUTION |
|
<EOS> I-EVOLUTION |
|
|
|
Mujer B-PRESENT_ILLNESS |
|
de I-PRESENT_ILLNESS |
|
25 I-PRESENT_ILLNESS |
|
años I-PRESENT_ILLNESS |
|
diagnosticada B-PAST_MEDICAL_HISTORY |
|
clínicamente I-PAST_MEDICAL_HISTORY |
|
de I-PAST_MEDICAL_HISTORY |
|
miocardiopatía I-PAST_MEDICAL_HISTORY |
|
hipertrófica I-PAST_MEDICAL_HISTORY |
|
obstructiva I-PAST_MEDICAL_HISTORY |
|
en I-PAST_MEDICAL_HISTORY |
|
tratamiento I-PAST_MEDICAL_HISTORY |
|
farmacológico I-PAST_MEDICAL_HISTORY |
|
con I-PAST_MEDICAL_HISTORY |
|
antiarrítmicos I-PAST_MEDICAL_HISTORY |
|
(Amiodarona) I-PAST_MEDICAL_HISTORY |
|
y I-PAST_MEDICAL_HISTORY |
|
betabloqueantes I-PAST_MEDICAL_HISTORY |
|
(Propanolol). I-PAST_MEDICAL_HISTORY |
|
La B-FAMILY_HISTORY |
|
madre I-FAMILY_HISTORY |
|
había I-FAMILY_HISTORY |
|
fallecido I-FAMILY_HISTORY |
|
súbitamente I-FAMILY_HISTORY |
|
a I-FAMILY_HISTORY |
|
los I-FAMILY_HISTORY |
|
48 I-FAMILY_HISTORY |
|
años I-FAMILY_HISTORY |
|
por I-FAMILY_HISTORY |
|
la I-FAMILY_HISTORY |
|
misma I-FAMILY_HISTORY |
|
enfermedad. I-FAMILY_HISTORY |
|
Una B-PRESENT_ILLNESS |
|
noche I-PRESENT_ILLNESS |
|
salió I-PRESENT_ILLNESS |
|
a I-PRESENT_ILLNESS |
|
cenar I-PRESENT_ILLNESS |
|
con I-PRESENT_ILLNESS |
|
los I-PRESENT_ILLNESS |
|
compañeros I-PRESENT_ILLNESS |
|
de I-PRESENT_ILLNESS |
|
trabajo I-PRESENT_ILLNESS |
|
regresando I-PRESENT_ILLNESS |
|
al I-PRESENT_ILLNESS |
|
domicilio I-PRESENT_ILLNESS |
|
sobre I-PRESENT_ILLNESS |
|
las I-PRESENT_ILLNESS |
|
4 I-PRESENT_ILLNESS |
|
horas I-PRESENT_ILLNESS |
|
de I-PRESENT_ILLNESS |
|
la I-PRESENT_ILLNESS |
|
madrugada. I-PRESENT_ILLNESS |
|
No I-PRESENT_ILLNESS |
|
manifestó I-PRESENT_ILLNESS |
|
ninguna I-PRESENT_ILLNESS |
|
sintomatología I-PRESENT_ILLNESS |
|
y I-PRESENT_ILLNESS |
|
se I-PRESENT_ILLNESS |
|
acostó I-PRESENT_ILLNESS |
|
en I-PRESENT_ILLNESS |
|
el I-PRESENT_ILLNESS |
|
sofá I-PRESENT_ILLNESS |
|
del I-PRESENT_ILLNESS |
|
salón. I-PRESENT_ILLNESS |
|
Poco I-PRESENT_ILLNESS |
|
después I-PRESENT_ILLNESS |
|
el I-PRESENT_ILLNESS |
|
perro I-PRESENT_ILLNESS |
|
comenzó I-PRESENT_ILLNESS |
|
a I-PRESENT_ILLNESS |
|
ladrar I-PRESENT_ILLNESS |
|
por I-PRESENT_ILLNESS |
|
lo I-PRESENT_ILLNESS |
|
que I-PRESENT_ILLNESS |
|
el I-PRESENT_ILLNESS |
|
padre I-PRESENT_ILLNESS |
|
se I-PRESENT_ILLNESS |
|
levantó I-PRESENT_ILLNESS |
|
encontrándola I-PRESENT_ILLNESS |
|
inconsciente. I-PRESENT_ILLNESS |
|
Se B-EVOLUTION |
|
avisó I-EVOLUTION |
|
a I-EVOLUTION |
|
los I-EVOLUTION |
|
servicios I-EVOLUTION |
|
de I-EVOLUTION |
|
emergencia I-EVOLUTION |
|
061 I-EVOLUTION |
|
que I-EVOLUTION |
|
se I-EVOLUTION |
|
limitaron I-EVOLUTION |
|
a I-EVOLUTION |
|
constatar I-EVOLUTION |
|
el I-EVOLUTION |
|
fallecimiento. I-EVOLUTION |
|
<EOS> I-EVOLUTION |